Structure of T6SS components and assessment of potential Gram-ve drug targets by Rao, Vincenzo A.
University of Dundee
DOCTOR OF PHILOSOPHY
Structure of T6SS components and assessment of potential Gram-ve drug targets
Rao, Vincenzo A.
Award date:
2012
Awarding institution:
University of Dundee
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 17. Feb. 2017
DOCTOR OF PHILOSOPHY
Structure of T6SS components and
assessment of potential Gram-ve drug
targets
Vincenzo A. Rao
2012
University of Dundee
Conditions for Use and Duplication
Copyright of this work belongs to the author unless otherwise identified in the body of the thesis. It is permitted
to use and duplicate this work only for personal and non-commercial research, study or criticism/review. You
must obtain prior written consent from the author for any other use. Any quotation from this thesis must be
acknowledged using the normal academic conventions. It is not permitted to supply the whole or part of this
thesis to any other person or to post the same on any website or other online location without the prior written
consent of the author. Contact the Discovery team (discovery@dundee.ac.uk) with any queries about the use
or acknowledgement of this work.
A thesis submitted for the degree of Doctor of Philosophy 
 
 
Structure of T6SS components and assessment of 
potential Gram-ve drug targets 
 
Vincenzo A. Rao 
 
Supervisor: 
Professor William N. Hunter 
 
 
 
 
The Wellcome Trust Biocentre  
University of Dundee 
Scotland 
August 2012 
  
Contents 
I 
CONTENTS 
  
CONTENTS                                   I 
LIST OF FIGURES                                      V 
LIST OF TABLES                          VIII 
ACKNOWLEDGEMENTS                               IX 
DECLARATION                               X 
SUMMARY                              XI 
ABBREVIATIONS                          XIII 
 
PART I – STRUCTURE OF T6SS COMPONENTS 
1. INTRODUCTION – THE TYPE VI SECRETION SYSTEM                                 2 
1.1 SECRETION IN GRAM-NEGATIVE BACTERIA                        3 
   1.1.1 AN OVERVIEW OF PROTEIN SECRETION SYSTEMS             4 
1.2 THE TYPE VI SECRETION SYSTEM                          6 
   1.2.1 ASSEMBLY AND FUNCTION: THE BACTERIOPHAGE-LIKE INJECTION APPARATUS   8 
   1.2.2 ASSEMBLY AND FUNCTION: THE MEMBRANE COMPLEX                        10 
1.3 Serratia marcescens DB10 T6SS                                        13 
   1.3.1 SMALL PROTEINS                                      14 
   1.3.2 Serratia marcescens                                    16 
1.4 AIMS                                    17 
 
2. MATERIALS AND METHODS                               19 
2.1 GENERAL MATERIALS                             20 
   2.1.1 REAGENTS                              20 
   2.1.2 BACTERIA                              20 
   2.1.3 GROWTH MEDIA                             20 
2.2 GENERAL METHODS                             21   
   2.2.1 CLONING                               21 
   2.2.2 RECOMBINANT PROTEIN PRODUCTION IN E. COLI                         22 
2.3 PROTEIN PURIFICATION                                23 
  
Contents 
II 
   2.3.1 BUFFERS                              23 
   2.3.2 CELL LYSIS AND PURIFICATION                           24 
   2.3.3 SIZE EXCLUSION CHROMATOGRAPHY                           25 
2.4 PROTEIN CRYSTALLOGRAPHY                            25 
   2.4.1 CRYSTALLISATION OF PROTEINS                           25 
   2.4.2 CRYSTALLISATION TECHNIQUES                           25 
   2.4.3 SPARSE MATRIX SCREENING                            26 
2.5 CRYSTAL STRUCTURE DETERMINATION                           27 
   2.5.1 THE PHASE PROBLEM                             27 
   2.5.2 PATTERSON MAPS                             27 
   2.5.3 SINGLE-WAVELENGTH ANOMALOUS DISPERSION (SAD)                        28 
   2.5.4 MOLECULAR REPLACEMENT                            29 
2.6 GENERAL SOFTWARE                             30 
2.7 FRAGMENT SCREENING                             30 
   2.7.1 REAGENTS                              30 
   2.7.2 BIOTINYLATION                             30 
   2.7.3 DIFFERENTIAL SCANNING FLUORIMETRY (DSF)                         31 
   2.7.4 SURFACE PLASMON RESONANCE (SPR)                           33 
   2.7.5 BIO-LAYER INTERFEROMETRY (BLI)                           34 
2.8 ENZYME KINETICS                              35 
 
3. RESULTS AND DISCUSSION: SmLip                            36 
3.1 AIMS                               37 
3.2 CONSTRUCTION OF THE PET15B-TEV-SmLip VECTOR                         37  
3.3 RECOMBINANT SmLip EXPRESSION AND PURIFICATION                         38 
3.4 CRYSTALLISATION AND DATA PROCESSING                          39 
3.5 STRUCTURE DETERMINATION OF SmLip                           41 
   3.5.1 PHASING                              41 
   3.5.2 MODEL BUILDING AND REFINEMENT                           42 
3.6 THE SmLip STRUCTURE                             44 
   3.6.1 OVERALL STRUCTURE                             44 
   3.6.2 ANALYSIS OF THE QUATERNARY STRUCTURE                          46 
  
Contents 
III 
   3.6.3 COMPARISON WITH STRUCTURAL HOMOLOGUES                          48 
3.7 DISCUSSION                              50  
 
4. RESULTS AND DISCUSSION: Rap1b                            54 
4.1 AIMS                               55 
4.2 RECOMBINANT Rap1b EXPRESSION AND PURIFICATION                         55 
4.3 CRYSTALLISATION AND DATA PROCESSING                            56 
4.4 STRUCTURE DETERMINATION OF Rap1b                           57 
   4.4.1 PHASING                               57 
   4.4.2 MODEL BUILDING AND REFINEMENT                           58 
4.5 THE Rap1b STRUCTURE                             59  
   4.5.1 OVERALL STRUCTURE                             59 
   4.5.2 DISULFIDE BOND FORMATION                            62 
4.6 DISCUSSION                              64 
 
PART II – ASSESSMENT OF POTENTIAL GRAM -VE DRUG TARGETS 
5. INTRODUCTION – FRAGMENT SCREENING                           69 
5.1 THE NEED FOR NEW ANTIMICROBIALS                             70 
   5.1.1 ANTIBACTERIAL DRUG DISCOVERY PIPELINE                          71 
5.2 TARGET ASSESSMENT                               72 
5.3 FRAGMENTS                                74 
5.4 AIMS                               76 
 
6. RESULTS AND DISCUSSION: PENICILLIN-BINDING PROTEIN 3                        78 
6.1 BACKGROUND                              79 
6.2 AIMS                                            80 
6.3 RECOMBINANT PaPBP3 & BpPBP3 EXPRESSION AND PURIFICATION                       80 
6.4 FRAGMENT SCREENING                             81 
   6.4.1 DSF                               81 
   6.4.2 BLI AND SPR                              84 
   6.4.3 COMPARISON OF FRAGMENT SCREENING METHODS                         87 
  
Contents 
IV 
6.5 CRYSTALLISATION SCREENING                            89 
6.6 DISCUSSION                              90 
 
7. RESULTS AND DISCUSSION: Pseudomonas aeruginosa INOSINE 5’-MONOPHOSPHATE 
DEHYDROGENASE                              93 
7.1 BACKGROUND                              94 
7.2 AIMS                               95 
7.3 RECOMBINANT PaIMPDH EXPRESSION AND PURIFICATION                        96 
7.4 FRAGMENT SCREENING                              97 
   7.4.1 DSF                               97 
   7.4.2 BLI                               99 
7.5 ENZYME KINETICS                              99 
7.6 CRYSTALLISATION AND DATA COLLECTION                        101                 
   7.6.1 MOLECULAR REPLACEMENT AND MODEL BUILDING                       103 
7.7 THE PaIMPDH STRUCTURE                           105 
   7.7.1 OVERALL STRUCTURE                           105 
   7.7.2 ACTIVE SITE                            106 
7.8 DISCUSSION                            108 
 
8. REFERENCES                            111 
 
9. APPENDICES              142 
 
 
 
  
List of Figures 
V 
LIST OF FIGURES 
 
1.1 The cell wall of bacteria.               4 
1.2 Secretion systems.               5 
1.3 Comparison with bacteriophage.              8 
1.4 The T6SS injection apparatus.            10 
1.5 The T6SS.               13 
1.6 Schematic representation of the T6SS genes in S. marcescens.        14 
1.7 Schematic representation of the genes encoding several small proteins.       16  
2.1 pET15b-TEV vector.             22 
2.2 Melting curves of PaPBP3.            31 
2.3 Principles of SPR.              33 
2.4 Bio-layer interferometry (BLI).            34 
3.1 Cloning of SmLip.             38 
3.2 Size exclusion chromatography.            39 
3.3 Crystals of SmLip.             40 
3.4 Crystal optimisation.             41 
3.5 Density modified map.             42 
3.6 The structure of SmLip.             45 
3.7 Crystallographic interfaces.            48 
3.8 Comparison with structural homologues.           49 
3.9 Stereo image of an overlay of SmLip and transthyretin  
in complex with thyroxine.              50 
3.10 The T6SS.              51 
3.11 Comparison with the EcTssJ crystal structure.          52 
4.1 Size exclusion chromatography.            56 
  
List of Figures 
VI 
4.2 Rap1b crystals.              56 
4.3 Density modified map.             58 
4.4 Rap1b and Rap2b comparison.            61 
4.5 A Cα trace of Rap1b and Rap2b.            62 
4.6 Disulfide bond.              63 
4.7 Toxins and self-resistance proteins.           65 
4.8 Tsi2 structure.              66 
4.9 Electrostatic surface potential.            67  
5.1 Drug discovery progress.             72 
5.2 An example of fragment-based drug discovery.          75 
6.1 Peptidoglycan biosynthesis.            79 
6.2 Size exclusion chromatography.            81 
6.3 Antibiotic binds.              82 
6.4 DSF fragment hits.             83 
6.5 BLI sensograms.              85 
6.6 SPR sensograms.              87 
6.7 DSF not suited to fragment screening.           88 
6.8 PaPBP3 alignment and structure.            91 
6.9 PaPBP3 small binding pocket.            92 
7.1 Proposed IMDH mechanism.            94 
7.2 The importance of XMP.             95 
7.3 Size exclusion chromatography.            96 
7.4 Thermal profile of PaIMPDH with ligands.          98 
7.5 BLI sensograms.              99 
7.6 PaIMPDH kinetics           101 
7.7 Crystals of PaIMPDH.           102 
  
List of Figures 
VII 
7.8 The structure of PaIMPDH.          106 
7.9 The PaIMPDH active site.          107 
7.10 IMPDH homologues.           109 
 
  
List of Tables 
VIII 
LIST OF TABLES 
 
1.1 Nomenclature of T6SS components.             7 
2.1 SmLip PCR parameters.             21 
2.2 Buffers.               23 
3.1 Crystallographic statistics.            43 
4.1 Crystallographic statistics.            59 
5.1 Bacterial isolates identified from U.S. intensive care units in 2003.       71 
5.2 Traffic light definitions for target assessment.          73 
5.3 Change in properties during optimisation from lead to drug.        75 
5.4 Potential drug targets screened.            76 
7.1 IMPDH kinetic parameters.          100 
7.2 PaIMPDH crystallisation.          102 
7.3 Crystallographic statistics.          104 
7.4 Functional IMPDH residues.          109 
 
 
  
Acknowledgements 
IX 
ACKNOWLEDGEMENTS 
 
I would like to thank my supervisor Prof. Bill Hunter for the opportunity to work in his 
lab and for his support and encouragement throughout my PhD. A thanks goes to all the 
WNH lab members, past and present, for making my time in the lab an enjoyable and 
unforgettable experience and for their advice and assistance throughout the years. In 
particular, I would like to thank Thomas Eadsforth for his support, guidance and 
friendship. A thanks also goes to both Sarah Coulthurst and Grant English for their 
collaboration and discussions on all things related to the T6SS.    
I would like to thank my family for their support while writing this thesis and 
the understanding they have all shown me. In particular, I would like to thank my 
brother Francesco for his encouragement and discussions.  
Finally, a special thanks goes to my fiancée Lynsey for her support and for 
always being there for me. Thank you.  
 
  
Declaration 
X 
Declaration 
 
I hereby declare that the following thesis is based on the result of investigations 
conducted by myself, and that this thesis is of my own composition. This thesis has not, 
in whole or in part, been previously presented for a higher degree. Work other than my 
own is clearly indicated in the text by reference to the relevant researchers or 
publications.  
 
 
 
 
Vincenzo A. Rao 
 
 
The work presented in this thesis is the work of the candidate V. A. Rao. Conditions of 
the relevant Ordnance and Regulations have been fulfilled. 
 
 
 
 
 
 
Prof. W.N. Hunter  
  
Summary 
XI 
SUMMARY 
 
The structure and potential function of two components of the type VI secretion system 
in Serratia marcescens have been investigated by X-ray crystallography. Chapters 1 and 
2 describe the background of the type VI secretion system and experimental methods 
respectively. In chapter 3, the solution of the structure of S. marcescens Lip is 
presented. This is an essential outer membrane lipoprotein that is conserved among 
bacterial species. It is part of a membrane-spanning sub-assembly that is thought to 
anchor the remaining components to the cell envelope. The crystal structure of SmLip 
was determined using single-wavelength anomalous dispersion methods targeting 
iodides that were present in the crystallisation solution. The structure was refined to 
1.92 Å and displays a fold similar to that of transthyretin; a protein that binds the 
hormone thyroxine. Despite the sequence identity between the two proteins being low, 
SmLip can be considered a new member of the transthyretin-like protein family. A role 
is suggested for loop 1 being involved in protein-protein interactions with other 
components of the type VI secretion system and therefore a potential drug target.  
 In chapter 4, the structure of S. marcescens Rap1b is described. This protein is 
thought to be part of a set of periplasmic resistance proteins that protect S. marcescens 
from succumbing to the effects of its own secreted toxins. The crystal structure of 
Rap1b was determined using single-wavelength anomalous dispersion methods 
targeting both iodides from a halide soak and endogenous sulfurs. The structure was 
refined to 1.88 Å and displays a helical rich fold not previously characterised. This 
structure is described and is suggested to represent this family of resistance proteins.  
 
In addition to determining the structure of components of the type VI secretion system, 
the assessment of two drug targets have been investigated by biochemical techniques. 
  
Summary 
XII 
The need for new antimicrobials and the importance of target selection in the drug 
discovery process is described in chapter 5. PBP3 from both Pseudomonas aeruginosa 
and Burkholderia pseudomallei is the focus of chapter 6. This protein is essential in 
bacteria as it catalyses the cross-linking of peptidoglycan. Peptidoglycan provides 
bacteria with structural rigidity and strength to withstand pressures that would otherwise 
rupture the cell. Sequence identity between the two homologues is approximately 40 %, 
with the catalytic residues conserved. The production of soluble protein and the results 
of screening for novel chemical fragments using several techniques are presented.  
The characterisation of P. aeruginosa IMPDH, an essential protein that is 
present in nearly all living organisms is described in chapter 7. This protein controls the 
pool of guanine nucleotides within cells. Fragments were identified using bio-layer 
interterformetry, a label free optical analytical technique that monitors biomolecular 
interactions in real time. Fragments were assessed for inhibitory effects using enzyme 
kinetics. The crystal structure of PaIMPDH was determined by molecular replacement 
and refined to 2.25 Å. This structure displays the catalytic domain with the active site 
loop fully ordered and in a conformation rarely observed.  
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1.1 Secretion in Gram-negative bacteria 
Protein secretion is the transport of proteins from the cytosol to the extracellular milieu 
and is a basic cellular function in both Gram-positive and Gram-negative bacteria 
(Gerlach and Hensel, 2007). While the secretion of proteins in Gram-positive bacteria 
has only the single membrane barrier to traverse, Gram-negative bacteria must 
overcome the inherent difficulty of a second membrane (Figure 1.1). These proteins 
must traverse the inner membrane (IM), the periplasm and then the outer membrane 
(OM) of the cell envelope before secretion is achieved. In some instances, the intended 
target of the secreted protein is a target cell, adding an additional membrane barrier to 
overcome (Fronzes et al., 2009; Mueller et al., 2008). In general secreted proteins have 
a multitude of functions, including the biogenesis of organelles such as pili and flagella, 
intercellular communication, nutrient acquisition, virulence, protein adhesins, effector 
proteins and the efflux of drugs (Gerlach and Hensel, 2007; Kostakioti et al., 2005). 
Protein secretion in Gram-negative bacteria is therefore associated with bacterial fitness, 
competition and also with virulence of pathogenic bacteria. The understanding of the 
mechanisms involved in protein secretion may provide opportunities for the 
development of new drug treatments against these pathogens. This is important as the 
increase in hospital-acquired infections from Gram-negative bacteria (Chopra et al., 
2008; Peleg and Hooper, 2010) and instances of multi drug resistance become a 
growing concern (Arias and Murray, 2009; Souli et al., 2008). 
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1.1.1 An overview of protein secretion systems 
Macromolecular complexes known as secretion systems have evolved in Gram-negative 
bacteria to facilitate protein secretion (Holland, 2010). One step or two step 
mechanisms are used to secrete proteins to the exterior of the cell (Figure 1.2; Holland, 
2010). Six secretion systems have been identified in Gram-negative bacteria (referred to 
as T1SS-T6SS), comprising of 3 to more than 20 subunits. The sixth secretion system is 
the subject of the studies presented in this thesis. All of the secretion systems have a 
different composition and arrangement of structural components, therefore utilising 
distinct mechanisms (Gerlach and Hensel, 2007; Holland, 2010). 
The different secretion systems can broadly be divided into two categories; those 
independent of the general secretory pathway (Sec) and twin-arginine translocation 
(Tat) pathway, and those that utilise the Sec or Tat pathway (Figure 1.2; Gerlach and 
Hensel, 2007). The T1SS secretes proteins directly from the cytoplasm to the exterior of 
the cell in a single step, with typical substrates being high-molecular weight toxins such 
as HlyA (Holland et al., 2005, Thanabalu et al., 1998). Substrates of the T2SS are 
targeted to the Sec or Tat pathway via a signal peptide sequence in order to traverse the 
inner membrane. Fully folded protein is then secreted across the periplasm and outer 
Figure 1.1 The cell wall of bacteria.  
The Gram-positive bacterial cell wall (A) has a single membrane present, with a large peptidoglycan layer 
providing rigidity and structural strength. The Gram-negative bacterial cell wall (B) has a second 
membrane present, sandwiching the comparatively smaller peptidoglycan layer. Note that porins and 
membrane embedded proteins are excluded for clarity. Lipid A is shown in orange. 
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membrane to the extracellular environment using the T2SS (Johnson et al., 2006). The 
T3SS forms both a membrane and periplasm-spanning complex, with an external needle 
like structure protruding from the cell surface. This system secretes bacterial virulence 
factors directly into host cells (Mueller et al., 2008). The T4SS exports both proteins 
and single-stranded DNA (ssDNA) in a manner similar to bacterial conjugation 
(Fronzes et al., 2009; Kostakioti et al., 2005). The T5SS, which includes the 
autotransporter system and two partner secretion pathways, transports substrates in two 
steps, utilising the Sec pathway initially. Once in the periplasm, proteins insert 
themselves into the outer membrane via their C-terminal domain, promoting 
translocation of the N-terminal domain across the outer membrane (Henderson et al., 
2004). 
 
 
 
 
 
Figure 1.2 Secretion systems.  
Secretion systems are macromolecular complexes consisting of several subunits varying from a simple 
membrane-spanning channel (T1SS) to more complex systems that act as molecular syringes (T4SS). 
Figure adapted from (Desvaux et al., 2009). 
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1.2 The type VI secretion system 
The type VI secretion system (T6SS) is the most recently identified of the Gram-
negative secretion systems and the least characterised. First identified in 2006 by its role 
in preventing predation of Vibrio cholerae by amoebae (Pukatzki et al., 2006), the T6SS 
is now recognised to be involved in a number of bacterial phenotypes (Jani and Cotter, 
2010). These include quorum sensing in Vibrio anguillarum (Weber et al., 2009), 
virulence of Burkholderia pseudomallei towards mice (Chen et al., 2011), biofilm 
formation by enteroaggregative Escherichia coli (EAEC) (Aschtgen et al., 2008), and 
antibacterial activity of Pseudomonas aeruginosa and Serratia marcescens (Murdoch et 
al., 2011; Russell et al., 2011). The gene cluster encoding a T6SS is found in the 
genome of approximately 25 % of Gram-negative bacteria (Bingle et al., 2008). 
Typically these clusters contain more than 20 genes, with the composition and 
organisation of these genes varying between bacterial species. Several species have a 
number of gene clusters corresponding to multiple T6SSs (Bingle et al., 2008; Boyer et 
al., 2009). For example, the genome of P. aeruginosa has three T6SS clusters (HSI-1 – 
HSI-3; Mougous et al., 2006) that are thought to have been acquired by horizontal gene 
transfer (Bingle et al., 2008). These clusters are not co-regulated, suggesting they each 
carry out different functions (Bingle et al., 2008). While the HSI-1 T6SS is known to 
secrete bacteriolytic effector proteins for a competitive advantage (Russell et al., 2011), 
the HSI-2 T6SS is reported to be involved in interactions with eukaryotic cells (Sana et. 
al., 2012). It is currently unclear what the function of the HSI-3 T6SS cluster is. 
Approximately 13 conserved genes have been identified as the minimum 
required for a functional T6SS, representing the core components of the secretion 
apparatus (Table 1.1; Boyer et al., 2009). Although the function of many of these 
components has yet to be determined, the genes have been validated as essential in 
several bacteria (Zheng et al., 2011; Zheng and Leung, 2007). In an attempt to unify the 
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nomenclature of these conserved genes, they have been named Tss (type six secretion) 
A – M (Table 1.1), while auxiliary components of the T6SS are designated Tag (Tss 
associated genes; Shalom et al., 2007). The common name of characterised 
components, where appropriate, will be used herein. 
 
Table 1.1 Nomenclature of T6SS components. 
Unified 
name 
Common 
name 
Information Homologue Associated 
reference 
TssA  Putative cytosolic protein   
TssB VipA Bacteriophage 
sheath 
(Bönemann et al., 
2009) 
TssC VipB 
Forms a large cogwheel 
like tube surrounding 
Hcp   
TssD Hcp Forms hexameric rings, 
putative pilus, always 
present in extracellular 
media 
Bacteriophage 
tube gp19 
(Bingle et al., 2008; 
Mougous et al., 
2006) 
TssE  Putative soluble protein   
TssF  Putative soluble protein   
TssG  Putative soluble protein   
TssH ClpV AAA+ ATPase required 
to disassemble the 
VipA/B complex 
Hsp100 (Pietrosiuk et al., 
2011) 
TssI VgrG Cell puncturing device Bacteriophage 
spike 
gp27/gp5 
(Leiman et al., 2009) 
TssJ SciN/Lip Outer membrane 
lipoprotein 
 (Felisberto-
Rodrigues et al., 
2011; Rao et al., 
2011) 
TssK  Putative cytosolic protein   
TssL IcmH Inner membrane protein T4bSS IcmH (Durand et al., 2012) 
TssM IcmF Inner membrane protein 
with ATPase activity 
T4bSS IcmF (Ma et al., 2012) 
 
 Many of the core components of the T6SS can be divided into two groups. The 
first is components that share structural similarities to bacteriophage tail tube, sheath or 
spike proteins (Leiman et al., 2009; Pukatzki et al., 2007). These proteins are thought to 
form a sub-assembly that resembles an inverted bacteriophage, forming the injection 
apparatus of the T6SS (Figure 1.3; Basler et al., 2012; Bönemann et al., 2010; 
Cascales, 2008). The second group is components that are embedded, or associated, 
with the inner or outer membrane. These proteins form a membrane-spanning sub-
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assembly that is thought to anchor the bacteriophage-like injection apparatus to the 
bacterial cell envelope (Aschtgen et al., 2010b; Durand et al., 2012; Felisberto-
Rodrigues et al., 2011). 
 
 
1.2.1 Assembly and function: the bacteriophage-like injection apparatus 
A hallmark of the T6SS is the presence of the protein hemolysin co-regulated protein 
(Hcp) in culture supernatant (Bingle et al., 2008; Cascales, 2008). Hcp is a conserved 
and essential component of the T6SS and is used as an indicator of a fully functional 
system (Zheng and Leung, 2007). The presence of Hcp is mutually dependent upon the 
protein valine glycine repeat protein G (VgrG); deletion of either Hcp or VgrG results 
in the absence of the other protein in culture supernatant (Pukatzki et al., 2007; Zheng 
and Leung, 2007). 
 The crystal structure of Hcp reveals six molecules assembled to form a 
hexameric ring approximately 80 Å wide with an internal diameter of approximately 40 
Figure 1.3 Comparison with bacteriophage. 
A) Schematic representation of the T4 bacteriophage tail components and their arrangement. B) The 
proposed model of the T6SS. Equivalent components are coloured the same. Figure edited from 
(Records, 2011). 
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Å, large enough to accommodate a small folded or unfolded protein (PDB 1Y12; 
Figure 1.4A, Mougous et al., 2006). Analysis of Hcp by electron microscopy reveals 
the Hcp hexamers assemble to form a tubular structure of approximately 100 nm in 
length (Figure 1.4A; Ballister et al., 2008). This nanotube spans the inner membrane, 
periplasm and outer membrane, possibly functioning as a conduit to translocate 
substrate from the cytosol to the extracellular milieu. The tertiary structure of Hcp 
displays structural similarity to that of bacteriophage tail tube protein (PDB 2K4Q; 
Leiman et al., 2009; Pell et al., 2009). 
The structure of the N-terminus of VgrG reveals a trimer (PDB 2P5Z; Figure 
1.4B), with sequence and structural comparisons indicating homology with 
bacteriophage tail spike proteins, in particular the proteins gp27 and gp5 (PDB 1K28; 
Figure 1.4C, Kanamaru et al., 1994; Leiman et al., 2009; Pukatzki et al., 2007). This 
has led to the suggestion that the T6SS functions similar to an inverted bacteriophage 
(Figure 1.3), with VgrG functioning as a cell-puncturing device located on the tip of the 
Hcp nanotube (Figure 1.4D). The presence of Hcp and VgrG in culture supernatant 
may therefore be a result of the Hcp nanotube extending and pushing VgrG out of the 
cell to the external environment, allowing VgrG to puncture target cells. As VgrG lacks 
an internal channel, the delivery of substrate would be achieved following disassembly 
of VgrG from the Hcp nanotube.  
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1.2.2 Assembly and function: the membrane complex 
Three conserved proteins in the T6SS are membrane-bound and form a large trans-
membrane complex, anchoring the bacteriophage-like injection apparatus to the cell 
envelop (Aschtgen et al., 2010b; Cascales and Cambillau, 2012; Durand et al., 2012). 
 The proteins IcmH and IcmF are localised to the inner membrane and have 
similarities to components within the T4SS (Bingle et al., 2008; Durand et al., 2012). 
IcmH is inserted into the inner membrane via a single transmembrane helix at the C-
terminus (Aschtgen et al., 2011). In most cases, this protein has a C-terminal 
Figure 1.4 The T6SS injection apparatus. 
A) The structure of Hcp forms a hexameric ring (PDB 1Y12; Mougous et al., 2006). These rings are able 
to assemble into long nanotubes that span the inner and outer membranes (Ballister et al., 2008). B) The 
structure of VgrG forms a trimer (PDB 2P5Z; Leiman et al., 2009) with similarities to the bacteriophage 
tail spike proteins gp27 and gp5 (PDB 1K28; C, Kanamaru et al., 1994). D) The Hcp nanotube harbouring 
VgrG on the tip to form a cell-puncturing device. 
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periplasmic domain that encompasses a peptidoglycan-binding motif. Instances where 
this periplasmic domain is absent, an auxiliary protein, TagL, compensates by 
possessing this binding motif and interacting with IcmH (Aschtgen et al., 2010a; 
Aschtgen et al., 2010b). A major portion of IcmH is located in the cytoplasm (Van 
Rheenen et al., 2004) and the crystal structure of this domain has recently been solved 
(PDB 3U66; Figure 1.5A, Durand et al., 2012). IcmH has eight α-helices comprising 
two three-helix bundles that are connected via two short α-helices. The function of this 
domain is unclear, it is possible this domain may act to aid in the recruitment of 
substrates to the T6SS (Durand et al., 2012), however there is no evidence for this. 
 The protein IcmF has several cytoplasmic residues at the N-terminus, followed 
by two transmembrane helices separated by a short loop and a cytoplasmic domain of 
approximately 330 residues (Cascales and Cambillau, 2012). This domain has Walker A 
and B motifs and is involved in energising the T6SS, possibly with the ATPase ClpV 
(PDB 3ZRI; Figure 1.5B, Ma et al., 2012; Pietrosiuk et al., 2011). A third 
transmembrane helix follows the cytoplasmic domain and a large periplasmic domain of 
approximately 740 residues comprises the rest of the protein. IcmF has been shown to 
interact with IcmH via their respective cytoplasmic domains (Ma et al., 2009; Zheng 
and Leung, 2007). In addition, IcmF has recently been shown via surface plasmon 
resonance (SPR) to interact with Lip, a lipoprotein located at the outer membrane 
(Felisberto-Rodrigues et al., 2011). Therefore IcmF links both the inner and outer 
membranes, forming a large trans-membrane complex (Figure 1.5C).  
 Our understanding of how T6SSs function has improved recently and has led to 
a proposed mechanism (Basler et al., 2012). It is thought that the conserved proteins 
VipA/VipB (Table 1.1, Figure 1.3) are homologous to the bacteriophage tail sheath 
protein gp18 (Aksyuk et al., 2009; Basler et al., 2012; Bönemann et al., 2010; Leiman 
et al., 2009). VipA/VipB polymerise to form a tubule with an inner diameter of 
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approximately 100 Å, large enough to encompass the nanotube of Hcp (approximately 
80 Å; Bönemann et al., 2009; Mougous et al., 2006). In bacteriophage, the tail sheath 
protein contracts to provide the energy required to push the tail spike through the outer 
membrane of target cells (Figure 1.3; Aksyuk et al., 2009). Similarly, the proteins 
VipA/VipB are able to assemble and contract to energise the expulsion of the Hcp 
nanotube harbouring VgrG, allowing the injection of substrates into target cells (Basler 
et al., 2012). This contractile bacteriophage tail-like structure has been shown to extend 
to the approximate length of the cell, before contraction to about 50 % of the extended 
length (Basler et al., 2012). The VipA/VipB sheath is then disassembled by ClpV 
(Figure 1.5B) via an ATP-dependent remodelling process (Bönemann et al., 2009; 
Pietrosiuk et al., 2011). ClpV, a member of the Hsp100/Clp family of AAA+ (ATPases 
associated with various cellular activities) proteins, forms a hexameric ring through 
which the VipA/VipB complex is threaded through and dissassembled upon ATP 
hydrolysis (Bönemann et al., 2009). The N-terminual domain of ClpV confers substrate 
specificity and mediates the binding with VipA/VipB subunits (Pietrosiuk et al., 2011).  
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1.3 S. marcescens Db10 T6SS 
A functional T6SS has been identified in S. marcescens strain Db10 (Figure 1.6), where 
this system is constitutively expressed (Murdoch et al., 2011). This system exhibits 
antibacterial activity against several bacterial species, including E. coli, Enterobacter 
cloacae and P. fluorescens (Murdoch et al., 2011). Significantly, this system is able to 
target and kill S. marcescens ATCC 274, a closely related strain with a similar T6SS 
Figure 1.5 The T6SS. 
A) The structure of the N-terminal cytoplasmic domain of IcmH (PDB 3U66; Durand et al., 2012). B) 
The N-terminal domain of the AAA+ ATPase ClpV. This domain is responsible for substrate specificity 
(PDB 3ZRI; Pietrosiuk et al., 2011). C) A schematic overview of the T6SS showing the postulated 
arrangement and interactions of several conserved components. Figure adapted from (Bönemann et al., 
2010; Cascales and Cambillau, 2012).  
  
Chapter 1 – Introduction: The type VI secretion system 
14 
(Murdoch et al., 2011). This suggests the Db10 strain secretes effector proteins to which 
the ATCC 274 strain lacks resistance against. Self-resistance proteins must therefore be 
present in the Db10 strain, allowing the bacteria to survive and out-compete other 
bacteria. This would be similar to the antibacterial P. aeruginosa HSI-1 T6SS, where 
the immunity proteins Tsi1-3 (Type VI secretion immunity) negate the effects of the 
secreted toxins Tse1-3 (Type VI secretion exported; Hood et al., 2010; Russell et al., 
2011). These proteins are restricted to P. aeruginosa, allowing the targeting and killing 
of closely related species to give a competitive advantage (Russell et al., 2011). 
Potential candidates for similar proteins in the T6SS of S. marcescens have been 
identified (Figure 1.6; Murdoch et al., 2011). 
 
 
 
1.3.1 Secreted toxins and self-resistance proteins 
A number of genes with previously unknown function have been identified in the 
middle of the T6SS operon in S. marcescens (Figure 1.6; Murdoch et al., 2011). These 
genes (SMA2260 – 2262 and SMA2264 – 2266; Figure 1.7) encode small proteins with 
homologues in several other T6SSs, including those of Cronobacter sakazakii and E. 
cloacae (Murdoch et al., 2011). These small proteins exhibit low sequence identity to 
Figure 1.6 Schematic representation of the T6SS genes in S. marcescens. 
Genes are colour coded and labelled (top) according to the gene name (SMA2243 – SMA2281) and 
letters using the Tss unified nomenclature (Boyer et al., 2009). A key (bottom) shows the colour, Tss 
unified name and the common name of conserved components of the T6SS. Potential candidates for 
secreted effector / self-resistance proteins are boxed. Figure edited from (Murdoch et al., 2011). 
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one another, yet they can be classified into two distinct groups based on their isoelectic 
point (pI), secondary structure prediction and the presence of a signal peptide sequence 
(Figure 1.7).  
The basic proteins, Sm2261 and Sm2264, are predicted to be mainly helical with 
several strands and lack a signal peptide sequence. These proteins represent secreted 
toxins (English et al., 2012) and have been termed Ssp1 and Ssp2 (Small secreted 
protein; Figure 1.7) respectively. These toxins contribute to the antibacterial activity 
associated with this secretion system (English et al., 2012; Murdoch et al., 2011) and 
are analogous to the Tse1 and Tse3 toxins in the P. aeruginosa HSI-1 T6SS (Hood et 
al., 2010; Russell et al., 2011). Tse1 and Tse3 are peptidoglycan hydrolases delivered to 
the periplasm of a target cell (Russell et al., 2011). Ssp1 and Ssp2 exhibit no sequence 
similarity to other peptidoglycan hydrolases, yet both have been shown to be 
periplasmic-acting toxins with distinct functions (English et al., 2012).  
The remaining four acidic proteins (Sm2260, Sm2262, Sm2265 and Sm2266) 
represent cognate self-resistance proteins (English et al., 2012), providing protection 
against Ssp1 and Ssp2. These helical rich proteins have therefore been termed Rap 
(Resistance associated protein; Figure 1.7) and are located to the periplasm in order to 
bind and prevent the periplasmic Ssp proteins from harming the producing bacteria 
(English et al., 2012). This interaction between Ssp and Rap proteins has been shown to 
be in the nanomolar range and displays high specificity, with Ssp1 and Ssp2 interacting 
with Rap1a and Rap2a respectively (English et al., 2012). The function of the remaining 
Rap proteins, Rap1b and Rap2b, is thought to provide protection to either unidentified 
additional toxins, or against bacteria secreting similar toxins (English et al., 2012). 
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1.3.2 Serratia marcescens  
S. marcescens is a Gram-negative pathogen first described in the early 19th century due 
to its characteristic red pigment (Bizio, 1823). The bacterium targets 
immunocompromised individuals, causing a broad range of diseases including urinary 
tract infections (UTIs), pneumonia and meningitis (Hejazi and Falkiner, 1997). 
Infections are difficult to treat as S. marcescens is naturally resistant to most β-lactam 
antibiotics (Ball et al., 1977; Mahlen, 2011; Sleigh, 1983; Wheat et al., 1951). A survey 
carried out in 2008 revealed the Serratia species represents 2.0 % of all hospital-
acquired bloodstream infections and 2.8 % of all instances of hospital-acquired 
pneumonia in Europe (European Centre for Disease Prevention and Control; Sprenger, 
2010). With S. marcescens recognised as the most common Serratia species isolated 
from human infections (Laupland et al., 2008), this pathogen is a significant cause of 
hospital-acquired infections (Hejazi and Falkiner, 1997). It is also a tractable model 
Figure 1.7 Schematic representation of the genes encoding several small proteins. 
These small proteins are analogous to the Tse secreted toxins and Tsi resistance proteins in the HSI-1 
T6SS of P. aeruginosa (Hood et al., 2010; Russell et al., 2011). Figure adapted from (English et al., 
2012).   
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organism to study the structure-function relationships in the T6SS (Murdoch et al., 
2011).  
 
1.4 Aims 
Recent progress has been made in the structural and biochemical characterisation of the 
components of the T6SS (Basler et al., 2012; Cascales and Cambillau, 2012). This has 
resulted in the identification of two sub-assemblies, the first resembling the contractile 
tail of bacteriophage and the other a membrane spanning complex anchoring the first 
sub-assembly to the cell envelope. Individual deletion of several conserved components 
has demonstrated their involvement in forming a functioning T6SS (Zheng et al., 2011; 
Zheng and Leung, 2007). The interconnected and critical nature of these components for 
proper assembly of the T6SS makes them potential drug targets to explore further.  
 At the onset of the research carried out in this thesis, two crystal structures were 
available of T6SS components (Leiman et al., 2009; Mougous et al., 2006). The broad 
aim of this project was therefore to elucidate the structures of the other conserved 
components from the S. marcescens T6SS in the pursuit of understanding their function. 
In particular, the work described in chapter three was directed towards determining the 
structure of Lip (TssJ), an essential component of the T6SS in S. marcescens (Murdoch 
et al., 2011). The successful structure determination would allow us to infer its function 
through structural analysis and comparison with structures deposited in the Protein Data 
Bank (Berman et al., 2002). This would pave the way for further structural and 
biochemical studies to identify possible binding partners and obtain complexes, leading 
to the development of inhibitors that can potentially disrupt the assembly of a functional 
system (Felise et al., 2008; Shahian et al., 2009).  
In addition, a number of small proteins encoded on the T6SS operon with 
previously unknown function were recognised (Murdoch et al., 2011). Their position 
  
Chapter 1 – Introduction: The type VI secretion system 
18 
amongst conserved T6SS components suggested they were associated with this system 
in some way and may represent potential substrates for the S. marcescens T6SS 
(Murdoch et al., 2011). Structures of these proteins could not be modelled using the 
PHYRE protein fold recognition server (Kelley and Sternberg, 2009). Therefore the aim 
of this project was to gain further understanding of these proteins and their potential 
role within the secretion system. By determining the crystal structures of these proteins, 
comparisons with the recently characterised substrates in other bacterial species (Li et 
al., 2012; Zou et al., 2012) would be made. This is the focus of the research described 
in chapter four on the protein Rap1b.  
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2.1 General materials 
2.1.1 Reagents 
 All chemicals were of analytical grade and purchased from Sigma-Aldrich, BDH 
Chemicals, Merck or Fluka.  
Tobacco-Etch Virus (TEV) was made in-house by Kerri Barrack (University of 
Dundee) and provided ready to use at a concentration of 3 mg mL-1. All restriction 
enzymes were purchased from New England Biosciences (NEB). NuPAGE 10 % Bis-
Tris precast gels, MES SDS Running Buffer (20x) and SeeBlue Plus2 Prestained 
Standard (1x) were purchased from Invitrogen. InstantBlue gel stain was purchased 
from Expedeon.  
 
2.1.2 Bacteria 
S. marcescens strain Db10 genomic DNA was provided by Dr. Sarah J. Coulthurst 
(University of Dundee). Genomic sequence data were obtained from the Sanger 
Institute (www.sanger.ac.uk). The following cells were purchased from the respective 
companies; TOP 10 competent cells (Invitrogen), XL1 blue sub-cloning cells and E. 
coli BL21 (DE3) pLysS cells (Stratagene), E. coli BL21 (DE3) Rosetta-gami and E. coli 
BL21 (DE3) Gold cells (Novagen). 
 
2.1.3 Growth media 
Auto-induction (AI) media (Studier, 2005), lysogeny broth (LB) media (Bertani, 1951) 
and LB-agar plates were prepared, autoclaved and supplied by the media kitchen in the 
College of Life Sciences, University of Dundee. 
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2.2 General methods 
Standard molecular biology techniques were used, details of which can be obtained 
from Molecular Cloning: A laboratory manual (Maniatis, 1983). 
 
2.2.1 Cloning 
Polymerase chain reaction (PCR) was carried out to amplify the gene of interest from 
genomic DNA. This involves repeated heating/cooling cycles and enzymatic DNA 
replication using a heat stable DNA polymerase.  
A fragment of the gene encoding SmLip from S. marcescens was cloned using 
Pfu DNA polymerase (Promega) with PCR cycling parameters given in Table 2.1. 
 
Table 2.1 SmLip PCR parameters 
Order of addition Reagent Volume added PCR cycling 
conditions 
1 Sterile MiliQ water 31.25 µL 95°C for 45 sec 
then 
2 Pfu buffer 10x 5 µL 95°C  for 45 sec 
3 DNTPs 2 mM 5 µL 59°C for 45 sec 
4 DMSO 100 % 2.5 µL 72°C for 50 sec 
then 
5 Primers 10 pmole/µL 2.5 µL (F & R) 72°C for 10 mins 
6 Pfu polymerase 1 unit/µL 1 µL  
7 gDNA (200 ng) 0.25 µL  
Total  50 µL 36 cycles 
 
The gene of interest was digested out of either the PCR-BluntII-TOPO vector 
(Invitrogen) or pUC57 vector, using the appropriate restriction enzymes, before ligation 
into a pET15b (Novagen) cloning vector (Figure 2.1). This vector has been modified to 
encode a TEV cleavage site in place of the thrombin protease cleavage site (Figure 
2.1). Constructs were verified by DNA sequencing (DNA Sequencing Unit, University 
of Dundee). Plasmids were transformed into appropriate E. coli expression systems and 
the gene was expressed. 
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BglII               T7 forward primer    lac operator          XbaI                        rbs    
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA 
 
 
     NcoI              His-Tag                                     NdeI  XhoIBamHI   
TATACCATGGGCAGCAGCCATCATCATCATCATCACAGCAGCGGCGAAAACCTGTATTTTCAGGGCCATATGCTCGAGGATCCGGCTGCTAACAAAGCCCG
A 
MetGlySerSerHisHisHisHisHisHisSerSerGlyGluAsnLeuTyrPheGln*GlyHisMetLeuGluAspProAlaAlaAsnLysAlaA
rg       TEV protease site 
                                              
AAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
LysGluAlaGluLeuAlaAlaAlaThrAlaGluGlnEND 
                             T7term primer 
 
2.2.2 Recombinant protein production in E. coli 
A single colony of freshly transformed cells was used to inoculate 50 mL of LB media 
supplemented with carbenicillin and incubated, with aeration, at 37 °C overnight. From 
this starter culture, 10 mL was used to inoculate each litre of AI media with 
carbenicillin in a 2 litre flask. A detailed description of AI media is published (Studier, 
2005). In brief, cells use the glucose in the media as the primary source of energy before 
switching to metabolising lactose as a secondary energy source, requiring induction of 
the lac operon. This results in the transcription and over expression of our gene of 
Figure. 2.1 pET15b-TEV vector.  
The pET15b (Novagen) vector has been modified to include a TEV protease cleavage site, the * indicates 
the position where cleavage occurs. The multiple cloning sites are detailed.  
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interest. Inoculated cells were left incubating at 37 °C until an OD600 of 0.6 was 
reached. Cells were then grown overnight at 22 °C. 
Cells were harvested by transferring to 1 litre plastic flasks suitable for 
centrifugation, before centrifuging at 3,500 rcf (Beckman J6-MC with a JA6 rotor) for 
30 mins at 4 °C. The supernatant was removed and 25 mL of fresh media with 
carbenicillin was used to resuspend each cell pellet. The resuspension was transferred to 
50 mL falcon tubes and centrifuged at 3,500 rcf (Sigma 4K15 with a 373/E rotor) for 30 
mins at 4 °C. The supernatant was then discarded and the cell pellet was flash frozen in 
liquid nitrogen before storing at -20 °C. 
 
2.3 Protein purification 
2.3.1 Buffers 
Table 2.2 gives details of the different buffers used during the purification of each 
protein; 
 
Table 2.2 Buffers 
Name Buffer Used for the 
purification of: 
A 25 mM Tris-HCl, pH 7.5, 500 mM NaCl, 20 mM 
imidazole 
SmLip / BpPBP3 / 
PaPBP3 
B 25 mM Tris-HCl, pH 7.5, 500 mM NaCl, 500 
mM imidazole 
SmLip / PaIMPDH / 
BpPBP3 / PaPBP3 
C 25 mM Tris-HCl, pH 7.5, 250 mM NaCl SmLip / PaIMPDH / 
BpPBP3 / PaPBP3 
D 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM 
DTT, 25 mM imidazole 
Rap1b 
E 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM 
DTT, 500 mM imidazole 
Rap1b 
F 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM 
DTT 
Rap1b 
G 25 mM Tris-HCl, pH 8.5, 500 mM NaCl, 20 mM 
imidazole 
PaIMPDH 
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2.3.2 Cell lysis and purification 
The cell pellet was thawed using a 37 °C water bath and then resuspended with 7 mL of 
buffer (A, D or G; Table 2.2) supplemented with an EDTA-free protease inhibitor 
cocktail tablet (Roche) and 0.2 mg DNase I. The resuspended cells were then lysed 
using a One-Shot cell disruptor at a pressure of 30 kpsi before centrifugation at 37,500 
rcf (Beckman Avanti J-25 with JA25.50 rotor) for 30 mins at 4 °C. After centrifugation, 
the supernatant containing the soluble fraction was harvested and the pellet discarded. 
Affinity chromatography was used in the first step of purification. All over-
expressed proteins studied in this thesis have a hexa-histidine N-terminal tag introduced 
from the pET15b-TEV vector (Figure 2.1). This His-tag has high affinity for divalent 
metals, thus the cell lysate was loaded onto a 5 mL HisTrap™ HP column (GE 
Healthcare) pre-charged with Ni2+ and equilibrated in buffer (A, D or G; Table 2.2). A 
linear concentration gradient of imidazole was applied to out-compete and thus elute the 
protein from the column using buffer (B or E; Table 2.2). Fractions containing protein 
were confirmed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and were pooled together before dialysis into buffer (C or F; Table 2.2) at room 
temperature.   
Rap1b, BpPBP3, PaPBP3 and PaIMPDH were purified with their His-tag still 
present. However SmLip was further purified by cleavage of the His-tag. This was 
carried out by incubating the protein with His-tagged TEV at 30 °C for 4 hrs. This 
protease recognises the amino acid sequence Glu-Asn-Leu-Tyr-Phe-Gln-Gly with the 
cleavage occurring between the Gln and Gly residues (Figure 2.1). The resulting 
mixture of protein/TEV was loaded on to a HisTrap™ column, which bound the cleaved 
His-tag, the His-tagged TEV and any uncleaved protein. The protein, from which the 
His-tag had been cleaved, was present in the flow-through peak, and fractions were 
confirmed by SDS-PAGE before pooling of the protein.  
  
Chapter 2 – Materials and methods 
25 
2.3.3 Size exclusion chromatography 
Size exclusion chromatography was subsequently used to purify the protein further, 
separating proteins on the basis of their size; heavier proteins will pass through the 
column earlier than lighter proteins. Using a Superdex™ 200 26/60 column pre-
equilibrated with buffer (C or F; Table 2.2) on a ӒKTA system (GE Healthcare), the 
protein was collected into fractions and confirmed pure by SDS-PAGE. The size 
exclusion column had previously been calibrated with molecular weight standards, blue 
dextran (> 2,000 kDa), thyroglobulin (669 kDa), ferritin (440 kDa), aldolase (158 kDa), 
conalbumin (75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29.5 kDa), 
ribonuclease A (13.7 kDa) and aprotinin (6.5 kDa); (GE Healthcare; data not shown).  
Each fraction containing protein was then pooled into an Amicon 20 mL 
concentrator with an appropriate Mw cut-off and centrifuged at 3,500 rcf (Sigma 4K15 
with a 373/E rotor).  
 
2.4 Protein crystallography 
2.4.1 Crystallisation of proteins 
The crystallisation of proteins is based on the principles of thermodynamic equilibrium; 
the release of energy to achieve the minimal free energy state the system can reach 
(Rupp, 2010). This is the driving force of crystal growth. Protein molecules in a 
supersaturated solution, which is thermodynamically unstable, arrange themselves into 
an ordered lattice. This forms a crystalline aggregate and achieves a lower free energy 
state, which therefore brings about thermodynamic equilibrium in the system.  
 
2.4.2 Crystallisation techniques 
Two crystallisation methods were used in the studies presented in this thesis, the 
hanging drop method and the sitting drop method. Both methods use vapour diffusion 
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within a sealed environment to bring about crystallisation. This is achieved by placing a 
small mix of protein-precipitant alongside a reservoir of precipitant in a sealed 
environment. Due to the lower concentration of precipitant in the protein-precipitant 
mix, vapour diffusion occurs causing the net transfer of water to the reservoir until 
equilibrium is reached. The protein within the protein-precipitant mix becomes 
supersaturated and as a consequence, the protein is then forced out of solution and may 
form protein crystals.  
The hanging drop method uses a small drop of protein, 0.5 µL - 2 µL, mixed 
with an equal volume of precipitant placed carefully on to a siliconised cover slip. The 
cover slip is then inverted and placed on top of a chamber containing 500 µL – 1 mL of 
precipitant. The edge of the well contains paraffin grease, which ensures the cover slip 
is secured and that the well is sealed from the external environment. This technique was 
used to optimise crystals.  
The sitting drop method, as mentioned, uses vapour diffusion to achieve 
crystallisation of proteins. This technique uses a small drop of protein, 0.1 µL – 0.5 µL, 
mixed with an equal volume of precipitant. This drop is placed on a platform situated 
next to the reservoir containing 60 µL – 100 µL of precipitant. The well chamber is 
sealed from the external environment by an adhesive seal to allow vapour diffusion to 
take place. This technique was carried out in 96-well plates and is highly suited to 
screening a high number of crystallisation conditions using small volumes of protein. A 
Phoenix Liquid Handling System (Rigaku, Art Robins Instruments) was used to 
dispense the small volumes required for this technique. 
 
2.4.3 Sparse matrix screening 
To determine crystallisation conditions, a sparse matrix screen is performed which uses 
a large number of different conditions that have previously been used to crystallise other 
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proteins (Jancarik, 1991). The Classic, PEG, MPD and AmSO4 suites (Qiagen) and the 
JCSG+ and PGA suites (Molecular Dimensions) were used, each containing 96 unique 
conditions. These conditions vary pH over a broad range (pH 4.0 – pH 10.5) and 
contain different salts and/or precipitants. 
 
2.5 Crystal structure determination 
2.5.1 The phase problem 
Details on the theory and the phasing techniques outlined in this section can be obtained 
from Principles of X-ray Crystallography (Drenth and Mesters, 2006) and Biomolecular 
Crystallography (Rupp, 2010). 
Briefly, in order to obtain the three-dimensional crystal structure of a protein, 
three parameters are required that define an electromagnetic wave; the wavelength (λ), 
the amplitude (A) and the phase (φ) (Taylor, 2010). The first two parameters are 
obtained from the diffraction experiment, however in doing such an experiment, all 
information about the phase is lost. Phase information of scattered X-rays cannot be 
directly measured. There are three principle methods of determining the phase for a new 
protein structure; multiple isomorphous replacement (MIR), multi/single-wavelength 
anomalous dispersion (M/SAD) and molecular replacement. During this study, SAD 
and molecular replacement phasing methods were used, and so the method of MIR will 
not be discussed further. 
 
2.5.2 Patterson maps 
A Patterson map can be constructed without any prior knowledge of phases and can be 
computed from any raw crystallographic data. This type of map contains interatomic 
distance information and is based on the Patterson function described as 
€ 
P(u,v,w) = 1V hkl
∑ |Fhkl |2 e−2πi(hu+kv+ lw ) 
  
Chapter 2 – Materials and methods 
28 
The coordinates u, v and w locate a point in a Patterson map, as opposed to x, y and z 
that define a point within the unit cell. A contour map is produced that displays peaks 
for all interatomic distances, with the height of each peak a product of the 
corresponding electron density peak height. Patterson maps therefore can be used to 
solve the phase problem outlined in section 2.5.1 by locating heavy atoms in the unit 
cell of the protein, or by determining the orientation and translation of the search model 
during molecular replacement.   
 
2.5.3 Single-wavelength anomalous dispersion (SAD) 
Single-wavelength anomalous dispersion (SAD) is a method of obtaining phases based 
on the ability of elements to absorb X-rays and re-emit them with altered phases in a 
wavelength dependent manner (Taylor, 2010). This is called anomalous scattering or 
anomalous dispersion. The absorption of X-rays by heavy atoms invalidates Friedels 
law, meaning the reflections hkl are no longer equal in intensity to -h-k-l. This 
difference in symmetry-related reflections happens at all wavelengths, however it is 
more pronounced at the absorption edge of the heavy atom (Taylor, 2010).  
 This experimental phasing method was used to solve the structures of SmLip and 
Rap1b. Phases for SmLip were obtained using the iodides present in the crystallisation 
condition as a source of anomalous scattering. A quick halide soak (Dauter et al., 2000) 
with a high concentration of aqueous sodium iodide was used to obtained phases for 
Rap1b. Furthermore, several well-ordered sulfur atoms also provided a source of 
anomalous scattering. Anomalous scattering positions were identified using PHENIX 
(Adams et al., 2010) by Patterson methods as described in section 2.5.2 and phases 
were calculated using PHASER (McCoy et al., 2007). Model building was carried out 
using RESOLVE (Terwilliger, 2003).  
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2.5.4 Molecular replacement 
Molecular replacement is a method of determining the crystal structure of a protein 
utilising another protein structure that has previously been solved (Rossmann and Blow, 
1962). A protein with homologous amino acid sequence (and thus with similar fold), or 
containing functionally similar domains, can be used as a starting point to obtain new 
phases for a new structure. This typically requires more than approximately 25 % 
homology to succeed. The atomic structure factor phases depend on the location of the 
atoms in the unit cell, therefore the structure of the search model must be superimposed 
on to the target model before initial phases can be calculated. This process is separated 
into first finding the correct orientation and then the correct position for the search 
model.   
The search for the correct orientation (rotation search) is achieved by calculating 
Patterson functions for both the search and target models. The Patterson function Pcalc 
for the rotated search model is compared to the Patterson function Pobs of the target 
model through all possible rotations. The orientation is determined by the match of 
intramolecular Patterson vectors. If both models are in the same orientation, overlap of 
the Patterson maps will occur and summation of peaks will be produced. The search for 
the correct position (translation search) of the search model can be determined by 
matching intermolecular Patterson vectors, similar to the rotation search. Alternatively, 
comparing the expected structure factor amplitudes of the target model with the actual 
amplitudes from the diffraction data collected, can determine the correct position of the 
target. This is expressed as the R-factor and is carried out at all trial locations. The 
solution with the lowest R-factor is selected and initial electron density maps calculated. 
The resulting solution and maps are then inspected. This method of phasing was used 
for PaIMPDH using the program PHASER (McCoy et al., 2007).  
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2.6 General software 
PyMOL  (www.pymol.org; Schrodinger, 2010) was used to create molecular structure 
figures in all instances. Sequence alignments were created using T-coffee (Di Tommaso 
et al., 2011) in the M-coffee mode (www.tcoffee.crg.cat) and were annotated using 
ALINE (Bond and Schüttelkopf, 2009). The software package Adobe Creative Suite 5 
was used to edit, annotate and arrange figures accordingly. 
 
2.7 Fragment screening 
2.7.1 Reagents 
Biotin-ligase (BirA) was made in-house by Martin Zoltner (University of Dundee) and 
provided ready to use at a concentration of 5 mg mL-1. The following were purchased 
from the respective companies; biocytin (Sigma-Aldrich), 96-well and 384-well black 
plates (Matrix), “super” streptavidin biosensors (Fortebio), 96-well PCR plates (Thermo 
Scientific), adhesive PCR plate seals (4titude Ltd) and SYPRO Orange dye (Invitrogen). 
The Maybridge Ro3 fragment library (Maybridge) was dissolved and stored in 
100 % DMSO at a stock concentration of 40 mM.  In addition, the Drug Discovery Unit 
(DDU, University of Dundee) fragment library, comprising 652 commercially available 
fragments, was dissolved and stored in 100 % DMSO at a stock concentration of 100 
mM. 
 
2.7.2 Biotinylation 
PaIMPDH and BpPBP3 were cloned into a pET15b-TEV vector (see section 2.2.1) 
modified to include an N-terminal biotin acceptor peptide (BAP). Both proteins were 
expressed and purified as described in sections 2.2.2 and 2.3 respectively. Subsequently, 
20 µM protein underwent biotinylation (10 mM Tris-HCl pH7.5, 200 mM KCl, 5 mM 
MgCl2, 100 µM d-biotin, 500 µM ATP and 1 µM BirA) for 4 hrs at 30 °C. 
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 The sample was then loaded onto a 5 mL HisTrap™ HP column (GE 
Healthcare) to remove His-tagged BirA. Free biotin was removed by size exclusion 
chromatography (see section 2.3.3) and the incorporation of biotin onto the protein was 
monitored by MALDI-TOF analysis (Proteomics Facility, University of Dundee). The 
protein was subsequently flash frozen in liquid nitrogen with the addition of 1 % 
glycerol and stored at -20 °C until required. 
 
2.7.3 Differential scanning fluorimetry (DSF) 
The stability of most proteins decreases with temperature; as the temperature increases, 
the protein begins to unfold and denature. The temperature at which the concentration 
of folded/unfolded protein is equal to one another is considered the melting temperature 
(Tm) of the protein. Differential scanning fluorimetry (DSF), or thermal-shift assay, 
utilises the fluorescent dye SYPRO orange in order to determine the Tm of a protein. 
This dye has affinity for hydrophobic residues, which become exposed upon protein 
denaturing and results in a change in fluorescence (Figure 2.2; Neisen et al., 2007; 
Pantoliano et al., 2001). 
 
 
Figure 2.2 Melting curves of PaPBP3. 
The mid-point of the melting curve is considered the Tm value. The blue curve is PaPBP3 and the 
red curve is PaPBP3 in complex with cerbenicillin (Sainsbury et al., 2011). 
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This method can be used as a convenient way of determining whether a protein 
is folded or not. In addition, stabilising conditions can be determined in order to 
improve purification and crystallisation of a protein. This is achieved by comparing the 
Tm values for the protein in the absence and presence of the stabilising condition, with a 
positive difference (ΔTm) an indication that the protein is more stable. Furthermore, 
potential cofactors, compounds or fragments can be screened for a protein using the 
same principle, with a positive ΔTm suggesting potential binding with the protein. A 
negative ΔTm may also indicate potential binding, however this is likely to be 
unspecific. 
Fragment screening with the Maybridge Ro3 library was carried out with 
PaIMPDH, BpPBP3 and PaPBP3. Solutions of protein at 10 µM with 1000x SYPRO 
orange were made and 39 µL dispensed into a 96-well thin-wall PCR plate prior to 
adding 1 µL of fragment to each well. The plates were then sealed with adhesive PCR 
seal and heated in an Mx3005p qPCR machine (Stratagene) from 25 °C to 95 °C at a 
rate of 1 °C min-1. Fluorescence changes were monitored with excitation and emission 
wavelengths of 492 nm and 610 nm respectively. The change in fluorescence was 
plotted against temperature, producing a melting curve for the protein (Niesen et al., 
2007). Reference wells (i.e. wells consisting only of protein and dye) were used to 
compare Tm values. In order to rule out any effects caused by the presence of the buffer 
the protein is stored in, wells with buffer and dye were used as controls. Experiments 
were carried out in triplicate and nonlinear regression analysis was determined using the 
curve-fitting program Prism (GraphPad Software). A Microsoft Excel script was used 
for convenient observations and comparison of melting curves and thermal shifts 
(ftp://ftp.sgc.ox.ac.uk/pub/biophysics). The fragments were screened at a final 
concentration of 1 mM. 
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2.7.4 Surface plasmon resonance (SPR) 
Surface plasmon resonance (SPR) is an optical analytical technique used to detect and 
characterise biomolecular interactions (Hoa et al., 2007). When monochromatic 
polarised light is applied to the gold surface of a sensor chip, the intensity of the 
reflected light is reduced at a specific angle called the SPR angle. This angle depends on 
the refractive index at the surface of the sensor chip (Figure 2.3A). Immobilised protein 
(the ligand) on the surface of the sensor chip interacts with binding partners (the 
analyte) and an increase in the refractive index occurs, resulting in an altered SPR angle 
(Figure 2.3B). The change in the SPR angle is monitored by the reduced intensity of the 
reflected light and is measured in real time. The result is plotted as resonance units (RU) 
against time. The sensitivity of this technique is highly suited for studying the 
interaction between proteins and weak binding fragments (Hoa et al., 2007). 
 Biotinylated BpPBP3 was immobilised onto a streptavidin sensor (GE 
Healthcare) and screened against the DDU fragment library by Dr. Leah Torrie 
(University of Dundee). The final concentration of fragments used during the screening 
was 150 µM. 
 
 
 
Figure 2.3 Principles of SPR. 
Polarised light is reflected from the surface 
of the sensor chip. The intensity of the 
reflected light is reduced at the SPR angle 
(A). The interaction between ligand and 
analyte results in a change in the refractive 
index causing a change in the SPR angle (B). 
This change is monitored in real time. Figure 
edited from (Madeira et al., 2009). 
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2.7.5 Bio-layer interferometry (BLI) 
Bio-layer interferometry (BLI) is a label free optical analytical technique used to 
analyse biomolecular interactions. This technique monitors in real time the interference 
pattern of white light reflected from two surfaces within a biosensor (Wartchow et al., 
2011). The first surface is an internal reference layer, while the second surface is a layer 
of immobilised protein (Figure 2.4A). As the immobilised protein on the biosensor tip 
binds to the analyte in solution (Figure 2.4B), an increase in optical density occurs 
resulting in a shift in wavelengths (Figure 2.4C).  
 BLI was used to screen biotinylated PaIMPDH and BpPBP3 against the DDU 
fragment library, using streptavidin biosensors to immobilise protein at 25 µg mL-1 for 
10 mins. Biocytin at 10 µg mL-1 was then used to block any remaining free streptavidin 
binding sites for 60 sec prior to washing and equilibrating the biosensors in buffer for 5 
mins. The fragments were screened at a final concentration of 200 µM in 384-well 
format using an Octet Red system (Fortebio) in 16-channel mode. The temperature of 
the chamber was set to 25 °C. 
 
 
 
Figure 2.4 Bio-layer interferometry 
(BLI). 
Light is applied down a biosensor and an 
internal reference (A) is used to compare 
the wavelength of the light generated upon 
the binding of the analyte (B). This binding 
results in a shift in wavelengths (C) from 
the change in optical density at the 
biosensor surface. Figures obtained from 
www.fortebio.com.  
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2.8 Enzyme kinetics 
The enzymatic characterisation of PaIMPDH was determined spectrophotometrically 
using a Shimadzu UV-2450 to monitor the formation of NADH at 340 nm. This is 
based on the assay described previously for characterising human IMPDH (Carr et al., 
1993; Miller and Adamczyk, 1976). Assays for determining the Km and Vmax values of 
the substrate, inosine 5’-monophosphate (IMP), were performed at 30 °C in 100 mM 
Tris-HCl pH 8.0, 100 mM KCl, 3 mM EDTA, 1 µM PaIMPDH and between 500 µM 
and 25 mM IMP, with the concentration of NAD+ fixed at 5 mM. Conversely, assays for 
determining the Km and Vmax values of the cofactor NAD+ were performed between 10 
µM and 5 mM, with the IMP concentration fixed at 25 mM. Assays were carried out in 
triplicate in 1 ml volumes in 1 cm path-length acrylic cuvettes (Sarstedt). Reactions 
were initiated with the addition of IMP and the increase in absorbance of NADH 
monitored continuously for 5 mins. 
 The uncompetitive inhibitor mycophenolic acid (MPA; Allison and Eugui, 
2000) was dissolved in 100 % DMSO and the Ki value was calculated using 1 µM and 
10 µM MPA, with the concentrations of IMP being the same as was used to calculate 
the substrate Km. The concentration of NAD+ was fixed at 5 mM. Single point 
percentage inhibition was measured with the identified fragments. As a control, the 
additions of 0.1 %, 1 % and 10 % DMSO to enzyme reactions were compared to 
reactions in the absence of DMSO. The activity of the enzyme was comparable; 
therefore the final concentration of DMSO in experimental reactions were set to 1 % or 
less. Analyses of the kinetic data were carried out using the software Prism (GraphPad 
Software). 
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3.1 Aims 
The aim was to structurally characterise recombinant S. marcescens Lip (SmLip). A 
conserved component of the type VI secretion system (T6SS; Boyer et al., 2009), 
SmLip is an essential lipoprotein (Aschtgen et al., 2008; Murdoch et al., 2011), 
although its function within the T6SS is not fully understood. The crystal structure 
would allow us to compare with protein structures deposited in the PDB (Berman et al., 
2002) in order to infer its possible function within the T6SS. 
 
3.2 Construction of the pET15b-TEV-SmLip vector 
A truncated form of the S. marcescens lip gene encoding the amino acid residues 30 – 
176 was PCR amplified from genomic DNA (see section 2.2.1). Secondary structure 
prediction (XtalPred; Slabinski et al., 2007) and signal peptide prediction (SignalP; 
Petersen et al., 2011) were used as a guide for primer design and the following primers 
were used; forward primer 5’ – catatgGCCAAAAGCGTGCCGTCGCGTTACAG and 
reverse primer 5’ – ggatccTCAGTCGACCTTTTTTACGGGGCGCAGGC (lower case 
sequences correspond to the NdeI/BamHI restriction sites used for cloning). The PCR 
parameters are described in section 2.2.1. 
A single DNA band, corresponding to around 400 bp, was observed on a 1 % 
agarose gel (Figure 3.1A). The band was excised from the gel and DNA was extracted 
using a Qiagen Gel Extraction kit. The PCR product was ligated into the pCR-Blunt II 
TOPO® vector using the Zero Blunt® TOPO® Cloning Kit (Invitrogen). The SmLip 
gene was subsequently cut out of the pCR-Blunt II TOPO® vector using the 
NdeI/BamHI restriction enzymes (Figure 3.1B) at 37 °C for 1 hr. The SmLip insert was 
then ligated into the pET15b-TEV cloning vector using T4 DNA ligase (NEB).  
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3.3 Recombinant SmLip expression and purification 
The SmLip pET15b-TEV plasmid was transformed into E. coli Bl21 (DE3) pLysS cells 
(Stratagene). Cultures were grown in AI media (Studier, 2005) supplemented with 50 
µg L-1 carbenicillin as described in section 2.2.2.  
 Cell lysis was carried out as described in section 2.3.2. The supernantant 
containing soluble protein was harvested and loaded on to a 5 mL HisTrap™ HP 
column (GE Healthcare) pre-charged with Ni2+. A large peak at around 300 mM 
imidazole was obtained and appropriate fractions were pooled and incubated with His-
tagged TEV protease to remove the His-tag on SmLip. The resulting mixture was passed 
down a second 5 mL HisTrap™ HP column and the flow through fractions containing 
the cleaved protein were pooled (see section 2.3.2). The protein was loaded onto a 
calibrated size exclusion column (see section 2.3.3) where a single peak corresponding 
to a monomer was observed. Samples were taken for SDS-PAGE analysis (Figure 3.2) 
and appropriate fractions were pooled and concentrated to 10 mg mL-1, with a yield of 
2.5 mg L-1 of bacterial culture obtained. A theoretical extinction coefficient of 16960 M-
1 cm-1 at 280 nm, was used to estimate protein concentration (PROTPARAM; Gasteiger 
et al., 2005); the theoretical mass of one subunit is estimated as 16.1 kDa with a 
calculated isoelectric point (pI) of 5.4. The purified protein sample was stored at 4 °C 
until further use. 
 
Figure 3.1 Cloning of SmLip.  
A) The amplified PCR product is shown 
corresponding to approximately the correct 
size of the gene. B) SmLip (lower band) is 
cut out of the PCR-BluntII-TOPO® vector 
(top band). 
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3.4 Crystallisation and data processing 
Crystallisation screening with the Classic, PEG, MPD and AmSO4 suites (Qiagen) and 
the JCSG+, PGA (Molecular Dimensions) suites were set up initially with 10 mg mL-1 
of protein in 25 mM Tris-HCl pH 7.5 250 mM NaCl at 20 °C (see section 2.4.3). This 
was carried out using the sitting drop vapour diffusion method in 96-well plates using 
the Phoenix Liquid Handling System (Rigaku, Art Robins Instruments) (see section 
2.4.2). Multiple crystals grew in several crystallisation conditions after approximately 
two days (Figure 3.3A), however only two conditions produced diffraction quality 
crystals. The conditions were; 20 % polyethylene glycol (PEG) 3350, 200 mM KI and 
15 % PEG 3350, 200 mM NaCl (Figure 3.3B).  
 
Figure 3.2 Size exclusion 
chromatography.  
The absorbance (y-axis) at 280 nm 
(mAU) is plotted against eluted 
volume (ml) on the x-axis. A single 
absorbance peak after approximately 
190 ml eluted volume was observed, 
consistent with a retention volume 
for a protein of around 16 kDa. 4 ml 
fractions were collected.  
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 Crystals from the iodide containing condition were optimised (Figure 3.4A) and 
then characterised. Dataset I was measured in-house using a Rigaku MicroMax-007 
rotating-anode X-ray generator (copper Kα, λ=1.5418 Å) coupled to an R-AXIS IV++ 
image plate detector (Figure 3.4B). A single crystal from the chloride condition was 
stored in liquid N2 then subsequently used to measure a 1.92 Å high-resolution dataset 
(dataset II) at the European Synchrotron Radiation Facility (ESRF; Grenoble, France) 
on beam line ID29 using an ADSC Q315R detector. The addition of 10 % glycerol 
proved to be a suitable cryoprotectant for both conditions. Data were indexed and 
integrated using XDS (Kabsch, 2010), with space group C2 and unit cell lengths a= 
139.7 b= 77.8 Å and c= 54.5 Å (Table 3.1). Data were scaled and the space group 
Figure 3.3 Crystals of SmLip.  
A) Mulitple crystals of SmLip grew after approximately two days in several conditions B) Diffracting 
crystals in; 20 % polyethylene glycol (PEG) 3350 200 mM KI (left) and 15 % PEG 3350 200 mM NaCl 
(right). 
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suggested using SCALA and POINTLESS (Evans, 2006) from the CCP4 program suite 
(Winn et al., 2011).  
 
 
 
3.5 Structure determination of SmLip 
3.5.1 Phasing 
A search of the PDB using the amino acid sequence of SmLip indicated no similarity to 
any structures deposited. Dataset I was used to solve the structure of SmLip by SAD 
methods targeting the iodides present in the crystallisation condition (Dauter et al., 
2000). SAD is a method of obtaining phases based on the ability for elements, in this 
case iodide, to absorb X-rays (as well as emit them) in a wavelength dependent manner 
(Taylor, 2010; see section 2.5.3). Thirteen potential iodide positions were identified and 
phases were calculated, giving a figure-of-merit of 0.43 to 2.35 Å. Subsequently twelve 
of these positions were confirmed by refinement with this dataset (Figure 3.5). Density 
modification was carried out using solvent flattening, histogram matching and 
averaging on the basis of non-crystallographic symmetry (NCS). The resulting electron 
density clearly revealed the molecular structure (Figure 3.5).  
Figure 3.4 Crystal optimisation.  
A) Iodide containing condition optimised to 25 % PEG 3350 300 mM KI. B) In-house diffraction 
to 2.3 Å produced from optimised crystals.  
  
Chapter 3 – Results and discussion: SmLip 
42 
 
 
3.5.2 Model building and refinement 
The initial model consisted of 293 residues, with a correlation coefficient of 0.55 and 
Rwork and Rfree values of 46 % and 49 % respectively. The first round of model building, 
carried out manually in COOT (Emsley et al., 2010), extended this to 467 residues, with 
a correlation coefficient of 0.72 and Rwork and Rfree values of 33 % and 37 % 
respectively. NCS restraints were employed in the initial refinement calculations, which 
were performed using REFMAC5 (Murshudov et al., 2011). At this point the high-
resolution synchrotron data (dataset II, 1.92 Å resolution) was used to continue the 
analysis. The refinement proceeded with the release of NCS restraints, the incorporation 
of water molecules, a Na+ ion, ethylene glycol and a number of side chains with dual 
rotamer conformations. This dataset was derived from crystals grown in the presence of 
chloride instead of iodide. However, we did not assign any chloride ions noting that 
typical water molecules occupy the iodide binding sites previously identified. The 
refinement was terminated when there were no significant changes in Rwork and Rfree and 
inspection of the difference density map suggested that no further corrections or 
additions were justified. Crystallographic statistics are given in Table 3.1. 
 
 
Figure 3.5 Density modified map. 
Several iodides from the crystallisation 
condition were identified and used for 
SAD phasing. Map contoured at 1.5 σ.  
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Table 3.1 Crystallographic statistics. 
 Dataset I  Dataset II 
Space group / wavelength (Å) C2 / 1.5418 C2 / 1.007 
a, b, c (Å), β (°) 139.7, 77.6, 54.3, 98.4 139.7, 77.8, 54.5, 98.3 
Resolutiona (Å) 19.7 – 2.35 (2.48 – 
2.35) 
39.8 – 1.92 (2.02 – 1.92) 
No. reflections recorded 94650 (11192) 280802 (38597) 
Unique reflections 23495 (3109) 43478 (6188) 
Completeness (%) 98.3 (90.0) 98.2 (95.8) 
Multiplicity / <I/σI> 4.0 (3.6) / 30.9 (6.6) 6.5 (6.2) / 20.6 (3.7) 
Anomalous completeness (%) 95.7 (84.5) - 
Anomalous redundancy 2.0 (1.8) - 
Wilson B (Å2) 47.7 32.7 
Residues / waters - 541 / 336 
Rmergeb (%) 2.6 (17.1) 4.9 (44.2) 
Rworkc, Rfreed (%) - 22.0 / 29.2 
Ave. B-factor (Å2)   
Chain A, B, C, D 
Waters, Na+, ethylene glycol 
- 36.1, 41.6, 49.5, 59.8 
46.2, 37.8, 60.2 
Cruickshank DPIe (Å) - 0.2 
Ramachandran plot   
Most favoured  - 516 residues 
Additional allowed  - 21 residues 
Outliers  - Molecule D: Phe97, 
Asp129; molecule B: 
Pro142, Ser154 
RMSD on ideal valuesf   
Bond lengths (Å) / angles (°) - 0.01 / 1.42 
 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ 
∑hkl∑i Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> 
is the mean value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the 
observed structure factor and Fc is the calculated structure factor. d. Rfree is the same as Rcryst 
except calculated with a subset, 5 %, of data that are excluded from the refinement calculations. 
e. Diffraction Precision Index (Cruickshank, 1999). f. (Engh and Huber, 1991). 
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3.6 The SmLip structure 
3.6.1 Overall structure 
The asymmetric unit consists of four polypeptide chains, labeled A-D, with an 
estimated solvent content of 45 % and a Vm (Matthews, 1968) of 2.27 Å3 Da-1. Disorder 
was evident at several positions where it was not possible to interpret diffuse and weak 
electron density. Consequently several residues are absent from the model. Molecule A 
consists of residues 32 to 173, molecule B 33-142, 147-176; molecule C 34-50, 53-143 
and 147-175; molecule D 33-50, 55-175. The geometry and quality of the model was 
validated using MOLPROBITY (Chen et al., 2010) and the subsequent Ramachandran 
plot reveals 99.3 % of residues were found in the allowed region. There were four 
residues in the disallowed region with weak electron density and exhibiting above 
average B-factors (Table 3.1). The four SmLip polypeptide chains are similar with the 
root-mean-square deviations (RMSD) between superimposed Cα atoms ranging from 
1.3 Å (monomers A and B) to 0.8 Å (monomers A and D) with an average value of 0.95 
Å.  
The structure of SmLip is dominated by an eight-stranded β-sandwich with 
strands in the following order; 8-7-1-4 and 6-5-2-3 (Figure 3.6A). In addition, there are 
three short α-helical segments and three 310-helix turns, two of which are on a loop that 
extends away from the core of the protein (Figure 3.6B). This loop is located in close 
proximity to the N-terminus, which is anchored to the outer membrane via the lipidated 
Cys26 (Bos et al., 2007; Tokuda and Matsuyama, 2004). It is possible this loop region 
makes interactions with the outer membrane (Figure 3.6B). The two 310-helix turns 
could potentially distort to form an α-helix and embed into the membrane. This would 
increase stabilisation of the protein and perhaps ensure the protein is positioned 
correctly to form protein-protein interactions with other components within the T6SS. 
In addition, there are several other exposed loop regions that can be seen in the crystal 
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structure, with loop 1 protruding out from the core of the protein, potentially making 
interactions with other proteins in the periplasm.  
 
 
Figure 3.6 The structure of SmLip.  
A) The topology of SmLip shows the arrangement of the secondary structure, with β sheets coloured blue, 
α-helices coloured red and 310 helices coloured green. Image prepared using TopDraw (Bond, 2003). B) 
The structure of SmLip (PDB 4A1R) coloured using the same colour scheme as A. The structure is 
orientated with the N-terminus pointing towards the outer-membrane, where the excluded lipidated 
cysteine would anchor the protein into the membrane. C) Sequence alignment of SmLip with the 
homologous proteins from enteroaggregative E. coli (GenBank CBG37366.1) and P. aeruginosa (NCBI 
Reference Sequence NP_248770.1, PA0080). The secondary structure is depicted using the same colour 
scheme as A.  
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Despite SmLip being a conserved component of the T6SS (Boyer et al., 2009), 
there is a large degree of variation in the amino-acid sequences of homologous proteins. 
This is highlighted in the sequence alignment with homologues (Figure 3.6C), where 
SmLip shares approximately 20 % sequence identity with enteroaggregative E. coli 
(EAEC) Lip and nearly 40 % sequence identity with P. aeruginosa Lip. The 
conservation of a number of residues is noted in the region corresponding to loop 1 and 
loop 2, and at the secondary structure elements α1, α2 and β6 (Figure 3.6C). The side 
chain of Asn48 in loop 1 accepts a hydrogen bond from the main-chain amide of 
Gln126 in loop 4 and aids in defining the conformation of loop 4. The conserved region 
at loop 2 (Leu99-X-Pro101-Gly102) defines the structure of the turn after β3 and forms 
the loop (data not shown).  
 
3.6.2 Analysis of the quaternary structure 
Size exclusion chromatography indicates a monomer in solution for SmLip. However, 
four polypeptides are present in the asymmetric unit and their interactions were 
analysed using the PISA web service (Krissinel and Henrick, 2007). The accessible 
surface area (ASA) of the polypeptides range from 8,200 Å2 for molecule D to 8,510 Å2 
for molecule A. Each molecule in the asymmetric unit interacts with two of the other 
three and two types of protein-protein interface are formed between molecules A-B, C-
D (interface I) and A-C, B-D (interface II; Figure 3.7A). The largest interface is the 
type I interface and covers an area that is approximately 13 % of the ASA of the SmLip 
molecule. This coverage would indicate a potential for a biologically relevant dimer 
(Krissinel and Henrick, 2007). This interface is primarily formed by the anti-parallel 
alignment of two β7 strands (Figure 3.7B). Three aromatic residues, Phe147, Trp151 
and Phe153 contribute van der Waals interactions to the association and by virtue of 
their relative bulk also to the ASA. The type II interface covers approximately 6.5 % of 
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the ASA of a molecule, a level typical of values observed simply due to molecular 
packing in a crystal lattice. This interface is formed by the anti-parallel alignment of 
two β4 strands (Figure 3.7B).  
  Evidence against SmLip forming a tetramer in the cell can be found upon closer 
inspection of the amino acid sequence and the crystal structure. Analysis of the 
sequence of SmLip indicated the presence of a signal peptide (Petersen et al., 2011), and 
the lipidation of Cys26 at the N-terminus. This linkage anchors the protein to the 
membrane (Bos et al., 2007; Tokuda and Matsuyama, 2004). The spatial placement of 
the N-terminal residue of each polypeptide chain in the asymmetric unit suggests it is 
unlikely that an oligomeric assembly could form when the protein is anchored to the 
membrane. The N-termini of molecules A and D are on the same side of the tetrameric 
assembly, but are opposite to those of molecules B and C. As explained, there are only 
two interface types observed and there are no direct interactions formed between 
molecules A and D or molecules B and C, making the structure incompatible with an 
oligomeric assembly when located at the membrane. Bacterial two-hybrid studies 
indicate SmLip undergoes self-interaction, with this system unable to distinguish 
between dimerisation or higher order oligomerisation (Rao et al., 2011). This is 
consistent with the crystal structure showing a tetrameric assembly with a possible 
dimer. However, as discussed, this arrangement is incompatible with a membrane-
bound protein. This may be due to different concentrations and experimental conditions 
used. It is therefore more likely that SmLip is a membrane-bound monomer that 
functions by protein-protein interactions. SmLip is therefore able to undergo self 
interaction when unbound to the membrane, as observed from bacterial two-hybrid 
results (Rao et al., 2011).    
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3.6.3 Comparisons with structural homologues 
To infer the possible function of SmLip, a search for structural homologues using 
PDBeFold (http://pdbe.org/fold) was carried out. The closest match gave a Z-score of 
6.1 for sea bream transthyretin (PDB 1SN0; Eneqvist et al., 2004). Superimposing the 
two structures matches 84 residues with an RMSD of 2.7 Å (Figure 3.8A). The β-
strands align well, however transthyretin lacks the small α-helical domain present in 
SmLip and the loop regions fail to align (Figure 3.8A). The sequence identity between 
the two proteins is approximately 7 %. A clear structural relationship can be discerned, 
establishing SmLip as a new member of the transthyretin-like protein family. The only 
other member of this protein family is 5-hydroxyisourate hydrolase, an enzyme found in 
prokaryotes (EC 3.5.2.17; Hennebry et al., 2006), leading to the conclusion that this 
family represents an example of divergent evolution (Hennebry, 2009). The sequence 
identity shared with SmLip is 6 %, however a similarity in fold is still evident (Figure 
3.8B). It is unlikely SmLip has any hydrolase activity as the residues important for the 
Figure 3.7 Crystallographic interfaces.  
A) Schematic diagram of the two different interfaces observed in the crystal structure of SmLip and 
the ASA of each interface. B) The asymmetric unit, with the two interfaces labelled. Residues that 
contribute significantly to the type I interface (Phe147, Trp151 and Phe153) are depicted as sticks. 
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catalytic function of 5-hydroxyisourate hydrolase (His7, Arg41, His92 and Ser108) are 
absent. 
 
 
Transthyretin is a tetrameric protein involved in binding the hormone thyroxine 
and forming a complex with retinol-binding protein (Prapunpoj and Leelawatwattana, 
2009). The interface of the tetramer is formed by two of the eight β-sheets present (PDB 
2PAB; Blake et al., 1978). When superimposing the structure of SmLip onto 
transthyretin, one polypeptide overlays onto one transthyretin polypeptide. Furthermore, 
an overlay of SmLip with transthyretin places the thyroxine-binding site on the surface 
of SmLip (Figure 3.9). This is in contrast to the thyroxine-binding site in transthyretin, 
where binding occurs at the tetramer interface. This would suggest that it is unlikely that 
SmLip acts to bind hydrophobic ligands of the type that transthyretin can bind.  
 
 
Figure 3.8 Comparison with structural homologues.  
A) A clear structural relationship can be seen when SmLip is superimposed onto sea bream 
transthyretin (PDB 1SN0; orange). B) SmLip is also structurally similar to 5-hydroxyisourate 
hydrolase (PDB 2GPZ; magenta), another member of this protein family. SmLip is coloured using the 
same colour scheme as in Figure 3.6A.  
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3.7 Discussion 
The T6SS is implicated in a number of different phenotypes including the virulence of 
B. pseudomallei towards mice (Chen et al., 2011) and the antibacterial activity of S. 
marcescens (Murdoch et al., 2011; see section 1.2). Recently, a number of crystal 
structures of components of the T6SS have improved our understanding of the function 
and assembly of these components within the secretion apparatus (Figure 3.10). This 
has subsequently led to the proposal that the T6SS may function in a similar manner to 
that of an inverted bacteriophage (Bönemann et al., 2010; Cascales and Cambillau, 
2012; Records, 2011; see section 1.2).  
The lipoprotein SmLip is an essential component of the T6SS, with deletion of 
this gene resulting in a non-functional T6SS (Aschtgen et al., 2008; Murdoch et al., 
2011). The amino acid sequence of SmLip shows the presence of a signal peptide, with 
cleavage by signal peptidase II occurring between Gly25 and Cys26 (Figure 3.6C; 
Petersen et al., 2011). The residue after the lipidated Cys26, Met27 (+2 position), 
suggests that this protein is exported to the outer membrane via the Lol system (Bos et 
al., 2007; Tokuda and Matsuyama, 2004). The localisation of the EAEC Lip homologue 
Figure 3.9 Stereo image of an overlay of SmLip and transthyretin in complex with thyroxine. 
The polypeptide trace for SmLip is black, transthyretin red. Thyroxine is shown as sticks coloured 
purple for I, grey C, red O and blue N.  
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(EcTssJ) has previously been confirmed (Aschtgen et al., 2008), while the localisation 
of SmLip was confirmed using anti-Lip polyclonal antibodies to probe the major cell 
fractions (Rao et al., 2011).  
 
 
 During the course of these studies, the EcTssJ crystal structure became available 
(PDB 3RX9; Felisberto-Rodrigues et al., 2011). The authors note the same structural 
relationship with transthyretin that was observed with the SmLip structure (Rao et al., 
2011). Superimposing the EcTssJ structure with SmLip matches 120 residues with an 
RMSD of 1.5 Å (Figure 3.11A) and sequence identity of approximately 20 % (Figure 
3.11B). A noticeable difference between the two structures is the region comprising the 
two 310-helices between β6 and β7 in SmLip. While this region corresponds to a large 
loop of 18 residues that extends away from the core of SmLip, the EcTssJ structure 
comprises just a single 310-helix corresponding to only 9 residues. This difference 
Figure 3.10 The T6SS.  
Two distinct sub-assemblies have now been identified; one resembling contractile bacteriophage tail and 
the other a membrane spanning complex that anchors the first sub-assembly to the cell envelope. PDB; 
1Y12, 2P5Z, 3U66 and 3ZRI. Figure adapted from (Bönemann et al., 2010; Cascales and Cambillau, 
2012). 
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results in the EcTssJ structure being more compact and globular than that of SmLip. The 
significance of this, if any, has yet to be determined. However it is worth noting that this 
domain is involved in the type I interface between molecules A-B and C-D in the SmLip 
asymmetric unit (Figure 3.7B).  
 The three short α-helical segments in SmLip form a helical domain that is also 
present in the EcTssJ structure (Figure 3.11A). Deletion of this domain in EcTssJ 
results in reduced expression in vivo, with no expression observed in vitro (Felisberto-
Rodrigues et al., 2011).  
 
 
 Analysis of the SmLip structure suggests the possibility that loop 1 may be 
involved in protein - protein interactions with other components of the T6SS (Figure 
3.11A; Rao et al., 2011). This was confirmed in EcTssJ, with the deletion of the L1-2 
loop (loop 1 in SmLip) resulting in the absence of Hcp in culture supernatant (an 
indicator of a functional T6SS; Bingle et al., 2008; Felisberto-Rodrigues et al., 2011; 
Figure 3.11 Comparison with the EcTssJ crystal structure. 
A) The structure of EcTssJ (PDB 3RX9; cyan) is superimposed onto SmLip (coloured using the same 
colour scheme as Figure 3.6A). B) A structure-based sequence alignment of SmLip and EcTssJ. The 
alignment is coloured as in A. Note that the signal peptide sequence has been excluded for clarity.   
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see section 1.2.1). In addition, it was established that EcTssJ interacts with the protein 
TssM (Felisberto-Rodrigues et al., 2011), a large protein with an N-terminal 
cytoplasmic domain, three transmembrane helices, a periplasmic domain and has 
ATPase activity (Figure 3.10; Ma et al., 2012). EcTssJ was found to interact with the 
C-terminus of the periplasmic domain of TssM with a Kd of 2-4 µM via the L1-2 loop. 
Despite this loop also being present in SmLip (loop 1), there is little sequence 
conservation between them (Figure 3.11B). It was speculated that variation in the 
length and composition of this loop might confer specificity between EcTssJ and TssM 
homologues (Felisberto-Rodrigues et al., 2011). Indeed, loop 1 in the SmLip structure is 
comprised of 14 residues, more than is observed in the L1-2 loop in EcTssJ and is a 
possible consequence of variation between bacterial species within the T6SS.   
A possible chaperone-like role for EcTssJ has been proposed, ensuring proper 
folding or stability of the C-terminus of the periplasmic domain of TssM (Felisberto-
Rodrigues et al., 2011). A number of lipoproteins in other bacterial secretion systems 
carry out chaperone-like functions. In the T2SS, PulS is an outer membrane anchored 
lipoprotein responsible for the insertion of channel forming proteins into the outer 
membrane (Hardie et al., 1996). Furthermore, the lipoprotein InvH in the T3SS aids in 
the localisation and insertion of InvG to the outer membrane, forming the outer 
membrane translocation complex (Crago and Koronakis, 1998; Daefler and Russel, 
1998).   
The interaction between EcTssJ and TssM is essential for a functional T6SS, 
making the disruption between these two components a possible drug target (Felisberto-
Rodrigues et al., 2011). Potentially a small peptide or small molecule could out compete 
the L1-2 loop (loop 1 in SmLip) for binding to the complementary cavity of TssM 
(Felise et al., 2008; Shahian et al., 2009). This may represent a suitable target to pursue 
for the development of novel inhibitors in order to disrupt the assembly of the T6SS. 
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4.1 Aims 
The aim of this project was to structurally characterise S. marcescens resistance 
associated protein 1b (Rap1b). This protein is encoded on the operon of the recently 
identified S. marcescens T6SS (Murdoch et al., 2011), along with a number of other 
small auxiliary proteins (see section 1.3.1). A structure of Rap1b could not be modelled, 
therefore the crystal structure was sought to allow comparisons with known protein 
structures and potentially give insight into the role this protein has within the T6SS.  
 
4.2 Recombinant Rap1b expression and purification 
Full length Rap1b consists of 151 residues, with the first 32 residues constituting the 
signal peptide sequence targeting the protein to the periplasm (Petersen et al., 2011). 
The cloning of a truncated form of the S. marcescens Rap1b gene (residues 28-151) 
from genomic DNA into the pET15b-TEV vector was carried out by Grant English 
(University of Dundee).  
 Recombinant Rap1b was produced in E. coli Rosetta-gami™ (DE3) cells 
(Novagen). Cultures were grown in LB media (Bertani, 1951) supplemented with 100 
µg L-1 carbenicillin before induction with isopropyl β-D-1-thiogalactopyranoside to a 
final concentration of 1 mM for 24 hrs as described in section 2.2.2. The protein was 
purified as described in section 2.3 with the His-tag still present. The protein eluted 
from a size exclusion column as a single species of approximate mass of 30 kDa, 
corresponding to a dimer. Samples were taken for SDS-PAGE analysis (Figure 4.1) and 
fractions containing the protein were pooled and concentrated to 13 mg mL-1. A final 
yield of 3 mg L-1 of bacterial culture was obtained. The theoretical mass of one subunit 
is estimated as 14 kDa with a calculated pI of 6.3. The purified protein sample was 
stored at 4 °C until further use. 
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4.3 Crystallisation and data processing 
Initial crystallisation screens of Rap1b were carried out at 20 °C by the sitting drop 
vapour diffusion method in 96-well plates (see section 2.4.2). This was achieved with a 
Phoenix Liquid Handling System (Rigaku, Art Robins Instruments) and the 
commercially available PEG (Qiagen) and JCSG+ (Molecular Dimensions) screens. 
Crystallisation occurred at a protein concentration of 13 mg mL-1 and in the reservoir 
condition 0.5 M Li2SO4, 15 % PEG 8000 (Figure 4.2). This was further optimised using 
hanging drop vapor methods (see section 2.4.2) with drops consisting of 1 µL of protein 
at 8 mg mL-1 in 25 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 mM DTT and 1 µL of 0.55 
M Li2SO4, 5 % PEG 8000. Optimised crystals grew to a maximum dimension of 
approximately 0.25 mm, over five days.  
 
 
Figure 4.2 Rap1b crystals.  
A) Initial crystals of Rap1b grew over three days. These crystals gave diffraction in-house to 2.4 Å (B). 
Figure 4.1 Size exclusion chromatography.  
A single absorbance peak at 280 nm was 
observed, corresponding to a protein of 
around 30 kDa. 4 mL fractions were 
collected.  
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A single crystal from the optimised condition was soaked for approximately 20 
seconds in 125 mM aqueous sodium iodide. This was used to measure a 1.88 Å high-
resolution dataset in-house using a Rigaku MicroMax-007 rotating-anode X-ray 
generator (copper Kα, λ=1.5418 Å) coupled to an R-AXIS IV++ image plate detector. 
The high concentration of Li2SO4 present in the crystallisation condition proved to be a 
suitable cryoprotectant. Data were indexed and integrated using iMOSFLM (Powell et 
al., 2007), with space group P3121 and unit cell lengths a=b= 77.9 Å and c= 50.6 Å 
(Table 4.1). Data were scaled and the space group was suggested using SCALA and 
POINTLESS (Evans, 2006) from the CCP4 program suite (Winn et al., 2011). A 
Matthews coefficient (Matthews, 1968) of 2.72 Å3 Da-1 was calculated with 55 % 
solvent content, assuming a single polypeptide chain in the asymmetric unit.  
 
4.4 Structure determination of Rap1b 
4.4.1 Phasing 
Sequence analysis of Rap1b using BLAST (Altschul et al., 1997) and the PHYRE  
protein fold recognition server (Kelley and Sternberg, 2009) indicated little or no 
homology to known proteins. The high-resolution diffraction data recorded in-house 
was used to solve the structure of Rap1b by SAD methods targeting potential iodides 
from the halide soak and endogenous sulfurs (Dauter et al., 2000; see section 2.5.3). 
Seven potential anomalous scattering positions were identified and experimental phases 
were calculated, producing a figure-of-merit of 0.28 to 1.88 Å resolution. Density 
modification was carried out using solvent flattening and histogram matching. 
Subsequent refinement confirmed two of the anomalous scattering positions as iodides 
(Figure 4.3A), and five were confirmed as well-ordered sulfurs present in the amino 
acid sequence, including two involved in disulfide bond formation (Figure 4.3B).  
 
  
Chapter 4 – Results and discussion: Rap1b 
58 
 
 
4.4.2 Model building and refinement 
The initial model consisted of 108 residues, with a correlation coefficient of 0.51 and 
Rwork and Rfree values of 46.3 % and 52.9 % respectively. Subsequent model building in 
COOT (Emsley et al., 2010) extended this to 119 residues, with a correlation coefficient 
of 0.95 and Rwork and Rfree values improving to 18.3 % and 22.1 % respectively. 
Refinement calculations were performed using REFMAC5 (Murshudov et al., 2011) and 
translation/libration/screw analysis (TLS) was applied (Painter and Merritt, 2006). The 
refinement proceeded with the incorporation of water molecules, iodides, ethylene 
glycol and a number of side chains with dual rotamer conformations. The refinement 
was terminated when there were no significant changes in Rwork and Rfree and inspection 
of the difference density map suggested that no further corrections or additions were 
justified. The geometry and quality of the model was validated using MOLPROBITY 
(Chen et al., 2010) and the subsequent Ramachandran plot reveals 100 % of all residues 
in most favoured or allowed regions. Crystallographic statistics are given in Table 4.1. 
 
 
Figure 4.3 Density modified map. 
Substructure searching identified both iodides (A) from the halide soak and well-ordered intrinsic 
sulfurs (B). Map contoured at 1.5 σ. 
  
Chapter 4 – Results and discussion: Rap1b 
59 
Table 4.1 Crystallographic statistics of Rap1b. 
 Rap1b 
Space group  P3121   
a, b, c (Å) 77.9, 77.9, 50.6 
Resolutiona (Å) 67.5 – 1.88 (1.98 – 1.88) 
No. reflections recorded 162739 (21729) 
Unique reflections 14813 (2130) 
Completeness (%) 100.0  
Multiplicity / <I/σI> 11.0 (10.2) / 26.6 (5.9) 
Anomalous completeness (%) 100.0  
Anomalous redundancy 5.6 (5.1) 
Wilson B (Å2) 28.3 
Residues / waters / ligands 119 / 117 / 7 
Rmergeb (%) 5.3 (38.3) 
Rworkc, Rfreed (%) 18.3 / 22.1 
Ave. B-factor (Å2)  
Protein 
Waters, iodides, ethylene 
glycol 
21.1 
42.3, 49.4, 55.7 
Cruickshank DPIe (Å) 0.1 
Ramachandran plot  
Most favoured  118 residues 
Additional allowed  1 residue 
Outliers  0 
RMSD on ideal valuesf  
Bond lengths (Å) / angles (°) 0.02 / 1.51 
 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rcryst except calculated with a subset, 
5 %, of data that are excluded from the refinement calculations. e. Diffraction Precision Index 
(Cruickshank, 1999). f. (Engh and Huber, 1991). 
 
4.5 The Rap1b structure 
4.5.1 Overall structure 
Rap1b displays a compact globular structure with five α-helices (α2, α3, α4, α5 and 
α6) and two short α-helical segments (α1 and α7) located at either termini (Figure 
4.4A). The large loop between helices α4 and α5 corresponds to a chain break in the 
crystal structure, where it was not possible to interpret diffuse and weak electron 
density. Consequently residues Glu108 to Asp111 are absent from the model. A single 
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molecule of Rap1b is present in the asymmetric unit, however analysis of interactions 
using COOT (Emsley et al., 2010) indicates this can be superimposed on to a second 
molecule by the symmetry operator -x,-x+y,-z+1/3 to form a dimer (Figure 4.4A). The 
ASA of one molecule is approximately 8250 Å2, while the interface between the two 
molecules covers an area that is approximately 24 % of the ASA (Krissinel and 
Henrick, 2007).  
During the course of these studies, the crystal structure of another of the small 
proteins, Rap2b, became available from work carried out by Dr. V. Srikannathasan 
(University of Dundee). Rap2b (Figure 4.4B) displays a compact globular structure like 
Rap1b, however Rap1b is longer with additional residues at the N-terminus and the C-
terminus forming an additional short α-helix (α7; Figure 4.4C). Rap2b has four 
molecules in the asymmetric unit forming two dimers by the subunits A:B and C:D. The 
four molecules are comparable, with an RMSD between superimposed Cα atoms 
ranging from 0.5 Å (monomer B and D) to 0.7 Å (monomers A and C) with an average 
value of 0.58 Å. The ASA averages out at approximately 6330 Å2; the range is from 
6240 Å2 for molecule B to 6470 Å2 for molecule D. Each dimer covers an area that is 
approximately 20 % of the ASA. The large ASA used for dimer formation in both 
Rap1b and Rap2b suggests a biological relevance (Krissinel and Henrick, 2007) of these 
stable oligomers and is consistent with both proteins existing as stable dimers in 
solution (data not shown). 
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Despite a low sequence identity of approximately 20 % (Figure 4.4C), both Rap 
proteins display an obvious structural resemblance with one another (Figure 4.5). 
Superimposing the two structures matches 71 residues with an RMSD of 1.4 Å (Figure 
4.5). A conserved disulfide bond (Cys54 – Cys120 in Rap1b and Cys41 – Cys101 in 
Rap2b) brings together helices α2 and α5 and helps form a hydrophobic core. This core 
is comprised of helices α2, α3 and α5 interacting with the corresponding helices from 
Figure 4.4 Rap1b and Rap2b comparison. 
A) The structure of Rap1b is coloured with α-helices red. The α-helices in the symmetry related 
molecule are coloured brown. Iodides used in phasing are coloured orange. B) The structure of Rap2b is 
coloured blue, with the second molecule in the asymmetric unit coloured cyan. C) A structure-based 
sequence alignment highlights the conserved secondary-structure content in Rap1b (red cylinders) and 
Rap2b (blue cylinders). Residues involved in disulfide bond formation are coloured yellow. The signal 
peptide has been excluded.  
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the second molecule across the two-fold axis of symmetry (Figure 4.4A & B). This 
interaction contributes to dimer stabilisation by virtue of extensive van der Waals and 
hydrogen bond formation. 
 
To investigate the possible function of both Rap1b and Rap2b, a search for 
structural homologues using PDBeFold (http://pdbe.org/fold) was carried out. Using the 
monomer and crystallographic dimer of Rap1b as search models, the results indicated 
no similarity with other protein structures deposited in the PDB. The closest match gave 
a Z-score of 2.7, suggesting low statistical significance. Furthermore, a search using 
both the monomer and dimer of Rap2b as search models gave a Z-score of 2.2. Taken 
together, these results suggest the overall fold observed in both Rap1b and Rap2b is 
previously uncharacterised.  
 
4.5.2 Disulfide bond formation 
Several anomalous scattering positions were identified during SAD phasing and 
correspond to well-ordered sulfur atoms present in the amino acid sequence of Rap1b 
(Figure 4.4C). In particular, two of the identified sulfur positions correlate to cysteine 
residues involved in disulfide bond formation; Cys54 on the α2-helix and Cys120 on 
Figure 4.5 A Cα trace of Rap1b and Rap2b.  
Stereoview overlay of Rap1b (red) superimposed on to Rap2b (blue). Both structures are orientated as in 
Figure 4.4. 
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the α5-helix (Figure 4.4A & C). In addition, the structure of Rap2b also has a single 
disulfide bond present, comprising residues Cys41 and Cys101 (Figure 4.4B & C). An 
overlay of Rap1b onto Rap2b aligns the disulfide positions in both structures (Figure 
4.6). This disulfide bond formation takes place in the periplasm and is likely introduced 
by the thiol-disulfide oxidoreductase, DsbA (Shouldice et al., 2011). During initial 
expression tests of recombinant Rap1b and Rap2b, it was noted that soluble protein was 
produced only in E. coli Rosetta-gami™ (DE3) cells (Novagen); a cell line that 
promotes the formation of disulfide bonds (data not shown). This suggests the covalent 
bond is necessary for correct folding to occur and for enhanced stability of the proteins. 
The stabilisation effect of introducing a disulfide bond into a protein has been studied 
previously in T4 lysozyme (Matsumura et al., 1989; Wetzel et al., 1988). Furthermore, 
the presence of a disulfide bond may infer resistance to proteolytic degradation in the 
periplasm (Beck et al., 2008; Ireland et al., 2006).  
 
 
 
 
 
Figure 4.6 Disulfide bond.  
The position of the disulfide in both Rap1b and Rap2b align with one another. The same orientation and 
colour as Figure 4.4 is used.  
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4.6 Discussion 
An active T6SS was recently identified in the opportunistic Gram-negative pathogen S. 
marcescens (Murdoch et al., 2011). A cluster of genes located in the middle of the 
T6SS operon encodes several small auxiliary proteins (Figure 4.7A; English et al., 
2012; Murdoch et al., 2011). These small proteins can be grouped based on their pI, 
secondary structure prediction and the presence or absence of a signal peptide sequence 
(Figure 4.7A; see section 1.3.1).  
The proteins Rap1b and Rap2b are members of the Rap family of self-resistance 
proteins that have recently been characterised in the S. marcescens T6SS (Figure 4.7A; 
English et al., 2012). This family of proteins has been shown to confer protection 
against the secreted toxins Ssp1 and Ssp2 (Figure 4.7B; English et al., 2012) and is 
analogous to the Tsi and Tse substrates of the P. aeruginosa HSI-1 T6SS (Hood et al., 
2010; Russell et al., 2011; see section 1.3). The amino acid sequence of Rap proteins 
shows the presence of a signal peptide locating them to the oxidative periplasmic space 
(Figure 4.7B; Peterson et al., 2011) for correct folding and disulfide formation to occur 
(Shouldice et al., 2011). Homologues have been identified in several bacteria with 
members displaying a conserved disulfide bond and predicted helical fold (Figure 
4.7C; English et al., 2012).  
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The structures of Rap1b and Rap2b reveal an α-helical fold that is previously 
uncharacterised and is representative of Rap proteins (Figure 4.7C). Currently, the only 
other structure of an immunity protein associated with the T6SS is the cytoplasmic Tsi2 
protein from the HSI-1 T6SS of P. aeruginosa (Figure 4.8A; PDB 3RQ9 & 3STQ; Li et 
al., 2012; Zou et al., 2012). Tsi2 is an acidic protein that exhibits a novel helical fold 
and forms a dimer in solution, features that are shared with Rap proteins. However the 
structure of Tsi2 and the Rap proteins are unrelated (Figure 4.8B). Superimposing 
Figure 4.7 Toxins and self-resistance proteins. 
A) These small proteins have been identified as secreted toxins (Ssp) and cognate self-resistance proteins 
(Rap). Figure adapted from (English et al., 2012). B) The secreted proteins (Ssp) may be delivered to the 
periplasm of target cells as with Tse1 and Tse3 (Russell et al., 2011). To prevent self-intoxication, self-
resistance (Rap) proteins may be localised to the periplasm of the producing cell, binding to and negating 
the affects of the Ssp proteins. Figure adapted from (Bönemann et al., 2010; Cascales and Cambillau, 
2012). C) Sequence alignment of S. marcescens Rap2b and Rap2a with homologous proteins from 
Erwinia amylovora (GenBank CBA22869.1), Enterobacter cloacae (NCBI Reference Sequence: 
YP_003612051.1), Cronobacter sakazakii (NCBI Reference Sequence: YP_001439955.1), Salmonella 
typhimurium (NCBI Reference Sequence: NP_459276.1) and Pseudomonas syringae (NCBI Reference 
Sequence: YP_237109.1). The secondary structure of Rap2b (blue cylinders) and the predicted secondary 
structure of the P. syringae protein (purple cylinders) are shown. Cysteine residues involved in disulfide 
bond formation are colored yellow. The signal peptide sequences have been excluded.  
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Rap1b onto Tsi2 matches few residues, with the majority of secondary structure 
elements being distinct (Figure 4.8B). 
 
  
A common feature of toxin-antitoxin pairs is the opposing electrostatic 
properties (Yamaguchi and Inouye, 2011). This is observed with the secreted Ssp toxins 
(pI 9) and cognate Rap resistance proteins (pI 5-6; Figure 4.7A). Interestingly, the 
analysis of the Rap1b and Rap2b structures reveals a distinct crescent shaped basic 
patch on either side of the dimer (Figure 4.9). Residues Lys38, Lys90, Lys97, Arg101, 
Lys131, Arg143 and Lys151 (residues Lys67, Lys78, Lys86, Arg116 and Lys119 in 
Rap2b) form this patch (Figure 4.9). This basic crescent may help to orientate and 
ensure the correct binding to respective binding partners. The structure of a Ssp:Rap 
complex would provide further insight into the details of this interaction.  
 
Figure 4.8 Tsi2 structure. 
A) The structure of the Tsi2 dimer (PDB 3RQ9; Li et al., 2012). B) A single molecule of Tsi2 (green) 
superimposed onto a single molecule of Rap1b (red). For clarity the symmetry related Rap1b molecule is 
excluded. The same orientation as Figure 4.4 is used. 
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While highly specific interactions have been observed and characterised for the 
proteins Ssp1:Rap1a and Ssp2:Rap2a (English et al., 2012), it is not clear what 
resistance the proteins Rap1b and Rap2b provide against. These proteins are formed in 
the cytoplasm and are transported to the periplasm via the Sec pathway in an unfolded 
state. Upon transport to the periplasm, formation of the conserved disulfide bond occurs 
to ensure the correct folding of the proteins, allowing the proteins to correctly bind and 
protect against their respective toxins. It may be possible that these proteins self-protect 
against other uncharacterised toxins, however this is unlikely as a common pattern 
observed is Rap resistance proteins located adjacent to their toxin partner (Figure 
4.7A). A more likely role proposed for these proteins is to provide protection against 
similar toxins from different bacterial species, providing S. marcescens Db10 with a 
competitive advantage (English et al., 2012).   
 
 
Figure 4.9 Electrostatic surface potential.   
Calculated using the APBS plugin for PyMOL (Baker et al., 2001; Lerner, 2006; Schrodinger, 2010), 
the electrostatic charge is contoured at 1 kT/e and -1 kT/e and highlights the charge distrubution on 
Rap1b (A) and Rap2b (B). Negative (acidic) charge is red, positive (basic) charge is blue. Residues that 
contribute to the basic patches are identified.  
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5.1 The need for new antimicrobials  
Hospital-acquired infections (HAIs) pose a major clinical challenge to public health, 
affecting more than 2 million patients in Europe and resulting in approximately 175,000 
deaths annually (Chopra et al., 2008). In addition to the human cost of HAIs, the burden 
on healthcare budgets is estimated to be as high as $45 billion annually in the U.S. 
(Scott, 2009). As populations in developed countries get older and the number of 
immunosupressed individuals increases, this healthcare cost is set to rise (Chopra et al., 
2008). 
 HAIs are typically associated with surgical procedures or invasive medical 
devices (Peleg and Hooper, 2010) and can cause urinary tract infections as well as lower 
respiratory and bloodstream infections (Gaynes et al., 2005; Peleg and Hooper, 2010). 
The Gram-negative bacteria predominantly responsible for HAIs are the Acintobacter 
species, E. coli, Enterobacter species, Klebsiella pneumoniae, S. marcescens and P. 
aeruginosa (Table 5.1; Gaynes et al., 2005; Hidron et al., 2008). In particular, the 
opportunistic pathogen P. aeruginosa is recognised as a significant cause of HAIs (Kerr 
and Snelling, 2009), accounting for around 18 % of all instances of hospital-acquired 
pneumonia (Table 5.1; Gaynes et al., 2005). Furthermore, antibiotic resistance in P. 
aeruginosa and other bacteria is reported to be increasing (Hidron et al., 2008; Obritsch 
et al., 2004; Souli et al., 2008), resulting in a significant impact on the treatment of 
HAIs (Arias and Murray, 2009; Calfee, 2012). Instances of multidrug resistant bacteria, 
where resistance to three or more classes of antibiotics is observed (Souli et al., 2008), 
is reported to be 16 % of all HAIs in the U.S. during the period 2006-2007 (Hidron et 
al., 2008).  
 
 
 
  
Chapter 5 – Introduction: Fragment screening 
71 
Table 5.1 Bacterial isolates identified from U.S. intensive care units in 2003. 
 Percentage of isolates, by infection type 
Gram-negative 
pathogen 
Pneumonia 
(n =4365) 
Bloodstream 
infection 
(n = 2351) 
Surgical site 
infection 
(n = 2984) 
Urinary tract 
infection 
(n = 4109) 
Acintobacter 
species 
6.9 2.4 2.1 1.6 
E. coli 5.0 3.3 6.5 26.0 
Enterobacter 
species 
10.0 4.4 9.0 6.9 
K. pneumoniae 7.2 4.2 3.0 9.8 
S. marcescens 4.7 2.3 2.0 1.6 
P. aeruginosa 18.1 3.4 9.5 16.3 
Other 14.1 3.8 9.8 10.7 
Data taken from (Gaynes et al., 2005). 
 
5.1.1 Antimicrobial drug discovery pipeline 
Many large pharmaceutical companies have abandoned or scaled back their 
antimicrobial research, with few drugs currently in preclinical development (Boucher et 
al., 2009; Talbot et al., 2006). The stringent regulatory environment worldwide and 
concerns regarding length of patents (Fernandes, 2006; Katz et al., 2006) have 
contributed to the increase in costs associated with drug discovery (Bunnage, 2011; Paul 
et al., 2010). Consequently, pharmaceutical companies are now ensuring their 
investments generate substantial revenues to offset research and development costs 
(Vicente et al., 2006). This has resulted in a shift in focus towards the research and 
development of new drugs for treating chronic diseases, as revenue is maintained over a 
prolonged period of time in comparison to bacterial infections (Vicente et al., 2006). 
This lack of novel drugs in the drug discovery pipeline (Boucher et al., 2009; Talbot et 
al., 2006), coupled with the increase in antibiotic resistance in bacteria (Hidron et al., 
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2008; Souli et al., 2008), has the potential to cause future problems for the treatment of 
infectious diseases.  
 
5.2 Target assessment 
On average, a single drug takes approximately 13 years and close to $1 billion to get to 
the clinic from the drug discovery phase (Figure 5.1; Bunnage, 2011; Paul et al., 2010). 
This makes selecting potential drug targets an important step in drug discovery, as 
failure to select an appropriate target will be costly and resources will have been 
expended needlessly (Figure 5.1; Bunnage, 2011). The availability of complete genome 
sequences (http://www.ncbi.nlm.nih.gov/genome) has made the assessment and 
prioritisation of targets attainable. Databases such as the AEROPATH Target Database 
(http://aeropath.lifesci.dundee.ac.uk/) aid this process by amalgamating data from a 
number of sources and providing a pool of putative targets to assess. 
 
 
  
Each putative drug target is assessed against the criteria highlighted in Table 5.2 
and scored using a traffic light system to prioritise them (Frearson et al., 2007). 
Favourable scoring is indicative of a good quality target to pursue and therefore 
Figure 5.1 Drug discovery process. 
The stages of the drug discovery process are illustrated here, highlighting the increase in costs as a 
molecule progresses. The attrition rate of potential drugs at each stage results in few drugs reaching the 
market. VHS; validated hit series, LSI; lead series identified, CCS; clinical candidate selection. Figure 
edited from (Warrick et al., 2008). 
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underpins the entire drug discovery process (Bunnage, 2011; Frearson et al., 2007). A 
key criterion is the concept of druggability (Hopkins and Groom, 2002); is the target 
amenable to functional manipulation through interactions with small-molecule drugs 
that adhere to the Lipinski rule of five (Lipinski et al., 2001)? Predicting druggability 
(Cheng et al., 2007; Fauman et al., 2011) can streamline and enhance the process of 
target validation, ensuring targets most likely to succeed in the hit and lead 
identification process are selected (Hajduk et al., 2005). 
 
Table 5.2 Traffic light definitions for target assessment. 
Criterion Red Amber Green 
Target  
validation 
No or weak evidence 
that the target is 
essential for growth or 
survival. 
Either genetic or 
chemical evidence that 
target is essential for 
growth or survival. 
Genetic and chemical 
evidence that target is 
essential for growth or 
survival. 
Druggability No drug-like inhibitors 
are known and active 
site of target is not 
druggable. 
Drug-like inhibitors are 
known or active site 
potentially druggable. 
Drug-like inhibitors 
are known and 
druggable active site 
(i.e. clinical precedent 
within the target 
family.) 
Assay feasibility No in vitro assay 
developed and / or 
significant problems 
with reagents (cost or 
supply). 
In vitro assay exists, 
development into plate 
format feasible, but not 
achieved. 
Assay ready in plate 
format and protein 
supply assured within 
appropriate timelines. 
Toxicity Human homologue 
present and little or no 
structural or chemical 
evidence that selective 
inhibition is possible. 
Human homologue 
present but some 
structural or chemical 
evidence that selective 
inhibition is possible. 
No human homologue 
present or human 
homologue known to 
be non-essential. 
Resistance  
potential 
Target has multiple 
gene copies or isoforms 
within the same species 
and is subject to escape 
from inhibition. 
Target has isoforms 
within the same species 
or might be subject to 
escape from inhibition. 
Target has no known 
isoforms within same 
species and is not 
subject to escape from 
inhibition. 
Structural 
information 
No structure of target or 
closely related 
homologue. 
Structure without ligand 
available and / or poor 
resolution (> 2.3 Å) or 
opportunity to build a 
good homology model. 
Ligand bound 
structure of target (or 
ligand in closely 
related homologue) 
available at high 
resolution (< 2.3 Å). 
(Frearson et al., 2007). 
 
 
5.3 Fragments 
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The pharmaceutical industry uses high-throughput screening (HTS) of large chemical 
libraries to identify lead compounds that are developed to become marketed drugs 
(Erlanson et al., 2004; Hartshorn et al., 2005; Rees et al., 2004). However, over 90 % of 
compounds in preclinical development fail to progress to clinical trials as a result of 
poor target validation or failure in lead optimisation (Figure 5.1), resulting in 
compounds that are either toxic or have poor drug-like properties (Brown and Superti-
Furga, 2003). The ‘rule of five’ (Lipinski et al., 2001) was proposed as a framework to 
predetermine drug-like compounds most likely to have poor solubility/permeability. 
Lipinski and colleagues observed that this is more likely to occur in compounds that 
have; a molecular weight greater than 500 Da, clogP (lipophilicity) greater than 5, more 
than 5 hydrogen bond donors and 10 hydrogen bond acceptors (Lipinski et al., 2001). 
This framework can be used as a filter that can be applied to large HTS or virtual 
chemical libraries to aid in identifying lead compounds. 
The design and selection of chemical libraries can contribute to successful lead 
discovery and subsequent optimisation (Leach et al., 2006). This has resulted in a shift 
towards screening libraries comprised of smaller molecules and has been termed 
fragment screening (Erlanson et al., 2004; Leach et al., 2006; Scott et al., 2012). 
Fragments are small, weak binding molecules that can be developed and optimised into 
lead compounds with greater binding affinity and specificity (Figure 5.2; Ciulli and 
Abell, 2007; Leach et al., 2006; Scott et al., 2012). The premise for starting with such 
small molecules in the drug discovery process was the observation that in improving 
properties such as potency, the complexity and molecular weight of lead compounds 
also increases (Table 5.3; Hann et al., 2001).  
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Table 5.3 Change in properties during optimisation from lead to drug. 
Property Average value for leads Average value for drugs 
Mw 272.0 314.0 
H-bond donors 0.8 0.8 
H-bond acceptors 2.2 2.5 
ClogP 1.9 2.4 
Number of heavy atoms 19 22 
Data taken from (Hann et al., 2001). 
 
Thus in order to satisfy the Lipinski rule of five (Lipinski et al., 2001) and have 
favourable pharmacokinetic properties, starting molecules must be smaller to 
accommodate the optimisation process. The low molecular weight and complexity of 
fragments means they are highly efficient ligands (Hopkins et al., 2004) that can sample 
chemical space effectively (Lipinski and Hopkins, 2004). The simplistic nature of 
fragments results in few interactions with biological targets, giving rise to low binding 
affinities (Leach et al., 2006). Therefore detecting such weak binding requires a number 
Figure 5.2 An example of fragment-based drug discovery. 
A) A fragment was identified (red) and optimised to produce the B-Raf inhibitor Vemurafenib B) The 
crystal structure of B-Raf with Vemurafenib bound (PDB 3OG7; Bollag et al., 2010). Figure adapted 
from (Hoelder et al., 2012). 
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of biophysical techniques including bio-layer interferometry (BLI; Wartchow et al., 
2011), differential scanning fluorimetry (DSF; Pantoliano et al., 2001), nuclear 
magnetic resonance (NMR; Pellecchia et al., 2008), surface plasmon resonance (SPR; 
Hoa et al., 2007) and X-ray crystallography (Hartshorn et al., 2005; Murray and 
Blundell, 2010). Libraries used for fragment screening typically comprise around 1,000 
fragments and have been developed to adhere to a ‘rule of three’ (Congreve et al., 2003) 
framework that is akin to the Lipinski rule of five (Lipinski et al., 2001). 
 
5.4 Aims 
Several potential drug targets from Acinetobacter baumannii, B. pseudomallei and P. 
aeruginosa (Table 5.4) were selected for assessment based on the criteria described in 
Table 5.2 (Frearson et al., 2007). The search for fragments that have the potential to 
generate lead compounds for further studies has been carried out (Table 5.4) using 
several screening techniques described in section 2.7.  
 
Table 5.4 Potential drug targets screened 
Target Function Screened using: 
AbAccc/PaAccC Catalyses the first step in fatty 
acid biosynthesis 
DSF 
PaIMPDH Catalyses the rate-limiting step in 
the biosynthesis of guanine 
nucleotides 
DSF/BLI 
PaIspF Involved in isoprenoid 
biosynthesis 
BLI 
AbLpxC/PaLpxC Catalyses the first committed step 
in the biosynthesis of Lipid A 
DSF 
PaMurA Catalyses the first step in the 
biosynthesis of peptidoglycan 
DSF 
BpPBP3/PaPBP3 Catalyses the cross-linking of 
peptidoglycan 
DSF/BLI/SPR 
AbRibD Involved in riboflavin 
biosynthesis 
BLI 
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From these potential drug targets, two were selected for further characterisation 
(Table 5.4) and are the focus of the research described in chapters six and seven. The 
successful structure determination of both drug targets in complex with a ligand would 
aid in the understanding of the interactions required for specificity and selectivity and 
underpin the assessment of any identified chemical fragments. 
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6.1 Background 
Peptidoglycan is a macromolecule that forms a continuous layer on the exterior of the 
cytoplasmic membrane of bacteria (van Heijenoort and Gutmann, 2000; Vollmer et al., 
2008). It is formed by β-1,4 linked N-acetylglucosamine (GlcNAc) and N-
acetylmuramic acid (MurNAc) repeating units that are cross-linked via peptide bridges 
(Figure 6.1A; van Heijenoort, 2001; Vollmer and Bertsche, 2008; Vollmer et al., 2008). 
This cross-linking occurs at the final stages of peptidoglycan biosynthesis (Figure 
6.1B) and is carried out by membrane-bound penicillin-binding proteins (PBPs; 
Lovering et al., 2012; Vollmer et al., 2008).  
 
 
Figure 6.1 Peptidoglycan 
biosynthesis. 
A) The repeating unit of 
peptidoglycan in Gram-negative 
bacteria. B) The biosynthesis of 
peptidoglycan is a complex process 
comprising several enzymes (blue). 
Penicillin-binding proteins (PBPs) 
catalyse the polymerisation of Lipid 
II to nascent peptidoglycan strands 
and the cross-linking of strands to 
form mature peptidoglycan. Image 
adapted from (Lovering et al., 2012). 
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Peptidoglycan provides structural rigidity and the ability to withstand high 
internal osmotic pressures that would otherwise rupture the bacterial cell (van 
Heijenoort and Gutmann, 2000; Vollmer and Bertsche, 2008). The disruption or 
inhibition of peptidoglycan biosynthesis therefore results in cell lysis, making this 
pathway an ideal drug target (Kluge and Petter, 2010; Schneider and Sahl, 2010). This 
is demonstrated by antibiotics that target different stages of peptidoglycan biosynthesis 
(Lovering et al., 2012; Schneider and Sahl, 2010; Spratt and Cromie, 1988). 
 
6.2 Aims 
The aims of this project were to assess PBP3 from both P. aeruginosa (PaPBP3) and B. 
pseudomallei (BpPBP3) by producing soluble protein and identifying chemical 
fragments that bind (Ciulli and Abell, 2007; Leach et al., 2006; Scott et al., 2012). This 
information would inform as to whether or not it is possible to find and develop novel 
inhibitors. The crystal structure of PBP3 was sought to complement the fragment 
screening process by validating potential hits.  
 
6.3 Recombinant PaPBP3 & BpPBP3 expression and purification 
A truncated form of the P. aeruginosa ftsI gene encoding the amino acid residues 35 – 
579 was amplified from genomic DNA and cloned into the pOPINF vector containing a 
non-cleavable N-terminal His-tag. This construct was provided by the Oxford Protein 
Production Facility (OPPF; Sainsbury et al., 2011). In addition, the truncated form of 
the B. pseudomallei ftsI gene encoding residues 65 – 584 was purchased from 
GenScript™ with NdeI/XhoI restriction sites and cloned into the pET15b-TEV vector 
(see section 2.2.1). The B. pseudomallei ftsI gene was also cloned into a modified 
version of this vector incorporating a N-terminal BAP sequence (Martin Zoltner, 
University of Dundee). 
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Recombinant PaPBP3 and BpPBP3 were produced in E. coli BL21 (DE3) 
pLysS (Stratagene) and Gold (Novagen) cells respectively. Cultures were grown in AI 
media (Studier, 2005) supplemented with 50 µg L-1 carbenicillin as described in section 
2.2.2. The protein was purified and eluted from a size exclusion column (see section 
2.3) as a single species of approximate mass of 60 kDa, corresponding to a monomer. 
Samples were taken for SDS-PAGE analysis (Figure 6.2) and fractions containing the 
protein were pooled and concentrated to approximately 10 mg mL-1. A final yield of 2 
mg L-1 (PaPBP3) and 16 mg L-1 (BpPBP3) of bacterial culture were obtained. The 
purified protein was stored at 4 °C until further use.  
 
 
 
6.4 Fragment screening 
6.4.1 DSF 
DSF (Niesen et al., 2007; Pantoliano et al., 2001; see section 2.7.3) was used first to 
demonstrate that recombinant PaPBP3 and BpPBP3 bind β-lactam antibiotics and to 
determine their effect on protein stability. The thermal profile of PaPBP3 and BpPBP3 
display single melting curves with a melting temperature (Tm) of 37.3 ºC and 48.7 ºC 
Figure 6.2 Size exclusion chromatography. 
A single absorbance peak at 280 nm corresponds to a monomer of around 60 kDa for both PaPBP3 (left) 
and BpPBP3 (right). 4 ml fractions were collected. 
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respectively. Binding of the antibiotics piperacillin and azlocillin (Figure 6.3A) was 
confirmed by a large thermal shift of ∆Tm +17.6 ºC / +16.7 ºC for PaPBP3 (Figure 
6.3B) and ∆Tm +6.8 ºC / +5.6 ºC for BpPBP3 (Figure 6.3C). The disparity in the extent 
of the thermal shifts may be a result of the difference in Tm values (approximately 11 
ºC) between the two homologues.  
 
Fragment screening using the Maybridge library was carried out as described in 
section 2.7.3. The final concentration of protein and fragment were 10 µM and 1mM 
Figure 6.3 Antibiotic binds.  
A) The chemical structure of piperacillin and azlocillin. B) PaPBP3 (blue) and C) BpPBP3 (green) are 
stabilised when bound to piperacillin (purple, cyan) and azlocillin (black, red). The final concentration of 
protein and antibiotic were 10 µM and 100 µM respectively. All experiments were carried out in triplicate 
and nonlinear regression was used to calculate Tm values. 
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respectively. Several potential hits were identified for PaPBP3, giving thermal-shifts of 
over 5 °C (Figure 6.4). A single potential hit for BpPBP3 was identified giving a large 
thermal-shift of approximately 16 °C (Figure 6.4). However the melting curve of this is 
altered in comparison to the BpPBP3 reference, with a higher initial fluorescence 
reading observed (Figure 6.4). A further experiment using BLI showed no indication of 
this fragment binding to BpPBP3 (data not shown). 
 
 
Figure 6.4. DSF fragment hits.  
The thermal melting curve of PaPBP3 (blue) and BpPBP3 (green) are overlaid with the melting curve 
produced in the presence of the appropriate fragment (orange, purple, black and red). The chemical 
structures of the fragments are shown beneath the corresponding melting curves. The final concentration 
of protein and fragment were 10 µM and 1mM respectively. Screening of the Maybridge fragment library 
was performed once and nonlinear regression was used to calculate Tm values. Graphs are on a normalised 
scale to highlight the thermal-shifts observed.  
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6.4.2 BLI and SPR 
To increase the pool of potential fragment hits binding to BpPBP3, screening using BLI 
(Wartchow et al., 2011) was carried out with biotinylated protein as described in section 
2.7. BLI is a label free optical analytical technique used to analyse biomolecular 
interactions in real time (see section 2.7.5). Reference sensors were blocked with 
biocytin and used to correct for optical interference and variation in buffer composition 
between wells.  
The sensograms from the BLI experiment (Figure 6.5) plots the change in the 
interference pattern of white light (representing the change of thickness at the biosensor 
tip; y-axis) against time (x-axis; Wartchow et al., 2011; see section 2.7.5). Several 
potential hits were identified, where a fast on/off response was observed (Figure 6.5). 
This is a typical property of fragments due their weak binding affinities (Ciulli and 
Abell, 2007; Scott et al., 2012). Two of these hits were purchased from Maybridge for 
co-crystallisation.  
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Screening of BpPBP3 using SPR (Hoa et al., 2007; see section 2.7.4) was 
carried out to compare the results with those obtained using BLI. Dr. Leah Torrie 
(University of Dundee) performed this screening using a Biacore T100 (GE Healthcare) 
with biotinylated BpPBP3 (see section 2.7) immobilised onto a streptavidin sensor (GE 
Figure 6.5 BLI sensograms. 
Examples of the potential fragment hits identified, giving larger responses (blue) in comparison to the 
reference biosensors (red).  
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Healthcare) and the concentration of fragments at 150 µM. Several potential hits were 
identified that were not previously observed using BLI (Figure 6.6). The disparity in 
results may be due to the difference between the two techniques; one uses a dip and 
read format (BLI; see section 2.7.5) while the other passes the analyte across the sensor 
and is more sensitive to the affects of DMSO (SPR; see section 2.7.4). Furthermore, 
variation in the preparation and concentration of fragments may have contributed to the 
difference in hits observed. The fragments DDD00100522 and DDD00100506 were 
identified using both BLI (Figure 6.5) and SPR (Figure 6.6). However these were 
discounted as they appeared as potential hits in screening campaigns with other proteins 
(data not shown) and are therefore likely to be non-specific binders.  
 The identified hits are chemically similar to one another, comprising a benzene 
ring at the core of the molecule. This is generally fused to either a five or six member 
ring (Figure 6.5 & 6.6) and is comparable to the fragments identified using DSF with 
PaPBP3 (Figure 6.4). This may mimic the benzene ring present in piperacillin / 
azlocillin (Figure 6.3A) and suggests these hits represent good starting scaffolds to 
develop into novel drugs. The lack of a viable enzyme assay suitable for assessing 
whether or not these hits have an inhibitory effect is problematic. In general, enzyme 
assays for PBPs require radiolabelled benzylpenicillin and would monitor its binding to 
PBPs (Spratt, 1977). Competition of this binding with a fragment would not yield any 
results as its affinity compared to the radiolabelled substrate would be insignificant. 
Structural information would provide validation of fragment binding while informing 
on the position and interactions made with its surrounding environment.  
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6.4.3 Comparison of fragment screening methods 
DSF has demonstrated it is a technique well-suited for detecting large changes in 
protein stability typically associated with substrate or inhibitor binding (Figure 6.3B & 
C). This technique was used to guide co-crystallisation of PBP3 with antibiotics; those 
that induced the largest increase in protein stability were selected. However, with 
regards to fragment screening, DSF does not seem to be a sensitive enough method for 
identifying the weak binding typically associated with fragments (Figure 6.7). With the 
exception of PaPBP3, DSF has not generated any potential hits for BpPBP3 or any 
Figure 6.6 SPR sensograms. 
Examples of the hits from SPR. Sensograms are coloured by concentrations.  
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other protein screened so far using this technique (data not shown). The negative or lack 
of thermal shifts observed for the potential hits identified from biosensor-based methods 
(Figure 6.7) further demonstrates that this method is unsuitable for fragment screening. 
However with this in mind, DSF is still a convenient method that should still be 
considered for screening since no prior labelling or tagging of the target is required.   
 
 
 
BLI screening generated several hits for BpPBP3, indicating this is a technique 
more suited to identifying fragments. BLI has the advantage over SPR screening in that 
the technique is less sensitive to the effects of DMSO and provides results in a timely 
manner that is comparable to DSF, but without compromising sensitivity. Furthermore 
BLI does not require microfluidics, resulting in little maintenance and a lower cost of 
the system. However, SPR screening provides additional data, such as kinetic constants 
(Kd, Kon, Koff), for assessing fragment hits (Neumann et al., 2007). Screening of 
fragments at several concentrations would need to be carried out to obtain such 
information using BLI (Wartchow et al., 2011).  
The Maybridge Ro3 (Maybridge) and the DDU (University of Dundee) 
fragment libraries were used for DSF and biosensor-based screening respectively. Both 
Figure 6.7 DSF not suited to fragment screening. 
The thermal profile of BpPBP3 (green) compared to the fragments DDD00100567 (BLI; red) and 
DDD00100450 (SPR; purple).  
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libraries are comprised of small molecules adhering to a ‘rule of three’ framework 
(Congreve et al., 2003; see section 5.3) and are designed to maximise diversity while 
minimising over-representation of scaffolds. Analyses of results from BLI screening 
campaigns reveal several molecules appearing as hits for different drug targets (data not 
shown). This suggests a number of molecules within the DDU library are non-specific. 
A tailored library is therefore needed for fragment screening to remove undesirable 
molecules, such as those that exhibit non-specific binding. The DDU library comes 
close to this, however this library needs to be further improved using data generated 
from screening campaigns to guide the exclusion/inclusion of molecules. This would 
result in an evolving library optimised for screening using biosensor-based methods.  
 
6.5 Crystallisation screening 
The crystallisation of apo PaPBP3 and in complex with antibiotics (carbenicillin and 
ceftazidime) were successfully carried out by the OPPF (Sainsbury et al., 2011). 
Attempts by the OPPF to co-crystallise PaPBP3 with the fragments WNH4_C1, 
WNH6_E11 and WNH6_C8 identified using DSF (Figure 6.4) proved unsuccessful, 
prohibiting validation as true fragment hits.  
 Crystallisation screening of BpPBP3 was carried out as described in section 2.4 
in the absence and presence of antibiotics (piperacillin and azlocillin). Crystal trays 
were set up at concentrations between 10 and 15 mg mL-1 of protein and between 100 
µM and 1 mM antibiotic at 20 °C. In addition, co-crystallisation with the fragments 
DDD00060895 and DDD00100567 identified using BLI (Figure 6.5) were carried out 
with 1 mM fragment. However, no crystals of BpPBP3 were obtained to validate these 
as true hits.  
 
 
  
Chapter 6 – Results and discussion: penicillin-binding protein 3 
90 
6.6 Discussion 
The biosynthesis of peptidoglycan (Figure 6.1) is an essential process for bacteria, 
providing structural strength and integrity to the cell (Sauvage et al., 2008). The 
enzymes involved in the polymerisation (glycosyltransferase) and cross-linking 
(transpeptidase) of peptidoglycan are the targets of β-lactam antibiotics and are termed 
penicillin-binding proteins (PBPs; Sauvage et al., 2008; Spratt and Cromie, 1988). PBPs 
can be classed into a high molecular mass (HMM) and low molecular mass (LMM) 
group (Sauvage et al., 2008), with HMM PBPs essential for cell survival (Spratt and 
Cromie, 1988) and LMM PBPs having little or no effect (Korsak et al., 2010). The 
HMM PBPs can be further divided into class A and B enzymes, with the class A 
members being bi-functional (glycosyltransferase and transpeptidase activity) and class 
B members being mono-functional (transpeptidase activity; Sauvage et al., 2008).  
PBP3 is a HMM class B enzyme that is essential for cell division (Botta and 
Park, 1981; Spratt, 1975; Typas et al., 2011), with the deletion of the gene encoding 
PBP3 resulting in filamentation (Botta and Park, 1981; Denome et al., 1999). This 
enzyme is a validated target of β-lactam antibiotics such as piperacillin and azlocillin 
(Spratt and Cromie, 1988). The present study of PBP3 from P. aeruginosa and B. 
pseudomallei provides information on the production of soluble protein and protein-
ligand interactions. These homologues share 40 % sequence identity, with many of the 
essential residues involved in catalysis conserved (Figure 6.8A). The crystal structures 
of apo PaPBP3 (PDB 3OC2 & 3PBN) and in complex with antibiotics (Figure 6.8B; 
PDB 3OCN, 3OCL & 3PBO) represent the first structures of PBP3 to be determined 
(Han et al., 2010; Sainsbury et al., 2011).  
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The information these structures provide will aid the development of novel 
drugs by exploiting structural features. For example, the appearance of a small binding 
pocket (Figure 6.9) resulting from conformational changes induced by inhibitor binding 
gives rise to the possibility of targeting this pocket to restrict the conformational 
flexibility of the PBP3 active site (Sainsbury et al., 2011). If this small pocket is formed 
Figure 6.8 PaPBP3 alignment and structure. 
A) Sequence alignment of PaPBP3 (NCBI reference sequence: NP_253108, PA4418) with BpPBP3 
(Uniprot Q63QJ1). The three structural motifs conserved among PBPs are highlighted in red, with α-
helices and β-sheets coloured blue and green respectively. B) The structure of PaPBP3 with the antibiotic 
ceftazidime (yellow) bound in the active site (PDB 3OCN; Sainsbury et al., 2011). 
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upon substrate binding, then a drug targeting this position has the potential to lock the 
active site into a single conformation, preventing further substrate binding. 
 
 
Biosensor-based screening identified a number of hits for BpPBP3 (Figure 6.5 
& 6.6). The chemical fragments all contain a benzene ring at the core of the molecule 
and possibly mimic the same chemical group in, for example, piperacillin. This 
indicates these fragments may represent starting scaffolds for novel drugs to be 
developed. These hits could not be validated as co-crystals could not be produced, nor 
could their potential inhibitory affects be ascertained due to a lack of a suitable enzyme 
assay. However, the fragments may be characterised in future using isothermal titration 
calorimetry (ITC) or BLI to determine their thermodynamic and kinetic parameters 
(Drinkwater et al., 2010; Wartchow et al., 2011). This information would provide 
confirmation of binding in the absence of an enzyme assay and structural data. 
Figure 6.9 PaPBP3 small binding pocket. 
Conformational changes resulting from carbenicillin binding in the active site of PaPBP3 (PDB 3OCL) 
creates a small binding pocket occupied by a well-ordered glycerol molecule (Sainsbury et al., 2011). 
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7.1 Background 
First characterised in 1957 (Magasanik et al., 1957), inosine 5’-monophosphate 
dehydrogenase (IMPDH; EC 1.1.1.205) is an enzyme present in nearly all living 
organisms and catalyses the first committed step in the biosynthesis of guanine 
nucleotides (Hedstrom, 2009). This enzyme converts inosine 5’-monophosphate (IMP) 
to xanthosine 5’-monophosphate (XMP), using the reduction of NAD+ to NADH to 
drive the reaction forward (Figure 7.1A; Hedstrom et al., 2011). The reaction occurs 
first with a catalytic cysteine residue attacking the C2 position of the IMP substrate and 
undergoing a dehydrogenase reaction that expels a hydride to the NAD+ cofactor to 
form NADH and the covalent product intermediate E-XMP* (Figure 7.1A; Hedstrom et 
al., 2011). The formation of NADH leads to its expulsion from the dinucleotide binding 
site and the movement of a mobile flap that occupies the now empty binding site. An 
arginine residue then acts as a general base catalyst, allowing the hydrolysis reaction to 
take place to convert the E-XMP* intermediate into XMP (Figure 7.1B; Hedstrom et 
al., 2011).  
 
 
The XMP product can be converted to the nucleotide guanine 5’-monophosphate 
(GMP), which is essential for proliferating cells (Jackson et al., 1975). Through the 
action of multiple enzymes, GMP provides the critical precursors for glycosylation, 
Figure 7.1 Proposed IMPDH mechanism.  
The IMPDH mechanism consists of two distinct reactions; A) a dehydrogenation and B) a hydrolysis 
reaction. Residue numbering is based on Tritrichomonas foetus IMPDH (Whitby et al., 1997). Figure 
adapted from (Hedstrom et al., 2011). 
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DNA (dGTP) and RNA (GTP) synthesis (Figure 7.2; Allison and Eugui, 2000; 
Hedstrom, 2009; Sintchak and Nimmesgern, 2000). Other important roles of guanine 
nucleotides include signal transduction pathways and providing the co-factor for G-
proteins (Allison and Eugui, 2000). Rapidly proliferating cells, such as cancer cells or 
cells involved in microbial infection, have a high demand for guanine nucleotides 
(Hedstrom, 2009; Hedstrom et al., 2011). This demand in most cases cannot be met by 
the occurrence of salvage pathways that may be present in the organism (Figure 7.2; 
Allison and Eugui, 2000; Hedstrom et al., 2011). Genetic evidence exists highlighting 
the importance of IMPDH with knock out studies carried out in several bacterial species 
indicating the gene encoding IMPDH is essential (de Berardinis et al., 2008; Kobayashi 
et al., 2003; Liberati et al., 2006). IMPDH can therefore be considered a potential drug 
target as inhibition can have an effect on proliferating cells (Hedstrom et al., 2011).  
 
 
7.2 Aims 
The aims of this project were to assess P. aeruginosa IMPDH (PaIMPDH) by 
producing purified protein and developing both a supply of crystals for structural 
studies and an enzyme assay to characterise PaIMPDH. In addition, identifying 
chemical fragments (Ciulli and Abell, 2007; Leach et al., 2006; Scott et al., 2012) that 
can be used as novel starting scaffolds for further drug development were sought.  
Figure 7.2 The importance of XMP.  
XMP is converted to GMP to make 
precursors for DNA/RNA synthesis. 
GPRT; guanine phosphoribosyl 
transferase, NK; Nulceoside kinase, 
XPRT; xanthine phosphoribosyl 
transferase Figure adapted from 
(Sintchak and Nimmesgern, 2000). 
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7.3 Recombinant PaIMPDH expression and purification 
Full length PaIMPDH (residues 1 – 489) was cloned from genomic DNA into both the 
pET15b-TEV vector and a modified version of this vector that incorporates an N-
terminal BAP sequence (see section 2.72). This was carried out by Sharon Shepherd 
(University of Dundee). 
Recombinant PaIMPDH was produced in E. coli BL21 (DE3) pLysS cells 
(Stratagene). Cultures were grown in AI media (Studier, 2005) supplemented with 50 
µg L-1 carbenicillin as described in section 2.2.2. The protein was purified as described 
in section 2.3 with the His-tag still present. PaIMPDH eluted from a size exclusion 
column as two species of approximate mass of 50 kDa and 200 kDa, corresponding to a 
monomer and tetramer respectively. Samples were taken for SDS-PAGE analysis 
(Figure 7.3). IMPDHs are known to form catalytically active tetramers in solution 
(Hedstrom, 2009), therefore fractions containing the tetrameric protein were pooled and 
concentrated to 22 mg mL-1. A final yield of 25 mg L-1 of bacterial culture was 
obtained. The purified protein was stored at 4 °C for structural studies. Aliquots were 
flash frozen with the addition of 2 % glycerol for fragment screening and kinetic 
analysis.  
 
 
 
 
Figure 7.3 Size exclusion chromatography.  
Two absorbance peaks at 280 nm are observed 
corresponding to proteins of 50 kDa and 200 kDa. 
4 mL fractions were collected. 
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7.4 Fragment screening 
7.4.1 DSF 
The thermal profile of PaIMPDH (Figure 7.4) was determined to establish if this 
enzyme is amenable to DSF (Niesen et al., 2007; Pantoliano et al., 2001; see section 
2.7.3) prior to commencing fragment screening. The thermal profile of PaIMPDH is 
composed of two distinct curves with a Tm of 46.5 °C and 78.7 °C. To determine if each 
melting curve correlates with either the substrate binding site or the dinucleotide 
binding site, a number of DSF assays were carried out in the presence of ligands. 
Analysis of the results indicates a shift of ΔTm +2 °C in the second melting curve as a 
result of the substrate (IMP) and cofactor (NAD+; Figure 7.4A). When IMP and NAD+ 
are assayed individually, no thermal shift is observed in this melting curve (Figures 
7.4B & C). Taken together, this suggests the ΔTm +2 °C thermal shift observed with 
IMP and NAD+ (Figure 7.4A) is a result of the formation of the covalent intermediate 
E-XMP* or the product XMP. The second melting curve with a Tm of 78.7 °C can 
therefore be assigned to the substrate binding site.  
 DSF assays carried out with NADH result in a large thermal shift of ΔTm +18 °C 
in the first melting curve (Figure 7.4D). As noted previously, when NAD+ is tested no 
thermal shift is observed (Figure 7.4C), thus this appears to be a result of the difference 
between the reduced and oxidised forms of the cofactor. The reason for this large shift 
is unclear. However, the reaction mechanism of IMPDH involves the movement of a 
mobile flap (approximately 20 residues) into the dinucleotide binding site (Figure 7.1B; 
Hedstrom et al., 2011). It is possible the large thermal shift observed is linked to this, 
with the mobile flap inducing thermal stability in the enzyme. It is therefore possible to 
assign the first melting curve, with a Tm of 46.5 °C, to the dinucleotide binding site. 
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With the thermal profile of PaIMPDH established, fragment screening using 
DSF was carried out with the Maybridge fragment library as described in section 2.7.3. 
The screening was carried out in the presence of NAD+ to occupy the dinucleotide 
binding site and thus prevent fragments binding to this site. The premise for this was to 
promote the finding of fragments that bind to the substrate site as the dinucleotide site is 
a common requirement of many enzymes. Analysis of the results showed no positive 
thermal shifts to indicate fragment binding. It is likely that the low binding affinity of 
fragments (see section 5.3) is below the threshold that can be detected using DSF.  
Figure 7.4 Thermal profile of PaIMPDH with ligands.  
The stability of PaIMPDH in the presence of ligands was analysed with DSF. A) A thermal shift of ΔTm 
+2 °C in the second melting curve is observed with the addition of IMP and NAD+. B & C) This is not 
observed when either IMP or NAD+ are analysed individually. D) A thermal shift of ΔTm +18 °C is 
observed when NADH is assayed. Experiments were carried out in triplicate and nonlinear regression was 
used to calculate Tm values. Graphs are on a normalised scale to highlight the thermal-shifts observed. 
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7.4.2 BLI 
Fragment screening using BLI (Wartchow et al., 2011) was carried out with 
biotinylated PaIMPDH as described in section 2.7. As with DSF fragment screening, 
NAD+ was present to occupy the dinucleotide site and promote binding to the substrate 
site. Several potential hits were identified, where a fast on/off response was observed 
(Figure 7.5). These fragments were purchased from Maybridge for further analysis.  
 
7.5 Enzyme kinetics 
To assess the potential fragment hits identified using BLI, enzyme assays were carried 
out as described in section 2.8. PaIMPDH has a specific activity of 1.0 µmol min-1 mg-1 
and calculated Km values for NAD+ and IMP of 197 (± 10) µM and 3.3 (± 0.2) mM 
respectively (Figure 7.6A & B). The Km value for the substrate is unexpectedly distinct 
Figure 7.5 BLI sensograms.  
Fragment screening using BLI resulted in a number of potential binding fragments being identified for 
further analysis. Reference sensors are coloured red.  
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from other IMPDH homologues (Table 7.1; Carr et al., 1993; Hager et al., 1995; 
Hedstrom et al., 2011). It is unclear as to why such a low substrate affinity is observed 
for PaIMPDH (Table 7.1), however this result was consistent across multiple 
experiments carried out on different occasions with different batches of protein (data 
not shown). The Km for the cofactor is higher than the reported values of other bacterial 
homologues (with the exception of Helicobacter pylori) and is comparable to the values 
reported for the homologues in parasites (Table 7.1). In general, bacterial IMPDH have 
lower affinity for the substrate and cofactor compared to human homologues 
(Hedstrom, 2009; Zhang et al., 1999a). This difference in kinetic properties can be 
exploited to achieve selective inhibition (Hedstrom, 2009; Zhang et al., 1999a). The 
inhibitor mycophenolic acid (MPA; Allison and Eugui, 2000; Bentley, 2000; Carter et 
al., 1969) is an example of a selective inhibitor as it displays selectivity towards 
eukaryotic IMPDHs. This inhibitor is 1000 times more potent against human IMPDH 
compared to prokaryotic IMPDHs (Figure 7.6B, Table 7.1; Allison and Eugui, 2000; 
Hedstrom, 2009; see section 2.8).  
 
Table 7.1 IMPDH kinetic parameters. 
IMPDH Km IMP (µM) Km NAD+ (µM) Ki MPA (nM) 
Human Type I 14-18 42-70 11-33 
Human Type II 4-9 6-32 7-14 
Aerobacter aerogenes 60 800 No data 
Borelia burgdorferi 30 1100 8000 
Cryptosporidium parvum 29 150 9300 
E. coli 61 2000 ~20,000 
Helicobacter pylori 18 73 No data 
Mycobacterium 
tuberculosis 
78 1000 62,000 
P. aeruginosa 3300 197 8500 
Streptococcus pyogenes 62 1180 > 10,000 
T. foetus 1.7 150 9,000 
Edited from (Hedstrom et al., 2011). 
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Single point percentage inhibition with the fragments DDD00100611, 
DDD00058106, DDD00060410 and DDD00100409 were carried out at 1mM 
(dissolved in 100 % DMSO) as described in section 2.8. Each fragment reduced enzyme 
activity by approximately 25 to 50 % (Figure 7.6C). However it should be noted that 
upon addition of the fragment DDD00060410 to the reaction mixture, precipitation 
became visible and may have affected the results.  
 
 
 
7.6 Crystallisation and data collection 
The crystal structures of PaIMPDH in complex with the fragments identified in section 
6.4.2 were required to assess them further. Thus conditions that promote co-
crystallisation of PaIMPDH with ligands (Figure 7.7, Table 7.2) were sought by 
Figure 7.6 PaIMPDH kinetics. 
The Km for the cofactor (A) and substrate (B) were calculated. The known IMPDH inhibitor, MPA, was 
tested to measure its effect on PaIMPDH (B). The fragments identified from BLI were tested at a single 
concentration of 1 mM to see if an inhibitory effect could be observed (C). All experiments were carried 
out in triplicate and analyses of data were carried out using Prism (GraphPad Software). 
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screening multiple conditions (see section 2.4). This was carried out at 20 °C using the 
sitting drop vapour diffusion method (see section 2.4) with 9 mg mL-1 of protein 
solution. Ligand soaking experiments with apo crystals (Table 7.2) were not carried 
out. 
 
Table 7.2 PaIMPDH crystallisation. 
Ligand Crystals Condition / Days / 
Status 
Figure 
Apo Yes 0.2 M sodium acetate, 
40 % MPD, 35 days, 
dataset measured to 
2.25 Å 
6.7A 
250 µM NAD+ No   
250 µM NADH Yes 10 % PEG 8000, 0.1 M 
HEPES pH 7.5, 8 % 
Ethylene glycol, 38 
days, diffraction to  
3.6 Å 
6.7B 
2 mM IMP / 250 µM 
NAD+ 
Yes 10 % PEG 6000, 0.1 M 
HEPES pH 7.0, 8 days, 
no diffraction  
6.7C 
1 mM mycophenolic acid No   
1 mM DDD00100611 Yes 0.2 M sodium 
thiocyanate, 20 % PEG 
3350, 6 days,  
no diffraction 
6.7D 
1 mM DDD00058106 No   
1 mM DDD00060410 No   
1 mM DDD00100409 No   
 
 
 
Figure 7.7 Crystals of PaIMPDH. 
A) Apo crystal used to measure a medium 
resolution dataset. B) Crystals with NADH, 
C) IMP/NAD+ and the D) DDD00100611 
fragment. 
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A single apo-crystal of PaIMPDH was grown in 0.2 M sodium acetate, 40 % 2-
methyl-2,4-pentanediol (MPD; Figure 7.7A) and was of diffraction quality. This was 
used to measure a 2.25 Å dataset in-house using a Rigaku MicroMax-007 rotating-
anode X-ray generator (copper Kα, λ=1.5418 Å) coupled to an R-AXIS IV++ image plate 
detector. The high concentration of MPD present in the crystallisation condition was a 
suitable cryoprotectant. Data were indexed and integrated using XDS (Kabsch, 2010), 
with space group I4 and unit cell lengths a=b= 115.5 Å and c= 56.4 Å (Table 7.3). 
Data were scaled and the space group suggested using SCALA and POINTLESS (Evans, 
2006) from the CCP4 program suite (Winn et al., 2011). The asymmetric unit consists 
of a single polypeptide chain with an estimated solvent content of 60 % and a Vm 
(Matthews, 1968) of 2.94 Å3 Da-1.  
 
7.6.1 Molecular replacement and model building 
A search of the PDB using the amino acid sequence of PaIMPDH showed 54 % 
sequence identity with Bacillus anthracis IMPDH (PDB 3TSB). The in-house data were 
used to solve the structure by molecular replacement using PHASER (McCoy et al., 
2007), giving a Z-score of 23.4. The initial model consisted of 261 residues, with a 
correlation coefficient of 0.75 and Rwork and Rfree values of 37.2 % and 41.8 % 
respectively. Subsequent model building in COOT (Emsley et al., 2010) extended this 
to 293 residues, with a correlation coefficient of 0.96 and Rwork and Rfree values 
improving to 16.1 % and 19.8 % respectively. Refinement calculations were performed 
using REFMAC5 (Murshudov et al., 2011) and translation/libration/screw analysis 
(TLS) was applied (Painter and Merritt, 2006). The refinement proceeded with the 
incorporation of water molecules and a number of side chains with dual rotamer 
conformations. The refinement was terminated when there were no significant changes 
in Rwork and Rfree values and inspection of the difference map suggested that no further 
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corrections or additions were justified. The geometry and quality of the model was 
validated using MOLPROBITY (Chen et al., 2010) and the subsequent Ramachandran 
plot reveals 99.7 % of residues were in the allowed region. A single residue was found 
in the disallowed region and disorder was evident at several positions where it was not 
possible to interpret diffuse and weak electron density. Consequently a large number of 
residues are absent from the final model. The polypeptide chain consists of residues 1 – 
91, 205 – 370 and 426 – 467. Crystallographic statistics are given in Table 7.3. 
 
Table 7.3 Crystallographic statistics. 
 PaIMPDH 
Space group (Å) I4 
a, b, c (Å) 115.5, 115.5, 56.4 
Resolutiona (Å) 19.1 – 2.25 (2.37 – 2.25) 
No. reflections recorded 86989 (12454) 
Unique reflections 16612 (2476) 
Completeness (%) 94.6 (97.0) 
Multiplicity / <I/σI> 5.2 (5.0) / 16.3 (4.3) 
Wilson B (Å2) 29.3 
Residues / waters 293 / 131 
Rmergeb (%) 9.1 (48.9) 
Rworkc, Rfreed (%) 16.1 / 19.8 
Ave. B-factor (Å2)  
Protein / waters 22.2 / 39.3 
Cruickshank DPIe (Å) 0.2 
Ramachandran plot  
Most favoured  284 
Additional allowed  8 
Outliers  1 
RMSD on ideal valuesf  
Bond lengths (Å) / angles (°) 0.01 / 1.2 
 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rcryst except calculated with a subset, 
5 %, of data that are excluded from the refinement calculations. e. Diffraction Precision Index 
(Cruickshank, 1999). f. (Engh and Huber, 1991). 
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7.7 The PaIMPDH structure 
7.7.1 Overall structure 
Monomers of IMPDH are known to contain two distinct domains; a catalytic domain 
that forms a triose-phosphate isomerase (TIM) barrel fold and a subdomain containing 
two cystathione β-synthase (CBS)/Bateman domains (Bateman, 1997; Hedstrom, 2009; 
Sintchak and Nimmesgern, 2000). The CBS domain is involved in maintaining cellular 
ATP/GTP concentrations (Pimkin and Markham, 2008) but is not required for enzyme 
activity (Nimmesgern et al., 1999). This domain protrudes out from the catalytic 
domain (Figure 7.8A) and is highly flexible (Hedstrom, 2009). As a result, this region 
is often disordered in IMPDH structures (Hedstrom, 2009).  
The structure of PaIMPDH displays only the TIM barrel fold of the catalytic 
domain (Figure 7.8B). A single molecule of PaIMPDH is present in the asymmetric 
unit and the catalytic tetramer is formed by the crystallographic 4-fold axis with the 
operators -y,x,z, -x+1/2,-y+1/2,z-1/2 and -y+1/2,x-1/2,z-1/2 (Figure 7.8C). The 
tetramer has square planar geometry with the large missing region (114 residues) 
located to the corners of the tetramer (Figure 7.8C). PaIMPDH has over 50 % sequence 
identity with many bacterial and parasitic homologues, including Streptococcus 
pyogenes IMPDH (PDB 1ZFJ; Zhang et al., 1999b). Superimposing the two structures 
matches 293 residues with an r.m.s.d of 1.1 Å (Figure 7.8D). The missing residues 92 – 
204, 371 – 425 and 468 – 489 correspond to the CBS domain, mobile flap (involved in 
the hydrolysis reaction) and the C-terminus of PaIMPDH respectively (Figure 7.8D).  
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7.7.2 Active site 
The active site of PaIMPDH is created by a loop (residues 297 – 315) formed near the 
C-terminal ends of β-sheets (Figure 7.9A), a common feature of proteins with a TIM 
barrel fold (Nagano et al., 2002). This loop is flexible and adopts different 
conformations at different stages of the catalytic cycle (Figure 7.9A; Hedstrom, 2009; 
Josephine et al., 2010) and is often disordered in crystal structures (Hedstrom, 2009). 
Recent studies have shown that the active site loop controls the transition between 
Figure 7.8 The structure of PaIMPDH. 
A) The structure of S. pyogenes IMPDH (PDB 1ZFJ; Zhang et al., 1999b) shows the catalytic domain, 
CBS domain and most of the residues comprising the mobile flap. B) The structure of PaIMPDH shows 
the catalytic domain only. β-sheets and α-helices are coloured blue and red respectively. C) View along 
the crystallographic 4-fold axis showing the PaIMPDH tetramer. D) Superimposing PaIMPDH with 
SpIMPDH highlights the missing residues in PaIMPDH as corresponding to the CBS domain, mobile 
flap and C-terminus. 
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dehydrogenase and hydrolase activities (Josephine et al., 2010). This loop is fully 
ordered in PaIMPDH with an average B-factor of 22.5 Å2 for this region, comparable to 
the average for the whole protein (Table 7.3). It displays an “open” conformation 
(Figure 7.9A; Josephine et al., 2010) in contrast to the “closed” conformation observed 
in SpIMPDH when substrate is bound (Figure 7.9A; Zhang et al., 1999b). The 
flexibility of the active site loop is further exemplified in the hIMPDH2 structure in 
complex with the inhibitor 6-Cl-IMP (PDB 1B3O & 1NFB; Figure 7.9B; Colby et al., 
1999). The active site loop undergoes a conformational change that results in the short 
helix nearby being unwound and deformed to allow the catalytic Cys residue to attack 
the C6 position of the purine ring of 6-Cl-IMP (instead of the C2 position in the reaction 
with IMP; Colby et al., 1999; see section 7.1; Figure 7.9B). 
 
Figure 7.9 The PaIMPDH active site. 
A) The active site loop of PaIMPDH (white) compared to SpIMPDH (yellow). B) The chemical structure 
of the inhibitor 6-Cl-IMP. The active site loop of hIMPDH2 (teal; PDB 1NFB) distorts by unwinding the 
α-helix to allow the catalytic Cys to attack the C6 position of 6-Cl-IMP (Colby et al., 1999). Residues and 
ligands from SpIMPDH and hIMPDH2 are highlighted with ` and * respectively.  
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7.8 Discussion 
The characterisation of targets entering the drug discovery process is an important step 
in developing novel drugs (Bunnage, 2011; Frearson et al., 2007; see section 5.2). In 
general, IMPDHs have many of the desired attributes of an attractive drug target (see 
section 5.2). However, the occurrence of purine salvage pathways in organisms (Figure 
7.2; Allison and Eugui, 2000; Hedstrom et al., 2011; Sintchak and Nimmesgern, 2000) 
complicates drug development as escape from inhibition may be possible (Hedstrom et 
al., 2011). In addition, the presence of human IMPDH homologues (Carr et al., 1993; 
Hager et al., 1995; Weber, 1983) makes selective inhibition of IMPDH essential for any 
novel drugs (Hedstrom et al., 2011). Two isoforms of human IMPDH exist, hIMPDH1 
and hIMPDH2, sharing a sequence identity of 84 % (Carr et al., 1993; Hager et al., 
1995). Yet despite such high sequence identity, selective inhibition towards hIMPDH2 
has been achieved (Barnes et al., 2001a; Barnes et al., 2001b). Bacterial IMPDHs in 
general have 40-50 % sequence identity and have different kinetic properties compared 
with the human homologues (Figure 7.10, Table 7.1; Hedstrom, 2009), making 
selective inhibition possible (Hedstrom et al., 2011). 
The apo structure of PaIMPDH was solved and reveals the active site loop in the 
“open” conformation in the absence of any ligand (Figure 7.9). This represents only the 
second apo IMPDH structure (Legionella pneumophila IMPDH, PDB 3R2G) where this 
loop is in this conformation and is well ordered. The structure of Borrelia burgdorferi 
IMPDH (PDB 1EEP) also displays this “open” conformation, however a sulfate ion 
occupying the IMP phosphate binding site stabilises this conformation (McMillan et al., 
2000). A sequence alignment of PaIMPDH with IMPDH homologues shows many of 
the essential residues involved in catalysis are highly conserved (Figure 7.10, Table 
7.4; Hedstrom, 2009). Nevertheless, variation in the residues interacting with the 
adenosine and pyrophosphate portions of NAD+ (Figure 7.10) has been observed 
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(Hedstrom et al., 2011). This variation can be exploited to develop selective inhibitors 
(Hedstrom et al., 2011), an example of which is the inhibitors of Cryptosporidium 
parvum IMPDH (Gollapalli et al., 2010; Umejiego et al., 2008).  
 
 
Table 7.4 Functional IMPDH residues. 
Residue (numbering based on T. foetus) Interactions / Role 
Interactions with IMP:  
Cys319 Essential catalytic residue. 
Ser317 / Tyr405 Forms H-bonds to the ribose phosphate via 
hydroxyl groups. 
Gly360 / Gly381 Forms H-bonds to the ribose phosphate via main 
chain amides. 
Asp358  Forms H-bonds to the ribose hydroxyls of IMP. 
Glu408 (often a Meth) / Gly409 / Glu431 (a Gln in 
hIMPDH2) 
Interacts with the purine ring of IMP via main 
chain H-bonds. 
Interactions with NAD+:  
Asp261 Forms H-bonds with ribose hydroxyls of the 
nicotinamide portion of NAD+. 
Gly312 / Gly314 Forms H-bonds with the carboxamide of NAD+. 
Mobile flap:  
Arg418 / Tyr419 Only residues that are completely conserved in 
this region. Essential for catalysis. 
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Figure 7.10 IMPDH homologues. 
Sequence alignment of PaIMPDH (NCBI Reference Sequence: NP_252459.1, PA3770) with homologues 
from T. foetus (GenBank ABI11203.1), Homo sapians (NCBI Reference Sequence: NP_000875.2), 
Bacillus anthracis (UniProt Q81W29) and S. pyogenes (UniProt P0C0H6). Residues involved in 
interactions with IMP are coloured green. Conserved residues interacting with NAD+ are coloured blue 
and non-conserved residues interacting with the adenosine and pyrophosphate portions are coloured 
magenta and orange respectively. The two conserved residues on the mobile flap are coloured red. 
Residues missing in the PaIMPDH structure are highlighted with a dashed line beneath them.   
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Fragment screening of PaIMPDH was carried out in the presence of NAD+ to 
identify chemical fragments that might bind in the substrate binding site (see section 
7.4). Specificity could be achieved further in the drug discovery process by fragment 
linking/growing (Scott et al., 2012) into the adjacent dinucleotide binding site 
(Hedstrom et al., 2011). Several potential fragment hits were identified using BLI 
(Figure 7.5) with single point inhibition studies indicating each fragment has an 
inhibitory effect on the enzyme activity of PaIMPDH (Figure 7.6C). However, no 
structural information about these fragments could be obtained as diffraction quality co-
crystals could not be produced. The structure of PaIMPDH in complex with a fragment 
would provide confirmation of fragment binding and provide data as to the position and 
interactions made by the fragment. Failure to obtain a complex structure of PaIMPDH 
in future may be offset by mutagenesis studies. If the identified fragments truly bind to 
the active site of PaIMPDH, then mutation of conserved residues in this region can help 
define the residues involved in forming the interaction. This would aid in potentially 
optimising the fragments into drug-like compounds. Further experiments will 
subsequently be required to fully characterise the inhibitory effects of these fragments 
on enzyme activity by calculating IC50 values for each. In addition, the distinct Km value 
for the IMP substrate (Figure 7.6B; Table 7.1) would in future need to be verified and 
an explanation for the vast difference with other IMPDH homologues explained.  
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We report the first crystal structures of a penicillin-binding protein (PBP),
PBP3, from Pseudomonas aeruginosa in native form and covalently linked to
two important β-lactam antibiotics, carbenicillin and ceftazidime. Overall,
the structures of apo and acyl complexes are very similar; however,
variations in the orientation of the amino-terminal membrane-proximal
domain relative to that of the carboxy-terminal transpeptidase domain
indicate interdomain flexibility. Binding of either carbenicillin or ceftazi-
dime to purified PBP3 increases the thermostability of the enzyme
significantly and is associated with local conformational changes, which
lead to a narrowing of the substrate-binding cleft. The orientations of the
two β-lactams in the active site and the key interactions formed between the
ligands and PBP3 are similar despite differences in the two drugs, indicating
a degree of flexibility in the binding site. The conserved binding mode of
β-lactam-based inhibitors appears to extend to other PBPs, as suggested by
a comparison of the PBP3/ceftazidime complex and the Escherichia coli
PBP1b/ceftoxamine complex. Since P. aeruginosa is an important human
pathogen, the structural data reveal the mode of action of the frontline
antibiotic ceftazidime at the molecular level. Improved drugs to combat
infections by P. aeruginosa and related Gram-negative bacteria are sought
and our study provides templates to assist that process and allows us to
discuss new ways of inhibiting PBPs.
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Introduction
The bacterial cell wall consists of N-acetylgluco-
samine-N-acetyl muramic polymers cross-linked via
the penultimate D-alanine residues of muramyl
pentapeptides to form a peptidoglycan network
that is essential for normal cell survival. Penicillin-
binding proteins (PBPs) are membrane-bound
enzymes involved in the final stages of bacterial
cell wall synthesis on the periplasmic side of the
membrane. They have been classified into a high-
molecular-mass (HMM) group, members of which
are essential for cell viability, and a low-molecular-
mass (LMM) group, members of which appear
dispensable for normal cell growth.1 HMM PBPs
are further divided into class A enzymes, which
catalyze both the polymerization of a peptidoglycan
from disaccharide peptides (glycosyltransferase)
and the cross-linking of muramyl peptides (trans-
peptidase), and class B enzymes, which only possess
transpeptidase activity. HMM PBPs consist of two
domains: an N-terminal membrane-proximal do-
main and a C-terminal domain harboring transpep-
tidase activity. In the case of class A PBPs, the N-
terminal domain contains glycosyltransferase activ-
ity; the function of the equivalent domain in class B
PBPs is not known. The smaller LMM PBPs are D,D-
carboxypeptidases that remove the terminal D-
alanine from the muramyl peptide, thus controlling
the level of peptidoglycan cross-linking.1 As the
name indicates, PBPs are also the primary targets of
β-lactam antibiotics, which act as suicide substrates
by mimicking the D-alanyl-D-alanine stem peptide of
peptidoglycan precursors. β-Lactams block the
activity of transpeptidases and carboxypeptidases
by acylating the active site serine residue.2
Crystal structures have been reported for HMM
PBPs from the Gram-negative Escherichia coli
(PBP1b)3 and Neisseria gonorrhoeae (PBP2),4 and the
Gram-positive Streptococcus pneumoniae (PBP1b,5
PBP2x,6–10 and PBP2b11) and Staphylococcus aureus
(PBP2a12), including both apo-enzymes and com-
plexes with β-lactams. All of these structures show
similar active sites, featuring three conserved
catalytic motifs in the transpeptidase domain. The
β-lactams are covalently bound to the active site
serine via the carbonyl of the opened cyclic amide.
Resistance to β-lactams can be rationalized to some
extent by examining the structures of PBPs from
resistant bacteria, which have mutations in residues
close to the catalytic motifs.2,7,11
Our interest is primarilyPseudomonas aeruginosa, an
opportunistic pathogen that is responsible for severe
life-threatening infections, especially in patients
suffering from chronic respiratory diseases such as
cystic fibrosis.13 The genome of P. aeruginosa strain
PAO114 encodes fourHMMPBPs, including one class
A enzyme (PBP1a) and three class B enzymes (PBP2,
PBP3, and PBP3a), which are orthologues of the
corresponding enzymes in E. coli. PBP3 shares 42%
sequence identity with the corresponding protein in
E. coli and has been identified as the primary target of
a number of β-lactams used to treat pseudomonal
infections, including the cephalosporin analogues
cefsulodin15 and ceftazidime,16 piperacillin,17 and the
parenteral carbapenem, doripenem.18
Compared to many other Gram-negative bacteria,
P. aeruginosa is highly resistant to antibiotics and, as
with many bacterial pathogens, resistance increases
with repeated use and misuse of antibiotics. As is
typical of Gram-negative bacteria, antibiotic resis-
tance in P. aeruginosa is largely due to a combination
of β-lactamase production and the action of numer-
ous efflux pumps.19 However, treatment with high
doses of piperacillin has been shown to be associ-
ated with reduced binding to PBPs in clinical
isolates of P. aeruginosa.17 In laboratory strains
lacking β-lactamases, the overproduction of PBP3
in P. aeruginosa promotes reduced sensitivity to
cefsulodin;20 in a separate study, increased resis-
tance to cefsulodin was observed to be associated
with reduced binding to endogenous PBP3.15
PBP3 is a therapeutic target in P. aeruginosa, and we
have determined structures of this HMM PBP in its
native form and in complex with two relevant drugs,
carbenicillin and ceftazidime (Supplementary Mate-
rial, Fig. S1). Carbenicillin is a broad-spectrum
semisynthetic penicillin derivative and was one of
the first derivatives to display significant activity
against Pseudomonas.21 The aminothiazolyl-carrying
ceftazidime16 is similar to cefotaxime, the first third-
generation cephalosporin to be marketed, but differs
with a 2-carboxy-2-oxypropaneiminogroup replacing
a methoxy amino group. This difference increases
efficacy against P. aeruginosa, making ceftazidime one
of only a handful of drugs currently used to treat
Pseudomonas infections. Ceftazidime also displays
potent activity against another of the so-called
superbugs, Burkholderia pseudomallei, which was
previously known as Pseudomonas pseudomallei and
is the causal agent ofmelioidosis, a serious infection in
humans found mainly in Asia. Indeed, ceftazidime is
the frontline drug for the treatment of this disease.
We describe the crystal structures of apo-PBP3
and the acyl complexes with carbenicillin and
ceftazidime, as well as the similarities and differ-
ences between the three structures, and discuss
structural features that might be exploited to derive
novel inhibitors of therapeutic value.
Results and Discussion
Production of PBP3 and binding to β-lactams
A soluble version of recombinant P. aeruginosa
PBP3 was produced by truncating the sequence at
the N-terminus by 34 residues to remove the
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predicted transmembrane helix. The molecular mass
of the purified protein determined by size-exclusion
chromatography was approximately 54 kDa com-
pared to a calculated value of 61 kDa, indicating that
it is most likely a monomer in solution. Binding of
carbenicillin and ceftazidime to the recombinant
protein was confirmed using a thermal shift assay.
The assay used a real-time PCR machine to detect
changes in fluorescence during the thermal un-
folding of the protein in the presence of SYPRO
Orange. Significant temperature stabilization of the
protein was observed for both compounds, with
shifts in the midpoint transition temperature (ΔTm)
of 13.2±0.2 °C and 14.5±0.1 °C following incubation
with either 0.5 mM carbenicillin or 0.5 mM ceftazi-
dime, respectively (Fig. 1).
Overall structure
Three isomorphous structures of P. aeruginosa
PBP3 have been determined: apo-PBP3 at 2.0 Å
resolution, PBP3/carbenicillin complex at 2.4 Å
resolution, and PBP3/ceftazidime complex at 2.6 Å
resolution. The PBP3/carbenicillin complex was
derived from a sample obtained by cocrystallization,
and the ceftazidime complex was derived by
soaking a native crystal in mother liquor containing
the antibiotic. The initial structure was determined
using the coordinates of PBP2 from N. gonorrhoeae4
as molecular replacement model [Protein Data
Bank (PDB) code 3equ]. Crystallographic statistics
(Table 1) indicate that acceptable models have
resulted from the analyses. In all three structures,
residues 35–49, 492–497, and 560–577 are dis-
ordered and do not have sufficient electron density
to allow reliable model building.
PBP3 is a two-domain protein comprising a
C-terminal transpeptidase linked to an extended
N-terminal domain. Overall, PBP3 resembles
other class B PBPs, although it lacks the additional
C-terminal domain unique to the PBP2x structure
(Fig. 2). In common with these other class B PBPs,
there is an α-helical subdomain or “head” domain11
(residues 80–149) towards the N-terminus, which
Fig. 1. Thermal shift assay. (a) PBP3 screened with 500 μM carbenicillin, giving aΔTm of +13.2 °C. The blue curve is the
native protein, and the red curve is the complex. (b) PBP3 screened with 500 μM ceftazidime, giving a ΔTm of +14.5 °C.
The blue curve is the native protein, and the black curve is the complex.
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was not resolved in the PBP2 structure (Fig. 2 and
Table 2). The function of the N-terminal domain of
class B PBPs is not known but possibly serves to
position the transpeptidase domain away from the
inner membrane as part of a multienzyme complex
involved in cell wall biosynthesis.24
Despite a relatively low sequence identity, the
fold of the transpeptidase domain is highly con-
served among PBPs. For the class B enzymes, the
RMSD for the overlap of approximately 80% of the
Cα atoms is 1.5–2.0 Å, depending on the structure
(Table 2). The structural superimpositions also
revealed that the orientation of the transpeptidase
domains varied with respect to the N-terminal
domains in the different structures. For example, in
the overlay of the PBP3 and PBP2b transpeptidase
domains, the N-terminal domains of the PBPs were
rotated as rigid bodies by about 24° with respect to
each other (Table 2), indicating considerable rota-
tional freedom between the N-terminal domain and
the C-terminal domain.
Active site structure
The active site of PBP3 is located in a long cleft
running parallel with the β3 strand across the lower
part of the transpeptidase domain. The three
conserved structural motifs that are common to D,
D-peptidases and β-lactamases are found here and
have well-defined electron density (Fig. 3a). The
SXXK motif (S294-T295-V296-K297) is located at the
N-terminal end of α2 and includes the nucleophilic
S294, together with the α8–β2f loop (residues 407–
409) that forms the base of the cleft. The SXN motif
(S349-S350-N351) occurs in the α4–α5 turn, and
residues 328–334 (β2c and β2c–β2d loop) form one
side of the elongated cleft; the third motif KS/TG
(K484-S485-G486) is positioned on strand β3 and,
together with residues 530–533 in the β5–α11 loop,
forms the opposite side of the cleft. Unlike in
PBP2a,12 which is relatively resistant to β-lactam
inhibition, the catalytic S294 is positioned favorably
for acylation in an open substrate-binding pocket.
The three conserved structural motifs interact with
each other via a network of hydrogen bonds: the
hydroxyl group of S294 forms hydrogen bonds with
the side chains of both K297 and K484 (2.7 Å and
2.8 Å), which are hydrogen bonded to S349 and
N351, respectively (Fig. 3d). The position of K297
makes it one of the possible proton receptors from
the catalytic S294 during the acylation reaction, in
addition to the possible contribution of the β-lactam
carboxylate. There are eight water molecules in the
active site cleft of apo-PBP3, which form an
extensive hydrogen-bonding network with the
protein. The two loops connecting β3 and β4
(K490-A500) and β5 and α11 (S526-F531) are
disordered in the apo-enzyme.
Comparison of apo-enzyme and
acyl-enzyme complexes
In comparing the apo-PBP3 and acyl-PBP3 com-
plexes, it is apparent that the N-terminal domains
Table 1. X-ray data collection and refinement statistics
Data collection
X-ray source Diamond I04 ESRF ID23-2 Diamond I02
Data set PBP3 native PBP3/carbenicillin PBP3/ceftazidime
Wavelength (Å) 1.0000 0.8726 0.9750
Space group P212121 P212121 P212121
Unit cell parameters a, b, c (Å) 66.76, 81.51, 85.94 69.48, 83.44, 89.85 67.08, 81.81, 87.79
Resolution range (Å) 30.0–2.00 (2.07–2.00) 30.0–2.40 (2.49–2.40) 30.0–2.60 (2.69–2.60)
Unique reflections 32,803 (3150) 21,168 (2081) 15,047 (1331)
Completeness (%) 99.6 (96.7) 99.6 (99.9) 98.6 (89.3)
Redundancy 10.4 (5.7) 5.4 (4.9) 5.6 (3.7)
〈I/σ(I)〉 23.9 (3.0) 8.6 (1.9) 11.9 (2.5)
Rmerge 0.143 (0.575) 0.172 (0.582) 0.166 (0.545)
Refinement statistics
Resolution range (Å) 30.0–2.00 30.0–2.40 30.0–2.60
Number of reflections (working/test) 31,100/1649 19,881/1090 14,178/764
R-factora (Rwork/Rfree) 0.171/0.213 0.195/0.242 0.207/0.267
Number of atoms (protein/other) 3787/220 3801/158 3841/69
RMSD on bond lengths (Å) 0.007 0.007 0.006
RMSD on bond angles (°) 1.1 1.1 1.0
Mean B-factor (protein/other) (Å2) 32/38 30/33 21/16
Ramachandran plot
Residues in preferred regions (%) 469 (95.7) 474 (96.9) 373 (88.2)
Residues in allowed regions (%) 21 (4.3) 14 (2.9) 46 (10.9)
Residues in disallowed regions (%) 0 (0.0) 1 (0.2) 1 (0.2)
a Rwork and Rfree are defined by R=∑hkl‖Fobs|−|Fcalc‖/∑hkl|Fobs|, where hkl are the indices of the reflections (used in refinement for
Rwork; 5%, not used in refinement, for Rfree), and Fobs and Fcalc are the structure factors deduced frommeasured intensities and calculated
from the model, respectively.
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showgreater structural flexibility than theC-terminal
transpeptidase domains. Thus, the superposition of
the N-terminal β subdomains (residues 50–79 and
150–221) of the PBP3/carbenicillin and PBP3/cefta-
zidime complexes with the apo-enzyme resulted in
RMSDs of 1.3 Å and 1.1 Å for 166 and 169 equivalent
Cα atoms, and 7° and 5° differences in orientation for
the head subdomains, respectively. By contrast, the
C-terminal transpeptidase domains of both acyl-
PBP3 enzymes superimpose on the apo-enzymewith
RMSDs of 0.8 Å and 0.6 Å for the carbenicillin
complex and the ceftazidime complex for 319 of 324
overlapped Cα positions. This shows that acylation
does not significantly alter the overall conformation
of the transpeptidase domain. However, significant
local changes are observed in the substrate-binding
pocketwithmovement ofβ3 relative toα2, reinstating
the strict anti-parallel arrangement of the three β-
strands (β3, β4, and β5). Strands β3 and β4 of PBP3
bend towards the inhibitor around a hinge region
located at residue G486 on β3 and at residue L504
on β4, resulting in an approximately 4-Å movement
for the Cα atoms of K490 and A500, the last and the
first ordered residues of the β3 and β4 strands in
the apo structure, respectively (Fig. 4a). A similar
movement of the equivalent strands has been
observed following the binding of β-lactams to
other HMM5 and LMM PBPs.25 Ligand binding is
associated with an increased order of the β3–β4 and
β5–α11 loops, as shown by better electron density
for these residues in the two complexes. Both
carbenicillin and ceftazidime display well-defined
electron density in the acylated enzyme complexes
(Fig. 3b and c). The β-lactams are covalently bound
Fig. 2. The overall structure of PBP3. (a) A ribbon diagram of the PBP3/carbenicillin complex showing the overall
fold, antibiotic binding site, and bound glycerol. The diagram is rainbow-colored from blue at the N-terminus to red at
the C-terminus, and the secondary structure elements are labelled in accordance with previous studies.15,16 (b–e) A
comparison of the overall structure of native PBP3 (blue, orange, and red) with those of the PBP3/carbenicillin complex
(b), PBP3/ceftazidime complex (c), PBP2 of N. gonorrhoeae (d), and PBP2x from S. pneumoniae (e). This figure was
produced with PyMOL (www.pymol.org). The rest of the figures were drawn using BOBSCRIPT.22
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to the active site S294 and adopt similar orientations
that are maintained by hydrogen-bonding inter-
actions between S485 and T487 and a carboxylate
group on both compounds (Fig. 3d and e). The
alignment of the drugs with T487 resembles a short
segment of anti-parallel β-sheet. Note that ceftazi-
dime is susceptible to hydrolysis,26 and since the R2
piperidine moiety of ceftazidime is lost on β-lactam
ring opening, both compounds have similar chem-
ical groups at this position [i.e., one methyl
(ceftazidime) or two methyls (carbenicillin)], and
these are positioned near V333 and F531 (Fig. 3g).
The principal difference between the inhibitors
involves the nature and the size of the R1 sub-
stituent (Fig. 3b and c; Supplementary Material, Fig.
S1). In both complexes, the R1 amide linkage forms
hydrogen bonds with the main-chain carbonyl of
T487 and with the side chain of N351, and a cluster
of aromatic residues (Y501, Y530, and F531) forms
hydrophobic contacts with the R1 groups (Fig. 3e
and f). In the carbenicillin complex, the R1 carboxy-
late forms hydrogen bonds with the side-chain
hydroxyl of Y409 and a water molecule, which in
turn interacts with the main-chain amide of R489.
In order to accommodate the much larger R1 sub-
stituent on ceftazidime, the side-chain of Y409 is
rotated away from the position observed in the apo-
structure. This movement creates a subpocket
where van der Waals interactions involving E291,
G293, and A488 help to position the R1 aminothia-
zole ring and allows ring-stacking interactions with
Y409. The position of the aminothiazole ring is also
stabilized through bifurcated hydrogen bonds to
the main-chain carbonyl of R489 and to the side-
chain of E291, which is the only negatively charged
residue in the cleft (Fig. 3g). The main-chain amide
of R489 donates a hydrogen bond to the thiazole
nitrogen. In the ceftazidime complex, the side-chain
of R489 is rotated towards the ligand, allowing the
side chain to donate a hydrogen bond to the R1
dimethyl/carboxylate group (Fig. 3f and g).
Conservation of active-site residues in
B. pseudomallei PBP3
As mentioned earlier, ceftazidime is used to treat
infections with B. pseudomallei. The amino acid
sequences of PBP3 from P. aeruginosa and B.
pseudomallei were aligned (accession numbers
Q51504 and Q63QJ1, respectively; data not
shown). The enzymes share an approximately 40%
identity. Of 12 residues (in and around the active
site) that are critical for P. aeruginosa PBP3
reactivity and interaction with ceftazidime (K297,
V333, S349, N351, Y409, K484, S485, T487, R489,
Y501, Y530, and F531), 9 are strictly conserved. The
differences are that V333 changes to aspartate, R489
changes to tyrosine, and Y530 changes to histidine.
These are sterically conservative changes (e.g., the
aliphatic component of the aspartate side-chain
matches closely to a part of valine) and suggest that
our model of the PBP3/ceftazidime complex
reveals the structural basis for the action of cefta-
zidime in the treatment of melioidosis. Further-
more, this model provides a template for informing
inhibitor development.
Table 2. A comparison of class B PBP structures
PDB code Number of Cα equivalences Identical sequence RMSD (Å) Rotation (Å) Translation (Å)
Overlap of the C-domain onto PBP3 native (residues 222–558)
2wad-A 267 59 1.7 NA
1rp5-A 293 75 1.9 NA
1mwr-A 262 57 2.0 NA
3equ-A 302 126 1.5 NA
Overlap of the N-terminal subdomain (residues 50–79 and 150–221)
2wad-A 84 20 1.8 24.9 1.1
1rp5-A 97 28 1.3 2.5 0.4
1mwr-A 71 24 1.4 17.0 1.0
3equ-A 90 41 1.7 8.9 0.1
Overlap of the head subdomain (residues 80–149)
2wad-A 60 8 2.5 28.7 1.0
1rp5-A 67 7 1.9 60.3 2.1
1mwr-A 60 11 2.1 76.6 0.3
3equ-A
NA, not applicable.
The structures of the C-terminal transpeptidase domain, N-terminal β-stranded subdomain, and N-terminal β-stranded head subdomain
were sequentially aligned to PBP3 using SHP.23 The results show the RMSD for Cα atoms, and the rotation and translation distances
required to overlay all of the domains. In each case, molecule A in the PDB entries for the following structures was used for the
comparison: S. pneumoniae PBP2b (PDB code 2wad), S. pneumonia PBP2x (PDB code 1rp5), S. aureus PBP2a (PDB code 1mwr), and N.
gonorrhoeae PBP2 (PDB code 3equ).
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Fig. 3. The active site of PBP3. (a–c) 2Fo−Fc maps calculated after the final round of refinement and contoured at 1σ
showing the electron density for the three active site structural motifs in apo-PBP3, bound carbenicillin, and ceftazidime in
the two complexes, respectively. In (b) and (c), the carbon atoms of the acylated S294 are shown in cyan. (d–f) The active
sites of apo-PBP3, carbenicillin, and ceftazidime complexes. The protein main chains are shown as gray ribbons, side
chains are drawn as cyan sticks, and the inhibitor is shown in orange ball-and-sticks. The red spheres represent water
molecules, and the yellow broken lines represent potential hydrogen bonds. Residue V333 that makes contacts with the
bound inhibitors is not shown in (e) and (f) for clarity. (g) Comparison of the active sites of the PBP3/carbenicillin complex
(cyan) and the PBP3/ceftazidime complex (orange).
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Active site flexibility and variations
A common feature observed in the crystal
structures of PBPs is the flexibility of the active
sites, especially the loop linking β3–β4. This may be
an intrinsic property of these enzymes that is
required for substrate binding and release during
the catalytic process. Active site flexibility has also
been suggested to be a key mechanism for acquisi-
tion of drug resistance.11 Comparison of the
structure of antibiotic-sensitive wild-type PBPs
with those from resistant strains has shown that
mutations occur in residues close to but not actually
in the active site.4,11 The conformational change in
β3 and β4 strands introduced by inhibitor binding
opens up a small pocket on the other side of the β-
sheet that is occupied by water molecules in apo-
PBP3 (Fig. 4a). The crystal of the PBP3/carbenicillin
complex had been soaked with cryoprotectant
solution containing 20% glycerol prior to freezing
(no cryoprotectant was used for apo and ceftazi-
dime-soaked crystals). As a result, the pocket is
Fig. 4. Glycerol binding, comparison with PBP1b, and electrostatic properties of the active site. (a) A diagram showing
that the glycerol binding site is separated from the inhibitor binding site by β3–β4 strands and large conformational
changes of the two strands due to inhibitor binding. The main-chain backbones of apo-PBP3 and the PBP3/carbenicillin
complex are shown as gray and blue ribbons, respectively. (b) Comparison of the glycerol-binding site in the PBP3/
carbenicillin complex with that in the apo-enzyme. The main chains and side chains are shown as ribbons and sticks,
respectively (in gray and red for apo-PBP3; in blue and cyan for the carbenicillin complex), and the glycerol molecule is
drawn as orange sticks. (c) Comparison of the active sites of the PBP3/ceftazidime complex (orange) and the S.
pneumoniae PBP1b/cefotaxime complex (cyan). (d) Electrostatic surface showing the inhibitor-binding pocket of the
PBP3/carbenicillin complex. (a) and (c) were produced with PyMOL (www.pymol.org).
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occupied by a well-ordered glycerol molecule,
which makes hydrogen-bonding interactions with
S248, R284, D523, and a trapped water molecule,
and hydrophobic contacts with residues G247, S248,
F290, and V521 (Fig. 4b). This pocket could be
targeted for the design of a new type of inhibitor that
restricts active site “breathing.” The influence of
such a ligand could be to increase the free energy of
PBP3 ligand binding by restricting the conforma-
tional flexibility of the enzyme.27 A potential benefit
could be use in conjunction with β-lactams to
combat drug resistance.
Apart from the three conserved active site motifs,
residues lining the substrate-binding cleft of PBPs
are poorly conserved. Amino acid insertions and
deletions often occur among PBPs and result in
variations in the shape and size of the active site
clefts. For example, S. pneumoniae PBP2x has an
extended β3–β4 loop and a shorter linker between
β5 and α11, resulting in an active-site cleft that is
wider at one end and narrower at the other end
compared to PBP3. The structure of the complex of
S. pneumoniae PBP1b with cefotaxime, a close
analogue of ceftazidime, has been reported,11
enabling a direct comparison of binding modes
with the PBP3 complex. Superimposition of the
complexes reveals that the two inhibitors dock into
their respective targets in a remarkably similar way.
The orientations of the residues that form hydrogen
bonds with the common β-lactam core of the
inhibitors, namely S485 (PBP3)/T652 (PBP1b),
T487 (PBP3)/T654 (PBP1b), and N351 (PBP3)/
N518 (PBP1b), are closely matched (Fig. 4c). N656
(PBP1b) and R489 (PBP3), which interact with the R1
groups of cefotaxime and ceftazidime, respectively,
are also closely aligned, with their relative positions
determined by the size of the R1 substituents. These
observations point to a common binding mode for
cephalosporin analogues to the HMM PBPs. Resi-
dues E291, Y409, and R489 in PBP3, which make key
interactions with the R1 groups of ceftazidime, are
replaced in PBP1b by S457, G558, and N656,
respectively, likely reducing the affinity of PBP1b
for the inhibitor given the different nature of these
residues. More generally, sequence variation at
these three positions could be a major factor
contributing to the different specificities and affin-
ities of cephalosporin analogues across PBPs.
Finally, it is striking that in all published
structures of PBP/inhibitor complexes, the inhibi-
tors occupy the central portion of the active site
pocket, leaving a large volume of the cleft unoccu-
pied (Fig. 4c and d). It may be possible to design
inhibitors that utilize these “free” volumes to
increase protein–inhibitor interactions and/or to
prevent β-lactamase hydrolysis. Such modifications
offer the potential of enhancing binding affinity for
the target and of overcoming drug resistance caused
by β-lactamase production.
Experimental Procedures
Protein production
A truncated version of the ftsI gene, omitting the bases
encoding the first 34 amino acids (residues D35-G579),
was amplified by PCR using P. aeruginosa PAO1 strain
genomic DNA (ATCC strain 15692; LGC Standards Office,
UK). The template and primers were designed for ligation-
independent cloning via In-fusion™ technology (Clon-
tech). PCR with KODHiFi™ polymerase (Merck) used the
following forward and reverse primers: 5′-aagttctgttt-
cagggcccgGACCTGCACGTGATCGACC-3′ and 5′-
atggtctagaaagctttaGCCACGCCCTCCTTTTGC-3′, respec-
tively. The PCR product was purified using paramagnetic
microparticles28 (Agencourt AmPure™ System; Beckman
Coulter) and inserted into the vector pOPINF using the
protocol of Berrow et al.29 Recombinant clones were
identified by PCR with the gene-specific forward primer
and a T7 reverse primer, and verified by DNA sequencing.
Native PBP3 was produced in the E. coli strain Rosetta
pLysS (DE3) using autoinduction.30 Cells were grown in
2-L cultures of Overnight™ Express Instant TB media
(Merck) at 37 °C for 4 h, and the temperature was then
lowered to 25 °C. After incubation for a further 20 h, the
cells were harvested by centrifugation for 15 min at 6000g
and lysed using a Basic-Z Cell Disruptor (Constant
Systems) at 30,000 psi in the presence of 50 mM Tris–
HCl (pH 7.5), 500 mM NaCl, 0.2% Tween-20, 10 μg/ml
DNase, and an ethylenediaminetetraacetic-acid-free Pro-
tease Inhibitor Cocktail Tablet (Roche). The lysate was
centrifuged at 16,000g for 30 min to remove cell debris
before the soluble fraction was loaded onto a 1-ml
HisTrap FF column (GE Healthcare). The column was
washed with 50 mM Tris–HCl (pH 7.5), 500 mM NaCl,
and 20 mM imidazole before the elution of the protein in
50 mM Tris–HCl (pH 7.5), 500 mM NaCl, and 500 mM
imidazole. The protein was then injected onto a 16/60
HiLoad™ Superdex 75 column (GE Healthcare) and
eluted in 20 mM Tris–HCl (pH 7.5) and 200 mM NaCl.
Protein-containing fractions were analyzed by SDS-PAGE
(NuPage; Invitrogen) and combined, and the NaCl
concentration was adjusted to 400 mM to improve
protein solubility. Protein (4 mg/ml) was flash frozen
and stored at −80 °C.
Thermal shift assay
A thermal shift assay,31,32 using the fluorescent dye
SYPRO Orange (Invitrogen), was employed to demon-
strate that the recombinant PBP3 binds the β-lactams and
to determine their effect on protein stability. PBP3 was
screened with carbenicillin and ceftazidime. Solutions of
PBP3 at 4 μM, 1000× SYPRO Orange, and compounds at
500 μM concentration were made, and 40 μl was added to
a 96-well thin-wall PCR plate (Thermo Scientific). The
plates were sealed with adhesive PCR seal (4titude) and
heated in an Mx3005p qPCR machine (Stratagene) from
25 °C to 95 °C at a rate of 1 °C/min. Fluorescence changes
were monitored with excitation and emission wave-
lengths of 492 nm and 610 nm, respectively. Reference
wells (i.e., solutions consisting only of PBP3 and the dye)
were used to compare the melting temperature (Tm)
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values. In order to rule out any effects caused by the
presence of buffer, we used wells with buffer and 1000×
SYPRO Orange as controls. Experiments were carried out
in triplicate, and nonlinear regression analysis was
determined in the curve-fitting program Prism (GraphPad
Software). Tm values were calculated for each well and
compared to the reference Tm values to obtain ΔTm for
each compound. A Microsoft Excel script† was used for
convenient observations and comparison of melting
curves and thermal shifts.
Crystallization, data collection, and
structure determination
Protein crystallization was carried out using standard
Oxford Protein Production Facility protocols.33 Native
crystals were grown by sitting-drop vapor diffusion at
room temperature in 25% (wt/vol) polyethylene glycol
3350 and 0.1 M 2-[bis(2-hydroxyethyl)amino]-2-(hydro-
xymethyl)propane-1,3-diol propane (pH 7.8) containing
1% (wt/vol) protamine sulfate (Silver Bullet Screen;
Hampton Research). Acyl complexes were obtained by
either cocrystallization or soaking experiments. Crystals of
the carbenicillin complex were obtained in 20% (wt/vol)
polyethylene glycol 3350 and 0.2 M disodium tartrate
containing 0.5 mM carbenicillin. The PBP3/ceftazidime
complex was obtained by soaking native crystals in the
crystallization solution containing 10 mM ceftazidime for
30 min at room temperature. All crystals were flash frozen
in liquid nitrogen and then kept at −173 °C under a stream
of nitrogen gas during data collection. No cryoprotectant
was used apart from the carbenicillin complex, where a
crystal was soaked in solution containing 20% glycerol
(vol/vol) and 80% of the reservoir solution for a few
seconds before freezing. X-ray data were collected for the
carbenicillin complex on beamline ID23.2 of the European
Synchrotron Radiation Facility (ESRF; Grenoble, France),
and data sets from the native and ceftazidime-soaked
crystals were collected on beamlines I03 and I02 of the
Diamond Light Source (Harwell, UK), respectively.
The diffraction data were indexed and integrated with
DENZO, and merged with SCALEPACK.34 The statistics
of the data are shown in Table 1. The crystals belong to the
orthorhombic space group P212121, with one protein
molecule per asymmetric unit and an approximate bulk
solvent content of 44%. The structure of the PBP3/
carbenicillin complex was solved by molecular replace-
ment using the coordinates of N. gonorrhoeae PBP2 (PDB
code 3equ)4 as search model. The starting model shares a
34% sequence identity with P. aeruginosa PBP3 and lacks
the 72 residues that form the head subdomain. The
orientation and position of the model in the PBP3 crystal
were determined using the program MOLREP35 and
refined with rigid-body refinement using data from 30 Å
to 4.0 Å. The model was then subjected to restrained
maximum-likelihood refinement with REFMAC using all
data up to 2.3 Å resolution.36 The 2Fo−Fc map calculated
at this stage showed well-defined electron density for the
transpeptidase domain, which allowed the majority of
residues within the domain to be built with confidence;
the electron density for the N-terminal domain, especially
for the missing head subdomain, was poor and fragmen-
ted, but gradually improved after each round of refine-
ment andmodel rebuilding with Coot.37 Several rounds of
refinement and model rebuilding led to a model of 498
residues (out of 543), with good stereochemistry and an
R-factor of 0.196 (Rfree=0.250) for all data up to 2.3 Å
resolution. The structure of the PBP3/carbenicillin com-
plex was then used to determine the structures of the apo-
enzyme and the ceftazidime complex. The statistics for the
final refined structures are given in Table 1.
Accession numbers
The atomic coordinates and structure factors for apo-
PBP3, the PBP3/carbenicillin complex, and the PBP3/
ceftazidime complex have been deposited in the PDB
under accession codes 3oc2, 3ocl, and 3ocn, respectively.
Supplementary materials related to this article can be
found online at doi:10.1016/j.jmb.2010.10.024
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Lip is a membrane-bound lipoprotein and a core component
of the type VI secretion system found in Gram-negative
bacteria. The structure of a Lip construct (residues 29–176)
from Serratia marcescens (SmLip) has been determined at
1.92 A˚ resolution. Experimental phases were derived using
a single-wavelength anomalous dispersion approach on a
sample cocrystallized with iodide. The membrane localization
of the native protein was confirmed. The structure is that
of the globular domain lacking only the lipoprotein signal
peptide and the lipidated N-terminus of the mature protein.
The protein fold is dominated by an eight-stranded -sandwich
and identifies SmLip as a new member of the transthyretin
family of proteins. Transthyretin and the only other member
of the family fold, 5-hydroxyisourate hydrolase, form homo-
tetramers important for their function. The asymmetric unit
of SmLip is a tetramer with 222 symmetry, but the assembly
is distinct from that previously noted for the transthyretin
protein family. However, structural comparisons and bacterial
two-hybrid data suggest that the SmLip tetramer is not
relevant to its role as a core component of the type VI
secretion system, but rather reflects a propensity for SmLip
to participate in protein–protein interactions. A relatively low
level of sequence conservation amongst Lip homologues is
noted and is restricted to parts of the structure that might be
involved in interactions with physiological partners.
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1. Introduction
Protein secretion systems are critical to the virulence and host-
interaction processes of Gram-negative pathogens. Different
bacterial species possess different combinations of one or
more specialized proteinaceous machines that secrete toxins,
adhesins, hydrolytic enzymes and proteins able to manipulate
eukaryotic signalling pathways (Gerlach & Hensel, 2007;
Holland, 2010). The most recently discovered system, the type
VI secretion system (T6SS), is present in many Gram-negative
bacteria and is implicated in virulence in important human
pathogens including Pseudomonas aeruginosa (Cascales, 2008;
Filloux et al., 2008; Jani & Cotter, 2010). It has also been
shown to contribute to the virulence of economically signifi-
cant animal and plant pathogens (Liu et al., 2008; Blondel et
al., 2010; Sarris et al., 2010). Some T6SSs appear to target other
bacterial cells instead of, or in addition to, eukaryotic cells
(Hood et al., 2010; MacIntyre et al., 2010; Murdoch et al., 2011).
This suggests that T6SSs may contribute to allowing pathogens
to proliferate in polymicrobial infection sites and/or to persist
in different environmental reservoirs (Schwarz et al., 2010;
Murdoch et al., 2011). Serratia marcescens is an opportunistic
pathogen, a significant cause of hospital-acquired infections
and an important reservoir of antibiotic-resistance determi-
nants in the clinical environment (Hejazi & Falkiner, 1997).
It is also a tractable model organism in which to dissect the
structure–function relationships in the T6SS (Murdoch et al.,
2011).
Studies of the T6SS have started to reveal information
on the components and the biological role of this recently
discovered system (Cascales, 2008; Filloux et al., 2008;
Pukatzki et al., 2009; Bo¨nemann et al., 2010). T6SSs are large
multiprotein complexes encoded on variable gene clusters
characterized by the presence of genes encoding 13 ‘core’
components. These are thought to form the basic secretion
apparatus, which is coupled with ‘accessory’ components that
are conserved across many or only a few systems. Key core
components include the putative extracellular Hcp/VgrG
assembly, which is thought to form a cell-puncturing device
similar to that of bacteriophage tail structures (Pukatzki et al.,
2009). There are a number of predicted cytoplasmic proteins
(e.g. an ATPase called ClpV) and several inner membrane
proteins (e.g. IcmF and IcmH). Additionally, and the subject of
this work, the only outer membrane component reported to
date is a periplasmic-facing outer membrane lipoprotein (Lip;
Aschtgen et al., 2008).
Genetic studies indicate that in S. marcescens this lipopro-
tein (SmLip) makes an essential contribution to the basic
function of the T6SS and to T6SS-dependent antibacterial
killing activity (Murdoch et al., 2011). We now report the high-
resolution structure of SmLip determined following phase
determination using single-wavelength anomalous dispersion
(SAD) measurements based on the scattering properties of
iodide ions. The localization of the protein in S. marcescens
itself and bacterial two-hybrid data are reported to investigate
the propensity for self-association. The structure reveals a
remarkable similarity to transthyretin, a vertebrate hormone-
distribution protein, and comparisons suggest which parts of
SmLip may be involved in protein–protein interactions with
partner components of the T6SS.
2. Methods
2.1. Protein expression and purification
The S. marcescens lip gene (SMA2252; Murdoch et al.,
2011) encoding amino-acid residues 30–176 was amplified
from genomic DNA (strain Db10) using the forward primer
50-catatgGCCAAAAGCGTGCCGTCGCGTTACAG-30 and
the reverse primer 50-ggatccTCAGTCGACCTTTTTTACG-
GGGCGCAGGC-30 (the lower-case sequences correspond to
the NdeI/BamHI restriction sites used for cloning). The PCR
product was ligated into PCR-BluntII-TOPO using the Zero
Blunt TOPO Cloning Kit (Invitrogen) and then cloned into
a pET15b (Novagen) cloning vector modified to encode a
tobacco etch virus (TEV) protease cleavage site in place of the
thrombin protease cleavage site. The construct was verified
by DNA sequencing (DNA Sequencing Unit, University of
Dundee).
The recombinant protein was produced in Escherichia coli
BL21 (DE3) pLysS cells (Stratagene). Cultures were grown
for 3 h at 310 K in auto-induction medium (Studier, 2005)
supplemented with 50 mg l1 carbenicillin before overnight
growth at 295 K. Cells were harvested by centrifugation
(3500g at 277 K for 30 min). The cell pellet was resuspended
in buffer A (25 mM Tris–HCl pH 7.5, 500 mM NaCl, 20 mM
imidazole pH 8.5) supplemented with an EDTA-free Protease
Inhibitor Cocktail Tablet (Roche) and 0.2 mg DNase I
(Sigma–Aldrich). Cells were lysed using a continuous-flow
cell disrupter (Constant Systems) at 207 MPa and cell debris
was removed following centrifugation (40 000g at 277 K for
30 min). SmLip was purified using nickel-affinity chromato-
graphy with a 5 ml HisTrap HP column (GE Healthcare) pre-
charged with Ni2+. A step gradient of 5% buffer B (25 mM
Tris–HCl pH 7.5, 500 mM NaCl, 500 mM imidazole) was used
to remove histidine-rich proteins. A linear concentration
gradient of imidazole from 5 to 50% buffer B was applied to
elute the product, which was then dialyzed against buffer C
(25 mM Tris–HCl, 250 mM NaCl pH 7.5) at 277 K overnight
in the presence of His-tagged TEV protease. The resulting
mixture was applied onto the HisTrap column, which bound
the cleaved His tag, TEV protease and uncleaved SmLip. The
SmLip sample from which the His tag had been cleaved was
present in the flowthrough. Fractions were analyzed using
SDS–PAGE and those containing SmLip were pooled. The
protein was further purified by size-exclusion chromatography
using a Superdex 75 26/60 column (GE Healthcare) equili-
brated with buffer C on an A¨KTApurifier (GE Healthcare).
The column had previously been calibrated with the molecular-
weight standards blue dextran (>2000 kDa), thyroglobulin
(669 kDa), ferritin (440 kDa), aldolase (158 kDa), conalbumin
(75 kDa), ovalbumin (43 kDa), carbonic anhydrase (29.5 kDa),
ribonuclease A (13.7 kDa) and aprotinin (6.5 kDa) (GE
Healthcare; data not shown). The protein eluted as one peak
of approximate mass 17 kDa, corresponding to a monomer.
Fractions containing the protein were pooled and concen-
trated to 10 mg ml1 using Amicon Ultra devices (Millipore)
for subsequent use. The purity of the protein was confirmed by
SDS–PAGE and mass spectrometry (Fingerprint Proteomics
Facility, University of Dundee). A theoretical extinction co-
efficient of 16 960 M1 cm1 at 280 nm was used to estimate
the protein concentration (ProtParam; Gasteiger et al., 2005);
the theoretical mass of one subunit was estimated as 16.1 kDa
with a calculated isoelectric point of 5.4. The purified protein
sample was stored at 277 K until further use.
2.2. Crystallization, data collection and structure
determination
Initial crystallization screens were carried out at 293 K by
the sitting-drop vapour-diffusion method in 96-well plates.
This was achieved using a Phoenix liquid-handling system
(Rigaku, Art Robbins Instruments) and the commercially
available PEG (Qiagen) and JCSG+ (Molecular Dimensions)
screens. Crystallization occurred in two conditions, which were
further optimized using the hanging-drop vapour-diffusion
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method with drops consisting of 1 ml protein solution at
10 mg ml1 in 25 mM Tris–HCl pH 7.5, 250 mM NaCl and 1 ml
reservoir solution. The two conditions involved reservoirs
consisting of 20% polyethylene glycol 3350, 200 mM KI and
of 15% polyethylene glycol 3350, 200 mM NaCl. Monoclinic
blocks with minimum dimensions of approximately 0.3 mm
grew over 2 d and the addition of glycerol to 10% proved to be
a suitable cryoprotectant.
Crystals from the iodide-containing condition were char-
acterized first and data set I was measured in-house using
a Rigaku MicroMax-007 rotating-anode X-ray generator
(Cu K,  = 1.541 A˚) coupled to an R-AXIS IV++ image-plate
detector. A crystal from the second condition was stored in
liquid N2 and subsequently used to measure a high-resolution
data set (data set II) on beamline ID29 at the European
Synchrotron Radiation Facility (ESRF; Grenoble, France)
using an ADSC Q315R detector. All data were indexed and
integrated using XDS (Kabsch, 2010) and scaled using
SCALA (Evans, 2006) from the CCP4 program suite (Winn et
al., 2011).
Data set I was used to solve the structure by SAD methods
targeting the iodides present in the crystallization conditions
and to acquire a fairly complete model. The sites of potential
anomalous scattering ions or atoms were identified using
PHENIX (Adams et al., 2010) and experimental phases were
calculated using Phaser (McCoy et al., 2007). Density modifi-
cation was carried out using histogram matching, averaging on
the basis of noncrystallographic symmetry (NCS), and model
building was carried out using RESOLVE (Terwilliger, 2003).
NCS restraints were employed in the initial refinement
calculations, which were performed using REFMAC5 (Mur-
shudov et al., 2011). Inspection of the model and the fit to
electron-density and difference density maps was carried out
in Coot (Emsley et al., 2010). The analysis then switched to
the high-resolution synchrotron data set II when it became
available and this was used to complete the refinement.
MolProbity (Chen et al., 2010) was used to investigate model
geometry in combination with the validation tools provided in
Coot. Analyses of surface areas and interactions were made
using the PISA (Krissinel & Henrick, 2007) web service and
secondary-structure analysis was performed using DSSP
(Kabsch & Sander, 1983). Crystallographic statistics are
summarized in Table 1.
2.3. Bacterial two-hybrid analyses
For generation of the plasmid pSC072, the gene fragment
encoding SmLip amino acids 27–176 was PCR-amplified using
primers 50-TATAgcatgcGTAAAGAGGAGGCTGCATGTC-
TTCCGCCAAAAGC-30 and 50-TATAtctagaGAGTCGAC-
CTTTTTTACGGGGC-30 and cloned into the vector pUT18
(Karimova et al., 2001) using SphI and XbaI restriction sites.
The restriction sites are shown in lower case. For generation of
another plasmid, pSC080, the same gene fragment was
PCR-amplified using primers 50-TATAggatccAATGTCTTC-
CGCCAAAAGCG-30 and 50-TATAggtaccAATGATGACG-
ACCCCTATCGC-30 and cloned into vector pT25 (Karimova
et al., 1998) using BamHI and KpnI restriction sites (again
shown in lower case). Bacterial two-hybrid analyses were
performed following established protocols (Karimova et al.,
1998, 2000). E. coli BTH101 was transformed with pSC072 (or
pUT18 control) and pSC080 (or pT25 control) and the colour
of the resulting transformants was scored on MacConkey
media with 0.2% maltose (with a positive result being red).
For quantitative measurement of the interaction, -galacto-
sidase assays were performed as described by Murdoch et al.
(2011) on double-transformed BTH101 grown at 303 K in
Luria–Bertani broth (LB) and permeabilized with toluene.
Replicate assays were performed on independent transfor-
mants.
2.4. Cellular localization of Lip
Wild-type S. marcescens strain Db10 and the lip mutant
SJC10 (Murdoch et al., 2011) were grown for 8 h at 303 K
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Table 1
Crystallographic statistics.
Values in parentheses are for the highest resolution shell.
Data set I Data set II
Space group C2 C2
Wavelength (A˚) 1.5418 1.007
Unit-cell parameters (A˚, ) a = 139.7, b = 77.6,
c = 54.3,  = 98.4
a = 139.7, b = 77.8,
c = 54.5,  = 98.3
Resolution (A˚) 19.7–2.35 (2.48–2.35) 39.8–1.92 (2.02–1.92)
No. of reflections recorded 94650 (11192) 280802 (38597)
Unique reflections 23495 (3109) 43478 (6188)
Completeness (%) 98.3 (90.0) 98.2 (95.8)
Multiplicity 4.0 (3.6) 6.5 (6.2)
hI/(I)i 30.9 (6.6) 20.6 (3.7)
Anomalous completeness
(%)
95.7 (84.5) —
Anomalous multiplicity 2.0 (1.8) —
Wilson B (A˚2) 47.7 32.7
No. of residues/waters — 541/336
Rmerge† (%) 2.6 (17.1) 4.9 (44.2)
Rwork‡ (%) — 22.0
Rfree§ (%) — 29.2
Average B factors (A˚2)
Chain A — 36.1
Chain B — 41.6
Chain C — 49.5
Chain D — 59.8
Waters — 46.2
Na+ — 37.8
Ethylene glycol — 60.2
Cruickshank DPI} (A˚) — 0.2
Ramachandran plot
Most favoured — 516 residues
Additional allowed — 21 residues
Outliers — Molecule D: Phe97,
Asp129; molecule B:
Pro142, Ser154
R.m.s.d. on ideal values††
Bond lengths (A˚) — 0.01
Bond angles () — 1.42
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the intensity of
the ith measurement of reflection hkl and hI(hkl)i is the mean value of Ii(hkl) for all i
measurements. ‡ Rwork =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj, where Fobs is the observed
structure factor and Fcalc is the calculated structure factor. § Rfree is the same as Rcryst
except calculated with a subset (5%) of data that were excluded from the refinement
calculations. } Cruickshank (1999). †† Engh & Huber (1991).
in LB. Subcellular fractionation was performed following
an established method (Hatzixanthis et al., 2003). In brief,
following isolation of clean supernatant by centrifugation,
washed cell pellets were resuspended in 50 mM Tris–HCl pH
7.5, 40%(w/v) sucrose at 10 ml per gram of cells. EDTA was
then added to 5 mM (final concentration) and lysozyme was
added to 0.6 mg ml1 before incubation at 310 K for 30 min.
Sphaeroplasts were harvested by centrifugation and taken up
in an equivalent volume of 50 mM Tris–HCl pH 7.5 before
French pressure treatment. Following ultracentrifugation of
the resultant crude extract, the isolated membranes were
again taken up in an equivalent volume of 50 mM Tris–HCl
pH 7.5. This protocol ensured that equivalent proportions of
each cell fraction were assayed. 4 ml of each fraction was
mixed with SDS sample buffer (100 mM Tris–HCl pH 6.8,
3.2% SDS, 3.2 mM EDTA, 16% glycerol, 0.2 mg ml1
Bromophenol blue, 2.5% -mercaptoethanol) and separated
by 15% SDS–PAGE prior to anti-Lip immunoblotting. Whole-
cell samples comparing wild-type versus SJC10 were prepared
by resuspending cells from 100 ml culture in 100 ml SDS
sample buffer and boiling for 5 min prior to loading 6 ml onto
the gel. Following SDS–PAGE, proteins were electroblotted
onto polyvinylidine fluoride membrane (Millipore). SmLip
was detected by hybridization of the primary antibody poly-
clonal rabbit anti-Lip (1:4000) followed by the secondary
antibody HRP-conjugated goat anti-rabbit (Thermo; 1:10000)
and the use of an enhanced chemiluminescent detection kit
(Millipore).
3. Results and discussion
3.1. Structure determination
Full-length SmLip consists of 176 residues. A truncated
version of SmLip consisting of an N-terminal hexahistidine
tag plus a TEV protease recognition site followed by residues
Ala30–Asp176 was obtained in recombinant form and puri-
fied. The N-terminal 29 amino acids, which include the lipid-
ation signal peptide and the first four residues of the mature
protein, have been omitted. This sample gave monoclinic
crystals. The asymmetric unit consists of four polypeptide
chains, labelled A–D, with an estimated solvent content of
45% and a VM of 2.27 A˚
3 Da1.
Medium-resolution diffraction data were recorded in-house
and the anomalous scattering information was used in a SAD
approach to phasing. 13 potential iodide positions were
identified and produced a figure of merit of 0.43 to 2.35 A˚
resolution. Subsequently, 12 of these positions were confirmed
by refinement with this data set. The initial model constructed
in RESOLVE consisted of 293 residues, with a correlation
coefficient of 0.55 and Rwork and Rfree values of 46% and 49%,
respectively. The first round of model building in Coot
extended this to 467 residues, with a correlation coefficient of
0.72 and Rwork and Rfree values of 33% and 37%, respectively.
At this point the high-resolution synchrotron data (1.92 A˚
resolution) became available and were used to continue the
analysis. The refinement proceeded with the release of NCS
restraints and the incorporation of water molecules, an Na+
ion, ethylene glycol and a number of side chains with dual
rotamer conformations. This data set was derived from crystals
grown in the presence of chloride instead of iodide. However,
we did not assign any chloride ions to the structure, noting that
typical water molecules occupy the previously identified
iodide-binding sites. The refinement was terminated when
there were no significant changes in Rwork and Rfree and
inspection of the difference density map suggested that no
further corrections or additions were justified. Several dual
rotamers are incorporated into the model. Disorder was
evident at several positions, for example the N-terminus,
where it was not possible to interpret diffuse and weak elec-
tron density. Consequently, several residues are absent from
the model. Molecule A consists of residues 32–173; molecule B
of residues 33–142 and 147–176; molecule C of residues 34–50,
53–143 and 147–175; and molecule D of residues 33–50 and
55–175. The geometry of the model is acceptable (Table 1).
3.2. Self-association and localization in vivo
Previous work on SciN, the Lip homologue from entero-
aggregative E. coli, showed that the protein is localized in the
outer membrane, facing the periplasm (Aschtgen et al., 2008).
Examination of the amino-acid sequence of the N-terminus of
SmLip predicts that this is also an outer-membrane lipopro-
tein. The LipoP 1.0 algorithm (Juncker et al., 2003) predicts
that SmLip has a lipoprotein signal peptide and that signal
peptidase II cleavage occurs between Gly25 and Cys26, with
the cysteine subsequently being lipidated. Additionally, the
residue at the +2 position following cleavage is Met27 (i.e.
it is not an aspartate, which directs retention in the inner
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Figure 1
Detection of Lip–Lip self-interaction. The bacterial two-hybrid system
was used to detect an in vivo interaction between Lip (minus signal
peptide) fused to T25 (pSC080) and Lip (minus signal peptide) fused to
T18 (pSC072). The empty vectors pUT18 and pT25 represent negative
controls. The graph shows the output from the two-hybrid system
detected as -galactosidase activity expressed relative to the pUT18/pT25
baseline level (the maximal -galactosidase activity observed for the Lip–
Lip interaction corresponded to >5000 Miller units). Bars show mean 
SEM. Inset: colourimetric readout of the two-hybrid assay following
growth of E. coli BTH101 carrying the above plasmids on MacConkey–
maltose agar (red is a positive result).
membrane); therefore, SmLip should proceed to the outer
membrane via the Lol system (Bos et al., 2007).
In order to investigate whether SmLip undergoes self-
interaction, the bacterial two-hybrid system (Karimova et al.,
2000) was utilized in E. coli. This assay involves reconstitution
of adenylate cyclase activity from two non-interacting cyclase
fragments, called T18 and T25, from Bordetella pertussis. The
presence of cyclic AMP activates the transcription of maltose
and lactose catabolic operons by E. coli. This can be detected
by direct measurement of -galactosidase activity or by using
the observation that bacteria capable of fermenting maltose
acidify the medium and thus generate a red colour on
MacConkey–maltose indicator plates.
SmLip was introduced as both bait and prey by encoding
on plasmids pUT18 and pT25, and a strong positive result
was observed (Fig. 1). Mature SmLip (lacking the N-terminal
signal peptide) was used for this experiment, firstly to corre-
spond to the form of SmLip for which the structure was
solved and secondly to ensure that both partners were local-
ized together in the cytoplasm after fusion with T18 or T25.
This positive result indicates that Lip does indeed self-
associate within the cell and that neither localization in the
outer membrane nor other components of the type VI
secretion apparatus are required for self-interaction. We note,
however, that this system is unable to distinguish between
dimerization or higher order oligomerization.
As a control for any propensity of SmLip to form non-
specific interactions, in addition to the lack of interaction with
the T18 and T25 proteins demonstrated in Fig. 1 we tested
whether SmLip gave a positive bacterial two-hybrid result
with several cytoplasmic components of the T6SS (with which,
as a periplasmic protein, it should not interact). SmLip gave a
negative result (indistinguishable from the T25 + T18 negative
control) when tested against the proteins VipB, TssK and TssL
(data not shown).
In order to confirm the localization of the native Lip protein
in S. marcescens, we utilized an anti-Lip polyclonal antibody
to probe each of the major cellular fractions in this organism.
As shown in Fig. 2, native SmLip is found exclusively in the
membrane fraction, confirming the predicted localization of
the protein and the functionality of the signal peptide.
3.3. Overall structure
The SmLip polypeptide can be classified as a new member
of the transthyretin-like superfamily and a detailed compar-
ison will be given below. The protein displays a compact
globular structure dominated by an eight-stranded -sandwich
(Fig. 3; Supplementary Fig. S11). The order of the strands is
8–7–1–4 and 6–5–2–3. There are three short -helical segments
and three 310-helix turns. The four SmLip polypeptide chains
in the asymmetric unit are similar, with the root-mean-square
(r.m.s.) deviations between superimposed C atoms ranging
from 1.3 A˚ (monomers A and B) to 0.8 A˚ (monomers A and
D) with an average value of 0.95 A˚.
Although a set of core conserved proteins are encoded by
the T6SS gene clusters in different Gram-negative bacteria
(data not shown), there is a large degree of variation in the
amino-acid sequences of these proteins. Lip and its ortho-
logues, for example, are relatively poorly conserved.
Excluding the signal peptide and lipobox motif (Fig. 4), SmLip
shares only about 20% sequence identity with SciN, the
homologue from enteroaggregative E. coli. This increases to
near 40% in comparison with the homologue from the
P. aeruginosa HSI-1 T6SS. Sequence conservation is noted in
loop 1, near 1 and 2, in loop 2 and in the loop 4–6 region
(Fig. 4).
An alignment of SmLip with eight orthologues (Supple-
mentary Fig. S21) reinforces the observation of a low level
of sequence identity for this protein. Excluding two residues
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Figure 2
Cellular localization of native SmLip in S. marcescens. Anti-Lip
immunoblot of whole cells or cellular fractions prepared from wild-type
S. marcescens strain Db10 or the lip mutant SJC10 (WC, whole cell;
Peri, periplasm; Sph, sphaeroplast; Cyto, cytoplasm; Memb, membranes).
The predicted size of mature SmLip is 16 kDa.
Figure 3
The secondary structure and fold of SmLip. -Strands are shown as blue
arrows and -helices and 310-turns as red and green ribbons, respectively.
The N- and C-terminal residues are labelled and the orientation of the
protein with respect to the outer membrane and periplasm is suggested.
1 Supplementary material has been deposited in the IUCr electronic archive
(Reference: MN5005). Services for accessing this material are described at the
back of the journal.
in the lipobox motif, only six residues are strictly conserved:
Asn48, Leu99-X-Pro101-Gly102, Gly120 and Ala124. All six
residues appear to contribute to the conformation of specific
parts of the fold (data not shown). The side chain of Asn48
accepts a hydrogen bond from the main-chain amide of
Gln126, helping to define the conformation of loop 4. The
Leu99-X-Pro101-Gly102 segment defines the structure of the
turn after 3 leading into loop 2. Gly120 and Ala124 occur in
5 and contribute hydrogen bonds to form interactions with
2 and 6 on either side. An increase in size of the side chain
at either of these positions would be likely to be disruptive to
the formation of this -sheet, which forms one side of the
structure. There is no obvious hydrophobic, basic or acidic
surface feature on SmLip that is likely to be conserved within
the Lip proteins since the few conserved residues are mainly
buried.
The information provided in x3.2 identifies that the
N-terminus of the structure is placed close to the outer
membrane, hence the assignment of the orientation of SmLip
with respect to the outer membrane (Fig. 3). By extension, we
note that the areas of SmLip in which sequence conservation
is observed mainly appear to contribute to stabilizing parts
of the structure that jut out into the periplasm. They may
therefore serve to define the structure of parts of Lip that are
responsible for interaction with other
molecules in the periplasm.
3.4. The tetramer is likely to be a
crystallographic artefact
Gel-filtration data acquired during
purification indicated that SmLip is a
monomer in solution (data not shown).
In contrast, the bacterial two-hybrid
data revealed a propensity for self-
interaction and the asymmetric unit is
a tetramer displaying 222 point-group
symmetry (Fig. 5). The accessible
surface area (ASA) of the SmLip poly-
peptide averages out at approximately
8350 A˚2; the range is from 8200 A˚2 for
molecule D to 8510 A˚2 for molecule A.
Each molecule in the asymmetric unit
interacts with two of the other three and
two types of protein–protein interface
are formed between molecules A–B and
C–D (interface I) and between mole-
cules A–C and B–D (interface II). The
type I interface, which is larger, covers
an area that is approximately 13% of
the ASA of the SmLip molecule. Such
coverage certainly indicates potential
for a biologically relevant dimer. This
interface is primarily formed by the
antiparallel alignment of two 7 strands.
Three aromatic residues, Phe147,
Trp151 and Phe153, contribute van der
Waals interactions to the association and, by virtue of their
relative bulk, also to the ASA (data not shown). The type II
interface covers about 6.5% of the ASA of a molecule, a level
typical of the values observed simply owing to molecular
packing in a crystal lattice. This interface is formed by the
antiparallel alignment of two 4 strands. The areas of SmLip
involved in forming a tetramer are not conserved in the
homologues from E. coli or P. aeruginosa (Fig. 4) and it is
unlikely that such a tetramer is a generic feature of this
lipoprotein.
The spatial placement of the N-terminal residues in the
asymmetric unit is such that it is unlikely that an oligomeric
assembly could form when the protein is anchored in the
membrane by the lipidated Cys26 at the N-terminus. The
N-termini of molecules A and D are on the same side of the
tetrameric assembly but are opposite to those of molecules B
and C. As explained, there are no direct interactions formed
between molecules A and D or molecules B and C. That the
bacterial two-hybrid experiments reveal a propensity for self-
interaction of the truncated protein in the cytoplasm is in one
sense consistent with the crystal structure of the truncated
version of SmLip, which shows a tetrameric assembly con-
taining a plausible dimer. On the other hand, the structure
of the tetramer is incompatible with dimeric or tetrameric
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Figure 4
The primary and secondary structure of SmLip and sequence alignment with two homologues.
S. marcescens Lip is aligned with the homologous proteins from enteroaggregative E. coli
(GenBank CBG37366.1) and P. aeruginosa (NCBI Reference Sequence NP_248770.1, PA0080).
The secondary structure of SmLip is depicted with blue arrows for -strands and red and green
cylinders for -helices and 310-helices, respectively. Residues conserved in all three sequences are
shown in black boxes and those conserved in only two sequences are shown in grey boxes. The start
and finish of the lipobox motif are marked by red boxes; the residues at the start and end of the
sequence used in the structure analysis (Ala30–Asp176) are shown in blue boxes. The alignment was
generated using T-Coffee (Di Tommaso et al., 2011) in the M-Coffee mode and the figure was
prepared using ALINE (Bond & Schu¨ttelkopf, 2009).
structures if the N-terminus is membrane-bound. These
observations may be a result of the different concentrations
and experimental conditions used. We suggest that SmLip is
a membrane-bound monomer but displays a propensity to
interact with itself.
A reviewer commented on the possibility that the SmLip
tetramer might represent an inactive or alternative state of the
protein. This is an intriguing suggestion and raises questions
about how conversion to an active form might occur and how
the T6SS itself is regulated. We have no data to address this
issue and further studies would be required to investigate such
a possibility.
3.5. Comparisons with structural homologues
A search for structural neighbours in the Protein Data
Bank using the PDBeFold (http://pdbe.org/fold) and ProFunc
servers (Laskowski et al., 2005) gives a Z score of 6.1 with sea
bream transthyretin (Eneqvist et al., 2004; PDB entry 1sn0).
This matched 84 residues with an r.m.s.d. of 2.7 A˚. The -sheet
structures align well (Supplementary Fig. S3). The r.m.s.d. and
relatively low Z score reflect the low sequence identity shared
between the two proteins of approximately 7%. Nevertheless,
the structural relationship is clear and SmLip can be classed as
a new member of the transthyretin-like protein family. The
only other member of this protein family is 5-hydroxyisourate
hydrolase (EC 3.5.2.17; Hennebry et al., 2006), an enzyme that
is found only in prokaryotes, leading to the conclusion that this
represents an example of divergent evolution (Hennebry,
2009). The sequence identity shared between this hydrolase
and SmLip is only 6%, but the similarity in fold is evident
(data not shown). We carried out further comparisons seeking
to inform on Lip function.
Transthyretin binds the hormone thyroxine, self-interacts to
form a tetramer and also forms a complex with retinol-binding
protein (Blake et al., 1978; Wojtczak et al., 1992; Monaco et
al., 1995; Zanotti et al., 2008). In common with transthyretin,
SmLip forms a tetrameric assembly. However, the SmLip
oligomer is distinct and an overlay of one SmLip polypeptide
with a subunit from transthyretin does not produce an overlap
of any of the other polypeptides (data not shown).
Transthyretin forms a dimer by antiparallel self-association
of the 6 and 8 strands, creating a curved eight-stranded
-sheet (Blake et al., 1978). The binding of the hormone
thyroxine occurs at the tetramer interface created by the
convex surfaces of two of these eight-stranded -sheets as the
protein assembles as a dimer of dimers. The thyroxine-binding
residues in transthyretin are not conserved in SmLip and an
overlay of an SmLip polypeptide and transthyretin subunit
places the ligand-binding site on the surface of the former
(Supplementary Fig. S3). It is unlikely that SmLip acts to bind
hydrophobic ligands of the type that transthyretin can bind.
Transthyretin associates with retinol-binding protein using
residues in three turns: two from one subunit that link 1 to
2 and 4 to 5, and one from another subunit that links 1
to 2 (Monaco et al., 1995). These parts of the transthyretin
structure correspond to loops 1 and 3 of SmLip. Loop 1 is
directed out from the globular fold into the periplasmic space;
it is placed to interact with physiological partners and may
represent a binding site for other proteins/molecules.
In a recent study of Klebsiella pneumoniae 5-hydroxy-
isourate hydrolase, the residues important for catalytic func-
tion were confirmed as His7, Arg41, His92 and Ser108, which
together with Tyr105 form a polar and symmetric active site at
a dimer interface (French & Ealick, 2011). A structure-based
sequence alignment matches four of these catalytic residues
(with the exception being Ser108) to Asp42, Gly105, His161
and Val172, respectively, in SmLip. The polypeptides do not
overlay in the vicinity of Ser108 (data not shown) and it is
unlikely that Lip has any hydrolase activity.
The biological role of SmLip or its orthologues in the T6SS
has yet to be unambiguously defined. Structural comparisons
appear to rule out, rather than assign, a function. The pro-
pensity to self-associate using parts of the SmLip structure
that will be exposed in the periplasm suggests that this protein,
exploiting the lipid anchor, helps to bind and position different
components of the secretion apparatus at the outer mem-
brane. Future experiments, aided by the structural model, can
address this hypothesis.
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Summary
Protein secretion systems are critical to bacterial viru-
lence and interactions with other organisms. The Type
VI secretion system (T6SS) is found in many bacterial
species and is used to target either eukaryotic cells or
competitor bacteria. However, T6SS-secreted proteins
have proven surprisingly elusive. Here, we identified
two secreted substrates of the antibacterial T6SS from
the opportunistic human pathogen, Serratia marces-
cens. Ssp1 and Ssp2, both encoded within the T6SS
gene cluster, were confirmed as antibacterial toxins
delivered by the T6SS. Four related proteins encoded
around the Ssp proteins (‘Rap’ proteins) included two
specifically conferring self-resistance (‘immunity’)
against T6SS-dependent Ssp1 or Ssp2 toxicity. Bio-
chemical characterization revealed specific, tight
binding between cognate Ssp–Rap pairs, forming
complexes of 2:2 stoichiometry. The atomic structures
of two Rap proteins were solved, revealing a novel
helical fold, dependent on a structural disulphide
bond, a structural feature consistent with their func-
tional localization. Homologues of the Serratia Ssp
and Rap proteins are found encoded together within
other T6SS gene clusters, thus they represent founder
members of new families of T6SS-secreted and
cognate immunity proteins. We suggest that Ssp pro-
teins are the original substrates of the S. marcescens
T6SS, before horizontal acquisition of other T6SS-
secreted toxins. Molecular insight has been provided
into how pathogens utilize antibacterial T6SSs to
overcome competitors and succeed in polymicrobial
niches.
Introduction
Protein secretion systems and their substrates are central
to bacterial virulence and interaction with other organisms
(Gerlach and Hensel, 2007). Six different secretion
systems (Types I–VI) are used by Gram-negative bacteria
to transport specific proteins to the exterior of the bacterial
cell or further inject them into target cells. The most
recently described of these is the Type VI secretion
system (T6SS) (Filloux et al., 2008). T6SSs are complex
multi-protein assemblies that span both bacterial mem-
branes and inject effector proteins directly from the bac-
terial cytoplasm into target cells (Bonemann et al., 2010;
Cascales and Cambillau, 2012). T6SSs are encoded by
large, variable gene clusters that contain 13 ‘core’ essen-
tial components, believed to make up the basic secretion
apparatus. Two core proteins, Hcp and VgrG, form the
extracellular part of the secretion machinery and depend
on a functional T6SS apparatus for their movement to the
outside of the bacterial cell (indeed, the presence of Hcp
in the secreted fraction has provided a useful assay for
basic T6SS assembly and activity; Pukatzki et al., 2009).
Hcp and VgrG most likely form a needle-like membrane-
puncturing device related to the bacteriophage tail spike;
this structure is believed to be pushed to the outside of the
secreting cell and likely into target cells upon contraction
of a tail sheath-like structure (Leiman et al., 2009; Bone-
mann et al., 2010; Basler et al., 2012). T6SSs occur in
many pathogenic bacteria and are implicated in virulence
in important pathogens, including Burkholderia mallei,
Burkholderia pseudomallei, Burkholderia cenocepacia,
Vibrio cholerae, Aeromonas hydrophila, Edwardsiella
tarda and Pseudomonas aeruginosa (Zheng and Leung,
2007; Cascales, 2008; Jani and Cotter, 2010; de Pace
et al., 2010; Burtnick et al., 2011; Rosales-Reyes et al.,
2012). In several cases, the action of such ‘anti-
eukaryotic’ T6SSs appears to result in disruption of the
actin cytoskeleton (Pukatzki et al., 2007; Aubert et al.,
2008; Suarez et al., 2010). Exciting recent work has dem-
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onstrated that some T6SSs are used to target other bac-
teria, efficiently killing or inhibiting competitors. This has
been reported for T6SSs in P. aeruginosa, Burkholderia
thailandensis, V. cholerae and Serratia marcescens
(Hood et al., 2010; MacIntyre et al., 2010; Schwarz et al.,
2010; Murdoch et al., 2011). The discovery that certain
T6SSs may be ‘antibacterial’ rather than, or in addition to,
‘anti-eukaryotic’ is highly relevant to the competitive
fitness and success of pathogens, particularly within pol-
ymicrobial infection sites. Such a system could provide
the pathogen with a large competitive advantage against
other bacteria in the host or the environment, enabling it to
proliferate and mount a successful infection.
Identifying the proteins secreted by T6SSs is a priority,
as they will be the ‘effectors’ that directly act on target
eukaryotic or bacterial cells. A special case of T6-secreted
effector is the class of ‘evolved’ VgrG proteins found in a
minority of T6SSs which have extra C-terminal effector
domains, e.g. the actin cross-linking domain of V. chol-
erae VgrG1 that is translocated into mammalian cells
(Pukatzki et al., 2007; Jani and Cotter, 2010). However,
excluding the structural components VgrG and Hcp, very
few ‘true’ T6SS-secreted proteins have been confirmed so
far. Best characterized are three effector proteins, anti-
bacterial toxins named Tse1–3, secreted by the antibac-
terial HSI-1 T6SS of P. aeruginosa. Tse1 and 3 are
peptidoglycan hydrolases that attack the cell wall of target
bacteria (Hood et al., 2010; Russell et al., 2011). Tse2 is
active in the cytoplasm of target cells, where it efficiently
induces quiescence (Li et al., 2012). All three have adja-
cently encoded cognate ‘immunity’ proteins (Tsi1–Tsi3)
which protect the secreting cell from harming itself or
being harmed by its sibling neighbours (Hood et al., 2010;
Russell et al., 2011). Significantly, obvious homologues of
the Tse and Tsi proteins are not detectable outside of
P. aeruginosa (Hood et al., 2010). A recent report has also
identified a number of candidate T6SS substrates in
B. thailandensis, one of which was confirmed as a new
T6-secreted peptidoglycan amidase (Russell et al., 2012).
Opportunistic Gram-negative bacteria cause a large
proportion of problematic and antibiotic-resistant hospital-
acquired infections. Enterobacteria (especially extended-
spectrum b-lactamase producing isolates) are among the
leading culprits, including S. marcescens (Choi et al.,
2007; Lockhart et al., 2007). We previously reported that
S. marcescens Db10 possesses a T6SS with potent anti-
bacterial activity (Murdoch et al., 2011). How this activity
is mediated, in particular the antibacterial effectors
secreted by the T6SS, was unknown. Hence, we sought
to identify and characterize novel antibacterial effectors
secreted by the S. marcescens T6SS. We report the iden-
tification and characterization of two such effectors, Ssp1
and Ssp2, which are encoded within the T6SS gene
cluster and represent novel T6-secreted antibacterial
toxins. We have also identified and characterized the Rap
proteins, which include the cognate immunity proteins to
these toxins. Biochemical analyses demonstrated a tight
and specific interaction between secreted and immunity
proteins. These secreted toxins and immunity proteins
represent two new protein families, co-occurring within
T6SS gene clusters of many other organisms. Addition-
ally, determination of high-resolution crystal structures of
two members of the Rap protein family revealed that this
family possesses a previously undescribed protein fold
that is dependent on formation of a disulphide bond.
Results
The T6SS gene cluster harbours self-resistance
determinants and candidate secreted effectors
The T6SS gene cluster of S. marcescens Db10,
SMA2244–2281, contains 38 genes, including many with
no known function (Murdoch et al., 2011). We speculated
that encoded within this cluster might be T6-secreted
effectors and/or self-resistance determinants, the latter
preventing the T6SS-expressing cell from harming itself or
being harmed by its isogenic (sibling) neighbours. In order
to determine whether the cluster did indeed contain self-
resistance determinants (such as specific immunity pro-
teins analogous to the Tsi proteins), we generated a
mutant lacking the entire T6SS gene cluster (DT6SS) and
examined whether it was fully resistant to the T6SS of the
wild type strain. Co-culture of two target strains, wild type
Db10 and the DT6SS mutant, each with a wild type and a
DclpV attacker, showed that the DT6SS mutant had lost
resistance to T6SS-mediated inhibition or killing by the
wild type strain (Fig. 1A, left). Recovery of DT6SS was
decreased 100-fold when it was co-cultured with the wild
type strain, compared with when the wild type strain was
co-cultured with itself. This effect was dependent on a
functional T6SS in the attacker as there was no loss of
DT6SS when it was co-cultured with a DclpV mutant. The
ATPase ClpV is one of the core, structural components of
the T6SS and we have shown previously that it is essen-
tial for Hcp secretion and T6-mediated antibacterial killing
activity of S. marcescens Db10 (Murdoch et al., 2011). To
simplify the analysis of multiple mutants, we defined the
‘resistance index’ of a strain as the difference between
recovery when co-cultured with the wild type strain and
recovery when co-cultured with the DclpV mutant, specifi-
cally log2[recovery vs. wild type/recovery vs. DclpV]. The
wild type or other resistant strain will show no difference
and have a resistance index of 0. A target strain with
reduced ability to resist harm caused by the T6SS will
have a negative resistance index, exemplified by the
DT6SS mutant with a resistance index of -7.6 (Fig. 1A,
right). Self-resistance did not depend on an active T6SS,
2 G. English et al. 
© 2012 Blackwell Publishing Ltd, Molecular Microbiology
as a DclpV mutant had a resistance index of 0. Similarly,
mutants in other essential core T6SS components, Dlip,
DicmH and DtssK (Murdoch et al., 2011) also showed no
loss of self-resistance (data not shown). Therefore, genes
other than those encoding the core conserved T6SS com-
ponents were implicated in self-resistance. Our attention
was particularly caught by a locus in the middle of the
gene cluster, where six non-conserved genes, SMA2260–
2262, SMA2264–2266, are flanked by conserved T6SS
components. A mutant lacking all of these genes (but
maintaining intact SMA2263, encoding Hcp1) was also
tested and found to have a negative resistance index
(Fig. 1A). Hence, one or more of these genes contributes
to self-resistance and may encode immunity protein(s).
Closer examination of the proteins encoded by
SMA2260–2262 and SMA2264–2266 revealed two
classes of small proteins (Fig. 1B). SMA2261 and
SMA2264 were basic proteins with detectable sequence
similarity between them, no discernable cellular localiza-
tion signals and no predicted function. We hypothesized
that they might be secreted substrates, and, given subse-
quent results, named them Ssp1 and Ssp2 (Secreted
small protein). SMA2260, SMA2262, SMA2265 and
SMA2266 were proteins with classical Sec-dependent
Fig. 1. An internal locus in the
S. marcescens T6SS gene cluster encodes
secreted proteins and self-resistance
functions.
A. T6SS-mediated inhibition of self in the
absence of genes within the T6SS gene
cluster. Left: number of recovered target cells,
either wild type (WT) or DT6SS mutant
(DSMA2244–2281), following co-culture (1:1)
with the attacking strain, WT or DclpV (T6SS
inactive mutant). Right: resistance index,
defined as log2[recovery of target in presence
of wild type/recovery of target in presence of
DclpV], of wild type Db10, DclpV, DT6SS or a
mutant lacking genes SMA2260–2262 and
SMA2264–2266. Bars show mean  SEM
(n = 4).
B. and C. Schematic depiction of loci
containing genes encoding the Rap and Ssp
genes in S. marcescens Db10 (B) and
homologues in selected other organisms (C).
Rap family proteins are shown in purple, Ssp
family proteins in green, conserved T6SS
core genes in grey, and Hcp homologues in
dark grey. In (B) cellular localization and
theoretical mass and pI of the proteins are
given beneath the corresponding gene.
D. Secretion of Hcp1 by wild type and
mutants of S. marcescens Db10 as shown by
anti-Hcp1 immunoblotting of cellular and
secreted fractions. Drap1ab,ssp1 indicates a
mutant lacking the rap1a, rap1b and ssp1
genes; Drap2ab,ssp2 indicates a mutant
lacking the rap2a, rap2b and ssp2 genes;
Dssp1,ssp2 indicates a mutant lacking the
ssp1 and ssp2 genes, and Drap,ssp indicates
a mutant lacking all of the rap and ssp genes.
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N-terminal signal peptides, identified using SignalP
(Petersen et al., 2011), and thus predicted to be periplas-
mic. They also had no predicted function but shared
detectable sequence similarity with each other. We
hypothesized that they would represent specific immunity
proteins or other self-resistance determinants, and named
them Rap1a, Rap1b, Rap2a and Rap2b (Resistance
associated protein). The genes encoding all these small
proteins fall into two sets, either side of hcp1 and within
genes encoding T6SS structural proteins, vipB and fha
(Fig. 1B). Homologues of the Ssp and Rap proteins are
encoded within T6SS gene clusters in many other bacte-
rial species (and in at least one case apart from the T6SS)
and appear to always co-occur (see representative exam-
ples in Fig. 1C). We speculated that the S. marcescens
Ssp and Rap proteins represented previously unknown
combinations of T6-secreted effectors and cognate immu-
nity proteins. Importantly, mutants lacking one, some or all
of the small proteins exhibited wild type levels of Hcp
secretion (Figs 1D and S1). Thus, none of the Ssp or Rap
proteins is required for Hcp secretion, i.e. they play no
structural role in the T6SS.
Ssp1 and Ssp2 are Type VI-secreted effectors
Ssp1 and Ssp2 were shown to be secreted substrates of
the T6SS by immunoblotting secreted fractions from the
wild type strain, two T6SS mutants, DclpV and DtssE, and
the corresponding complemented strains, using specific
anti-Ssp1 and anti-Ssp2 antibodies. Both proteins were
detected in the culture supernatant, entirely dependent on
a functional T6SS (Fig. 2A). Neither protein was detect-
able in the cellular fraction, implying they were rapidly
turned over if not secreted (data not shown). Secretion of
Ssp2 was also independent of Ssp1, and vice versa,
again confirming they have no structural or accessory role
in the secretion machinery (Fig. 2A). In order to establish
if the Ssp proteins were antibacterial toxins contributing to
the killing or inhibition of the susceptible DT6SS mutant by
the wild type strain, the recovery of DT6SS in the pres-
ence of different mutants was determined. Recovery of
the DT6SS target was increased fivefold with the Dssp2
mutant, or any multiple mutant lacking ssp2, as attacker,
compared with the wild type attacker (Fig. 2B). In con-
trast, in this assay, loss of Ssp1 did not cause a statisti-
cally significant impairment in killing of DT6SS. None of
the Rap proteins was required for targeting of DT6SS
(Fig. 2B).
Self-resistance against the Ssp1 and Ssp2 toxins is
mediated by their cognate Rap partners
In order to assess the contribution of each of the rap (and
ssp) genes to self-resistance, single mutants were con-
structed. It rapidly became apparent that single mutants in
rap1a and rap2a had severe fitness defects on solid
media, both on rich (Fig. 3A) and minimal media (Fig. S2),
and particularly Drap2a. Culture spots and single colonies
of each mutant were ‘thinner’, smaller (in the case of
Drap2a), and with altered surface morphology. Examina-
tion of single cells showed that the Drap1a cells appeared
bigger and less uniformly shaped than wild type cells and
the Drap2a cells had striking phenotypes, being either
markedly distended or highly elongated (Figs 3A and S2).
These phenotypes could be complemented by expression
of the corresponding gene in trans (indeed, the additional
stress of the selective antibiotic made the phenotypes of
Fig. 2. Proteins Ssp1 and Ssp2 are secreted by the Type VI
secretion system and self-harm is mediated by Ssp2.
A. Immunoblot detection of Ssp1 and Ssp2 in the secreted fraction
of the strains indicated using antibodies against Ssp1, Ssp2 or
RNAP (lysis control); levels of RNAP in the cellular fraction are also
shown. Strains are: wild type S. marcescens Db10 (WT); mutants
Dssp1, Dssp2, DtssE, DclpV; mutants carrying vector control
plasmids (+VC, pSUPROM) and mutants carrying complementing
plasmids (DtssE + TssE, pSC045; DclpV + ClpV, pSC039).
B. Recovery of the DT6SS mutant as the target strain following
co-culture with the different attacking strains indicated, expressed
relative to recovery of DT6SS when co-cultured with wild type
Db10. Bars show mean  SEM (n  4); *** indicates a significant
difference compared with the wild type strain (P < 0.001).
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Drap1a and Drap2a mutants carrying vector control plas-
mids even more pronounced; Fig. 3A). In contrast, when
Drap1a was constructed in combination with Dssp1, or
Drap2a in combination with Dssp2, the double mutants
were readily made and were of normal appearance and
fitness on solid media (Figs 3A and S2). These observa-
tions are entirely consistent with Rap2a serving as the
immunity protein against the Ssp2 toxin and Rap1a being
the cognate immunity protein alleviating toxicity mediated
by Ssp1. Similarly, when Drap1a or Drap2a mutants were
constructed in combination with the DclpV mutation, the
double mutants were again apparently healthy on solid
media (Figs 3A and S2). Hence, self-toxicity depended on
a functional T6SS, implying it was caused by T6SS-
mediated injection of the toxin into a susceptible cell by its
neighbours (further supported by the observation that
Drap1a and Drap2a did not display comparable growth
defects in liquid culture, where contact-dependent target-
ing is unlikely to occur efficiently; Fig. S2).
An immunity function for Rap2a was directly demon-
strated in co-culture (antibacterial competition assay):
target strains containing a Drap2a mutation all showed a
negative resistance index (Fig. 3B; the single Drap2a
mutant was not tested because of its severe sickness).
Strains containing a Drap1a mutation did not have a nega-
tive resistance index, consistent with the lack of significant
contribution of Ssp1 to self-killing under the conditions of
these assays (Fig. 2B). To confirm that Ssp2 was directly
and entirely responsible for the inhibitory effect of a wild
type attacker strain on Drap2a, we showed that a Drap2a
Fig. 3. Self-resistance is mediated by specific Rap immunity proteins cognate to the secreted Ssp proteins.
A. Phenotypes of wild type S. marcescens Db10 (WT) and selected single and double mutants after growth on solid LB media for 24 h. For
each strain, representative images of the morphology of a culture spot (left, scale bar 2 mm), single colonies (middle, scale bar 1 mm) and
individual cells (right, scale bar 10 mm) are shown. Mutants carrying complementing plasmids are Drap1a + Rap1a (pSC538) and
Drap2a + Rap2a (pSC542); the vector control plasmid (VC) was pSUPROM.
B. Resistance index of wild type Db10 and the deletion mutants indicated as target strains.
C. Recovery of a Drap2a mutant (Drap2a,DclpV) as the target strain following co-culture with the different attacking strains indicated,
expressed relative to recovery of target when co-cultured with the DclpV mutant. All strains carry the vector control plasmid pSUPROM, except
for Dssp2 + Ssp2, in which the mutant carries the complementing plasmid pSC541. In (B) and (C), bars show mean  SEM (n  4);
*** indicates a significant difference compared with the wild type strain (P < 0.001).
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target strain is completely resistant to attack by a Dssp2
mutant, with recovery of Drap2a in the presence of a
Dssp2 attacker being the same as its recovery in the
presence of a DclpV attacker (Fig. 3C). Additionally, inhi-
bition of Drap2a target was restored to wild type levels
when the Dssp2 mutant attacker was complemented by
expression of Ssp2 in trans. The susceptibility of Drap2a
to killing by the wild type strain could also be fully com-
plemented (Fig. S2). Hence, Ssp2 and Rap2a represent a
specific, cognate toxin and immunity protein pair.
Biochemical studies confirm a strong interaction
between cognate secreted toxins and immunity proteins
Each of the Ssp and Rap proteins was overproduced and
purified (in the case of the Rap proteins, without their
N-terminal signal peptides). Complex formation was dem-
onstrated using size exclusion chromatography (SEC)
analysis. All Rap proteins were dimeric in solution,
whereas Ssp1 and Ssp2 were monomeric (Fig. 4A and B).
When equimolar amounts of Ssp1 and Rap1a were
mixed, all of the protein was detected in a higher molecu-
lar weight complex (Fig. 4A) and the same was also
observed on mixing Ssp2 and Rap2a (Fig. 4A). In con-
trast, no complex formation between Ssp1 and Rap1b or
between Ssp2 and Rap2b, no additional three-way com-
plexes and no ‘cross’ interactions between Ssp2 and
Rap1a or between Ssp1 and Rap2a were observed
(Figs 4B and S3). As mixing equimolar amounts of Ssp1
and Rap1a resulted in detection of only the complexed
species, with no unbound form of either protein detect-
able, this implied a 1:1 molar complex. The 1:1 molar
stoichiometry of the Rap1a–Ssp1 complex was confirmed
by quantitative analysis of the composition of the higher
molecular weight peak using in-gel SYPRO Orange stain-
ing (Rickman et al., 2004) (Fig. 4C). Given the dimeric
nature of Rap1a and an apparent complex mass by SEC
of around 55 kDa [predicted Mw of 1:1 molar complexes
are 34.6 kDa (1:1), 69.2 kDa (2:2), 104 kDa (3:3) or
138 kDa (4:4)], this is most consistent with a heterotetra-
meric Rap1a2–Ssp12 complex. Similar logic supported a
Rap2a2–Ssp22 complex (Fig. 4A and C). The SEC analy-
ses suggested stable complexes were formed between
the cognate Ssp and Rap proteins. Isothermal titration
calorimetry (ITC) analysis of complex formation between
Ssp1 and the Rap1a dimer and between Ssp2 and the
Rap2a dimer (Fig. 4D) showed that, in both cases,
binding was clearly exothermic and tight, at least in the
low nanomolar Kd range. Although apparent Kd values of
4–8 nM were obtained, this is approaching the limit of
accuracy for conventional ITC (Wiseman et al., 1989).
Finally, we took advantage of the tight Rap–Ssp interac-
tions to utilize immobilized Rap2a and Rap1a to affinity-
purify secreted Ssp2 or Ssp1, respectively, from culture
supernatant (Figs 4E and S3). Mass spectrometry not
only confirmed the identity of Ssp1 and Ssp2 but also
showed that Ssp2 is not processed on secretion, as
almost complete sequence coverage revealed intact N-
and C-termini (Fig. S3). For Ssp1, we observed an intact
C-terminus but the sequence of the very N-terminus cor-
responds to several tryptic peptides too small to be
detectable by standard mass spectrometry, so we were
unable to definitively confirm lack of processing at this end
(data not shown).
The secreted small proteins, Ssp1 and Ssp2, exert
distinct harmful effects when targeted to the periplasm
in Escherichia coli and are neutralized by coexpression
of the cognate immunity protein
In order to confirm the antibacterial toxin function of Ssp1
and Ssp2 and establish in which cellular compartment
they exerted their effect, each protein was produced in
E. coli, either in the cytoplasm or artificially targeted to the
periplasm (by the N-terminal fusion of the Sec-dependent
OmpA signal peptide: sp-Ssp2 or sp-Ssp1). The presence
of Ssp2 in the periplasm, but not the cytoplasm, prevented
growth of E. coli on LB and minimal media; this toxicity
was alleviated by the co-production of Rap2ab (Fig. 5A).
Periplasmic Ssp1 was also toxic and its effect alleviated
by co-production of Rap1ab (Fig. 5A). However Ssp1 tox-
icity was only observed at higher expression levels and on
minimal media. The periplasmic localization of the Rap
proteins in S. marcescens was confirmed by fractionation
and immunoblotting of epitope-tagged versions of the
protein (Fig. 5B, data not shown).
Next, we also determined whether Ssp2 and/or Ssp1
were essential for the observed antibacterial activity of the
S. marcescens T6SS against other bacterial species
(Murdoch et al., 2011). Neither protein was required for
T6SS-dependent killing of other bacteria (Fig. S4). This
implies redundancy of effector function, in other words
that other T6SS-secreted toxins are still able to cause
killing in the absence of Ssp1 and Ssp2.
The Rap family of proteins display a new fold
Bioinformatic analysis of the Rap protein sequences pre-
dicted similarities between them, despite relatively low
sequence conservation, e.g. mature Rap1b and Rap2b
share around 20% identity, as do mature Rap2a and
Rap2b. All four Rap proteins appeared to be highly acidic,
to carry an N-terminal periplasmic targeting signal
sequence of about 24 residues, and were predicted to have
similar a-helical structures (using PSIPRED). In addition, a
cysteine pairing appeared to be conserved. Intriguingly, no
structural relative of the Rap proteins could be identified;
hence, we sought to obtain three-dimensional models
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using single crystal X-ray diffraction. Soluble recombinant
Rap proteins were only obtained in high yield from E. coli
Rosetta-gami (DE3), a strain engineered to support disul-
phide bond formation, and were dimeric in solution (Fig. 4).
Well-ordered crystals of Rap1b and Rap2b were obtained
and the structures were elucidated at 1.9 Å and 2.0 Å
resolution respectively (Fig. 6, Table 1). A search for
structural relatives using PDBeFold (pdbe.org/fold) and
ProFunc (Laskowski et al., 2005) was performed using
monomers and dimers of Rap1b and Rap2b as templates.
The only matches were to short segments of a-helices with
Z-scores (< 3) indicating low statistical significance. The
lack of any convincing structural relationships indicates
that the fold observed in both Rap1b and Rap2b is previ-
ously uncharacterized.
The asymmetric unit of the Rap1b structure consists of a
single subunit and crystallographic symmetry generates
the dimer. Rap2b has two dimers, formed by subunits A : B
Fig. 4. In vitro interaction between cognate
secreted toxins and immunity proteins.
A. and B. SEC analysis of complex formation
between the proteins indicated. Ten
nanomoles of the protein (or of each protein
in the case of mixtures) was separated on a
calibrated Superdex 75 10/300 GL column.
The theoretical molecular mass of each
monomer is given.
C. In-gel SYPRO Orange staining and
quantification of the relative molar amounts of
Rap1a and Ssp1 (left) or Rap2b and Ssp2
(right) in samples from the complex-containing
peaks observed in SEC (A).
D. ITC analysis of the interaction between
Ssp1 and Rap1a (left) and Ssp2 and Rap2a
(right).
E. Affinity isolation of secreted Ssp2 from
culture supernatant using immobilized
immunity protein His-Rap2a as bait.
Supernatant samples (Supt) were prepared
from the strains indicated (WT, wild type). The
band indicated by arrowhead was identified
as Ssp2 by mass spectrometry.
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and C : D, in the asymmetric unit. The four subunits are
similar, with the root-mean-square deviation (r.m.s.d.)
between superimposed Ca atoms ranging from 0.5 Å
(subunit B and D) to 0.7 Å (subunits A and C). The two
proteins display obvious similarities in terms of secondary,
tertiary and quaternary structure (Figs 6 and S5). An
overlay of Rap1b and Rap2b subunits matches 71 Ca
atoms with a r.m.s.d. of 1.4 Å. Of note is the conservation
of the disulphide bond, a key structural feature, likely
critical to the stable folding of the subunit and subsequent
dimerization of the Rap proteins. The Rap subunit is con-
structed around a helical bundle of five helices (a2–a6). A
disulphide linkage (Cys54–Cys120 in Rap1b, Cys41–
Cys101 in Rap2b) tethers a2 and a5 together. This asso-
ciation in turn supports formation of a hydrophobic core
that is primarily aliphatic with residues contributed from a2,
a4, a5 and a6. Three helices (a2, a3, a5) form a concave
surface on one side of the monomer. A series of hydrogen
bonding interactions also helps to stabilize the arrange-
ment of a2 and a4. By virtue of being longer than Rap2b,
Rap1b has an extension of five residues at the N-terminus
and 13 at the C-terminus, the latter of which form a short
helix a7. These segments of Rap1b are on the surface of
the molecules at opposite ends of the dimer (Fig. 6).
The Rap proteins display an extensive dimerization
interface (Fig. 6), consistent with the observation that
each Rap protein exists as a stable dimer in solution
(Fig. 4A and B). The Rap1b dimer uses almost 24% of the
accessible surface area of a subunit in formation of the
dimer. In the case of Rap2b the value is 20%. Such
percentages are indicative of highly stable oligomers
(Krissinel and Henrick, 2007). The dimer is stabilized by
extensive van der Vaals interactions primarily involving
aliphatic residues, in conjunction with hydrogen bonding
interactions and solvent mediated bridging associations.
The most important contributions are from side-chains on
the concave surface, formed by a2, a3 and a5, interacting
with the partner across the molecular twofold axis of sym-
metry. Additional interactions involve a self-association of
the loop that links a2 and a3, together with the N-terminus
a1 and a5. Helices a2 and a5 are thus not only critical for
the fold of the Rap subunits but also to creating a suitable
interface that leads to a highly stable dimer. This obser-
vation, together with the conserved disulphide bond
(Fig. 7), ties in with the localization of Rap proteins to the
oxidative environment of the periplasm where correct
folding to support anti-toxin activity must occur.
Fig. 5. Differential periplasmic toxicity of Ssp1 and Ssp2 and
periplasmic localization of Rap proteins.
A. Growth of E. coli MG1655 transformed with (i) plasmids
expressing Ssp2 (pSC133), Ssp2 + Rap2a + Rap2b (pSC134),
OmpAsp-Ssp2 (pSC138) or OmpAsp-Ssp2 + Rap2a + Rap2b
(pSC144) from an arabinose-inducible promoter, or with the empty
vector (vector, pBAD18-Kn), on LB or M9 media containing 0.2%
glucose, 0.02% arabinose or 0.2% arabinose; or (ii) the equivalent
analysis using plasmids expressing Ssp1 (pSC151),
Ssp1 + Rap1a + Rap1b (pSC159), OmpAsp-Ssp1 (pSC152) or
OmpAsp-Ssp1 + Rap1a + Rap1b (pSC160).
B. Localization of RNAP (RNA polymerase, cytoplasmic marker
protein), MBP (maltose binding protein, periplasmic marker protein)
and HA-tagged Rap proteins. Wild type S. marcescens Db10
expressing Rap1a-HA (pSC538), Rap2b (pSC543) or the vector
control (pSUPROM) was subjected to fractionation (WC, whole cell;
PP, periplasm; CM, cytosol + membranes), followed by
immunoblotting with anti-RNAP, anti-MBP or anti-HA antibodies as
indicated.
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Importantly, sequence analysis and secondary struc-
ture predictions for the other Rap proteins, in S. marces-
cens and other organisms, suggest strongly that the novel
fold revealed by our crystallographic analyses is generic
for this entire family of proteins (Fig. 7). Not only are the
main a-helices observed in both crystal structures closely
mimicked by the structural predictions of the other
members of the family, the Cys residues contributing to
the structural disulphide bond are also conserved. Addi-
tionally, Rap2b shares slightly higher sequence identity
with Rap2a (23% identity for the mature proteins) than it
does with Rap1b (20% identity). Given the similarity of the
Rap1b and 2b crystal structures, discussed above
(Fig. S5), then this provides confidence that Rap2a
shares this new fold and indeed that the Rap fold is a
defining characteristic of this protein family, many
Fig. 6. Structural features of Rap1b and Rap2b dimers. The dimers are oriented to provide a view down their twofold axis of symmetry.
A. Ribbon diagram with helices of one Rap1b subunit coloured green, and the symmetry related molecule bronze. Elements of secondary
structure, the N- and C-terminal residues are labelled and I- ions are depicted as orange spheres. The disulphide bond is shown as yellow
sticks and labelled.
B. Ribbon diagram of Rap2b with helices of one subunit blue, and the partner cyan.
C. and D. Electrostatic surface representation of Rap1b and Rap2b dimers in the same orientation as in (A) and (B). The electrostatic charge
is contoured at 1 kT/e and -1 kT/e; negative (acidic) charge is red, positive (basic) blue. Residues that contribute to the basic patches are
identified.
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members of which are likely to represent T6SS immunity
proteins.
Discussion
In this study we have identified two proteins, Ssp1 and
Ssp2, as true (non-structural) secreted substrates of the
S. marcescens T6SS and confirmed them as new T6SS-
dependent antibacterial toxins. We have also demon-
strated, genetically and biochemically, that the highly
specific, cognate periplasmic immunity proteins, Rap1a
and Rap2a, efficiently neutralize the effect of the Ssp
proteins. The atomic structures of two other, related Rap
proteins reveal that the immunity proteins should exhibit a
novel protein fold likely only attained when they are
present in the periplasm.
Our examination of Ssp1 and Ssp2 suggested that
they represented novel antibacterial toxins, containing
a domain of unknown function, DUF4285, present in
prokaryotic and eukaryotic proteins. We were unable to
detect significant sequence similarity with well-known
peptidoglycan hydrolases and the structure prediction
program Phyre2 (Kelley and Sternberg, 2009) was unable
to assign them any peptidoglycan hydrolase-like struc-
ture. Nevertheless, as they are clearly periplasmic-acting
toxins (Fig. 5) and non-resistant mutants showed appar-
ent lytic and/or division defects (Figs 3A and S2), a cell
wall targeting function seemed most likely. This idea has
very recently been strongly supported by the observation
that related proteins exhibit peptidoglycan amidase activ-
ity in vitro (see below; Russell et al., 2012). Importantly,
through analysing secreted Ssp2 isolated from culture
supernatant, we have also shown for the first time that
T6-secreted effectors are not processed at either termi-
nus during secretion. It seems clear that Ssp1 and Ssp2
are not the only effector proteins secreted by the S. marc-
escens T6SS. First, Ssp mutants are still able to kill Pseu-
domonas fluorescens as effectively as wild type Db10
(Fig. S4), implying that other toxins secreted in their
absence are sufficient to maintain efficient antibacterial
killing. Additionally, the susceptibility of the DT6SS mutant
to self-targeting by the wild type strain is greater than that
of the Drap,ssp mutant (Fig. 1A), implying additional
immunity proteins and thus cognate secreted toxins within
the T6SS gene cluster. Moreover, the magnitude of killing
of the DT6SS mutant by wild type Db10 is less than that
observed during T6-dependent killing of other organisms
(Murdoch et al., 2011; Fig. S4), suggesting that additional
secreted toxins (and cognate immunity proteins) are
encoded elsewhere in the genome. Indeed, our unpub-
Table 1. Crystallographic statistics for the Rap1b and Rap2b structures.
Rap1b Rap2b
Space group P3121 P2221
a, b, c (Å) 77.9, 77.9, 50.6 48.1, 57.0, 122.4
Resolutiona (Å) 67.5–1.88 (1.98–1.88) 44.78–2.0 (2.1–2.0)
No. reflections recorded 162 739 (21 729) 271 849 (36 384)
Unique reflections 14 813 (2130) 23 666 (3390)
Completeness (%) 100.0 100.0
Multiplicity/<I/sI> 11.0 (10.2)/26.6 (5.9) 11.5 (10.7)/25.7 (10.0)
Anomalous completeness (%) 100.0 100.0
Anomalous redundancy 5.6 (5.1) 6.0 (5.5)
Wilson B (Å2) 28.3 20.6
Residues/waters/ligands 119/117/7 392/137/–
Rmergeb (%) 5.3 (38.3) 8.5 (35.0)
Rworkc, Rfreed (%) 18.3/22.1 18.9/24.8
Ave. B-factor (Å2)
Chain A, B, C, D 21.1 10.6, 9.8, 7.8, 8.9
Waters, iodides, ethylene glycol 42.3, 49.4, 55.7 14.6
Cruickshank DPIe (Å) 0.1 0.2
Ramachandran plot
Most favoured 118 residues 381
Additional allowed 1 10
Outliers 0 Gln74
R.m.s.d. on ideal values
Bond lengths (Å) angles (°) 0.02/1.51 0.02/1.79
a. Values in parentheses refer to the highest resolution shell.
b. Rmerge = ShklSi|Ii(hkl) - < I(hkl) > |/ShklSi Ii(hkl), where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean value
of Ii(hkl) for all i measurements.
c. Rwork = Shkl||Fo| - |Fc||/S|Fo|, where Fo is the observed structure factor and Fc is the calculated structure factor.
d. Rfree is the same as Rcryst except calculated with a subset, 5%, of data that are excluded from the refinement calculations.
e. Diffraction Precision Index (Cruickshank, 1999).
The PDB accession codes are 4AX2 (Rap1b) and 4B6I (Rap2b).
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lished work has identified four other, unrelated, candidate
substrates of the Serratia T6SS. Hence, we believe that
S. marcescens uses a species-specific arsenal of
secreted toxins to produce the potent and efficient target-
ing of a variety of competitor bacteria observed (Murdoch
et al., 2011).
Our work provides strong functional evidence for a new
family of related T6SS substrates (Ssp1 and Ssp2 homo-
logues) and family of related immunity proteins (Rap
homologues) found in many different bacterial species
and generally encoded within a main T6SS gene cluster of
that organism. Ssp- and Rap-like proteins are found asso-
ciated with a subset of T6SSs (some, but not all, closely
related to the S. marcescens T6SS), but whether these
T6SSs all exhibit antibacterial activity remains to be deter-
mined. While this report was in preparation, a bioinfor-
matic study identified four disparate families of predicted
T6-secreted peptidoglycan amidases, with Tse1 of
P. aeruginosa being a member of ‘Family 1’ (Russell et al.,
2012). Entirely consistent with our data, Ssp-like proteins
were recognized as one of these families, ‘Family 4’. A
related family of proposed cognate immunity proteins
identified as co-occurring with all Ssp/Family 4 proteins is
of course the Rap family proteins. Thus, in the nomencla-
ture proposed by Russell et al., Ssp1 and Ssp2 could be
classified as Tae4.1SM and Tae4.2SM, and Rap1a and
Rap2a as Tai4.1aSM and Tai4.2aSM. Unlike Families 1–3,
the Family 4/Ssp proteins are almost unrecognizable as
peptidoglycan amidases at a sequence and structure pre-
diction level. Nevertheless, the purified Ssp homologue
STM0277 from Salmonella enterica serovar Typhimurium
was able to hydrolyse peptidoglycan cross-links at the
D-Glu-mDAP bond of the acceptor stem (Russell et al.,
2012). Additionally, artificial expression and targeting of
STM0277 to the periplasm was shown to be toxic to
E. coli, with rescue by coexpression of the Rap homo-
logue STM0278. However, studies were not conducted to
show that STM0277 is a T6SS substrate or that it plays
a role in T6-mediated antibacterial activity, neither was
a role for STM0278 in self-resistance in the native,
T6-elaborating organism investigated. In contrast, we
have provided the comprehensive genetic, in vivo and
biochemical data necessary to confirm that Ssp/Family 4
proteins are indeed a novel family of T6-secreted antibac-
Fig. 7. Conservation of the Rap protein fold. Sequence alignment of S. marcescens Rap2b and Rap2a with homologous proteins from
Erwinia amylovora (GenBank CBA22869.1), Enterobacter cloacae (NCBI Reference Sequence YP_003612051.1), Cronobacter sakazakii
(NCBI Reference Sequence YP_001439955.1), Salmonella Typhimurium (NCBI Reference Sequence NP_459276.1) and Pseudomonas
syringae (NCBI Reference Sequence YP_237109.1). The secondary structure of Rap2b (blue cylinders) and the predicted secondary structure
of the P. syringae protein (purple cylinders) are shown. All proteins had similar predicted secondary structures (PSIPRED); the one shown is
representative. Cysteine residues involved in disulphide bond formation are coloured yellow. Alignment was generated using T-Coffee and
annotated using ALINE, using the mature proteins (i.e. without N-terminal signal peptides; numbering refers to the full-length proteins).
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terial toxins and moreover that the Rap family contains the
cognate immunity proteins. Interestingly, it was recently
reported that a mutant in the above Rap2a homologue in
S. Typhimurium, STM0278, had a defect in replication in
macrophages (Mulder et al., 2012). The reason behind
this is not clear, but it may reflect the fact that this mutant
has reduced fitness due to self-toxicity, just as we have
shown for the Drap2a mutant. It should also be noted that
Ssp–Rap pairs are not always found associated with
T6SS genes. A particularly interesting example is the
location of such a pair almost adjacent to genes encoding
a classical RelE–RelB toxin–antitoxin pair (T-AT;
Yamaguchi and Inouye, 2011) on a plasmid in Acineto-
bacter baumannii (Fig. 1). It is tempting to speculate that
an original source of T6 toxin/resistance pairs is from
plasmid T-AT systems.
The work of Russell et al. (2012) combined with our
demonstration that Ssp1 and Ssp2 function as
periplasmic-acting toxins is highly consistent with these
proteins having a peptidoglycan amidase enzymatic activ-
ity. Of particular note, conserved Cys and His residues
predicted by Russell et al. to represent the catalytic amino
acids mediating peptidoglycan amide bond hydrolysis can
be readily identified in Ssp1 and Ssp2. These are Cys50
(NTCAVRMS) and His133 (GHIDLIEP) in Ssp1, and
Cys50 (NACAIRMS) and His131 in Ssp2 (GHATLWNG),
with the equivalent, conserved regions in STM0277 being
(NACPIRMS and GHVTLWNG). However, crucially, our
data on the Ssp and Rap proteins in the context of T6SS-
mediated attack and defence in vivo reveal that the situ-
ation is more subtle than this. In particular, Ssp1 and Ssp2
are clearly not redundant, despite having the same pos-
tulated enzymatic function. Rather, they have distinct
activities or roles, with Ssp2 apparently more potent. In
particular, we noted that the Ssp-dependent morphologi-
cal phenotypes of the Drap1a and Drap2a mutants are
different (Figs 3A and S2), that toxicity in the E. coli peri-
plasm is only medium-dependent for Ssp1 (Fig. 5), and
that the two may be relevant in different biological con-
texts (e.g. Ssp1 does not significantly contribute to self-
targeting under the conditions of our standard assay, yet
is clearly required for the self-toxicity observed in a
Drap1a mutant). This specialization is consistent with a
clear specificity for only the cognate Ssp–Rap partner, as
we observed. In the native context, it is clear that none of
the other three Rap proteins can confer cross-resistance
to Ssp2 in the absence of Rap2a (nor did Ssp2 interact
with Rap1a biochemically). The molecular basis for the
difference between Ssp1 and Ssp2, which share 24%
sequence identity, is not yet clear and will require further
study, including determination of in vitro enzymatic activity
and atomic structures.
The S. marcescens Rap proteins represent founder
members of a new bacterial protein family, members of
which represent immunity proteins for T6-secreted toxins,
as exemplified by Rap1a and Rap2a. We have deter-
mined the structures of two members of this family, Rap1b
and Rap2b, revealing a new protein fold. Given the
sequence homology, conservation of key residues and
shared predicted secondary structure throughout all
members of the family (Fig. 7; Russell et al., 2012), this
fold appears to be shared across members from different
organisms. A conserved disulphide bond and the
observed stable dimerization interface, together with
canonical N-terminal signal sequences, are consistent
with a periplasmic localization for all Rap family proteins.
To date, the structures of two other T6 immunity proteins
have been solved. The first is the cytoplasmic Tsi2 protein
(Li et al., 2012; Zou et al., 2012). Like the Rap proteins,
Tsi2 exhibits a helical fold, is acidic and exists as a stable
dimer in solution. However, the structures of Tsi2 and the
Rap proteins are unrelated. Second, and very recent, is
the structure of the periplasmic Tsi1 protein, complexed
with the secreted peptidoglycan hydrolase effector, Tse1
(Ding et al., 2012). Tse1 possesses a strikingly accessible
active site, facilitating its promiscuous and toxic peptidog-
lycan amidase activity (Chou et al., 2012). Tsi1 binds to
Tse1 in a 1:1 complex, occluding the substrate-binding
site of Tse1 in order to neutralize its activity (Ding et al.,
2012). Critically, although the Rap1a/Rap2a proteins and
Tsi1 both mediate resistance to peptidoglycan hydrolase
toxins, their structures now appear to be entirely unre-
lated. Tsi1 exhibits an all b fold, related to a classical
b-propeller, whereas Rap family proteins exhibit a novel
helical fold. This indicates that the mechanisms by which
immunity proteins confer resistance may be divergent
even among those with effectors of similar function.
Rap1a and Rap2a have an obvious immunity phenotype
specific to their cognate secreted toxins, Ssp1 and Ssp2.
However, the role of Rap1b and Rap2b is not yet known.
While they do not appear to play a role in self-resistance,
they may play a role in resistance towards closely related
bacteria secreting similar toxins. It is worth noting that
other organisms also possess multiple Rap family pro-
teins for a given Ssp family protein (Fig. 1C and data not
shown); therefore, whatever the function of Rap1b and 2b
turns out to be, it may not be unique to Serratia.
Complementing our genetic and phenotypic demon-
stration of the cognate toxin-immunity function of Ssp1–
Rap1a and Ssp2–Rap2a, we report detailed biochemical
characterization of the interactions between these purified
T6-secreted toxins and immunity proteins. For efficient
self-protection, these interactions should be tight and
highly specific, as was observed. Formation of Ssp1–
Rap1a and Ssp2–Rap2a complexes is exothermic, with
low nanomolar Kd, and with a stoichiometry of 2:2. A
binding affinity of this order agrees well with the Kd of 3 nM
reported for the Tsi1–Tse1 interaction (Ding et al., 2012);
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however, the Tsi1–Tse1 complex has a stoichiometry of
1:1, again highlighting significant differences between dif-
ferent pairs of toxin-immunity proteins. The structure of a
Ssp–Rap complex and arrangement of the subunits has
yet to be determined, although it is likely that the two Ssp
proteins bind to the same part of each Rap monomer,
exploiting the twofold symmetry. Li et al. suggest that Tse2
interacts with an acidic patch on Tsi2 distal to the dimer
interface (Li et al., 2012). They also note that, like many
toxin–antitoxin pairs, the resistance proteins Tsi1–3 are
more acidic than the toxin proteins Tse1–3. This pattern is
strikingly followed with the Ssp (theoretical pI 9) and Rap
(theoretical pI 5–6) proteins. Nevertheless, while the
highly acidic Rap proteins bind their cognate Ssp part-
ners, which are noticeably basic, with high affinity, the
story is not as simple as charge complementarity. Surpris-
ingly for proteins with such low pI values, the striking
surface feature conserved in Rap1b and Rap2b structures
is a crescent-shaped basic patch on either side of the
dimer (Fig. 6C and D). It is possible that such a basic
crescent, if present on toxin-binding Rap proteins, may
contribute to orientation of the partner during binding;
conversely, it might contribute to the lack of Ssp binding
by Rap1b and Rap2b. Additionally, all four S. marcescens
Rap proteins are acidic and both Ssp proteins basic,
yet only two, highly specific interactions are observed
(Rap1a–Ssp1 and Rap2a–Ssp2). While charge comple-
mentarity would be expected to be important for specific
complex formation, it is likely that shape considerations
play an equally important role. The structure of a toxin-
immunity protein complex will be necessary to delineate
the molecular features that govern specific Rap–Ssp
association. We are working towards that goal.
In summary, our data support a model (Fig. 8) whereby
Ssp1 and Ssp2 are toxins secreted by the S. marcescens
T6SS into the periplasm of a neighbouring cell. If this is an
isogenic sibling, the cognate Rap proteins provide an
efficient protective barrier, effectively binding and seques-
tering the toxin, whereas if it is a competitor, Ssp1/2 are
free to attack the cell wall. However, Ssp1 and Ssp2 are
only two of multiple distinct T6-secreted toxins. This pro-
vides the observed redundancy of function: if Ssp1/2 are
missing, the other toxins still cause the efficient death of a
competitor. This ‘belt and braces’ approach provides great
robustness: if a competitor becomes resistant to one or
two toxins, the others will still provide the ability to kill or
inhibit the competitor efficiently. Of course, the toxic effect
of Ssp1/2 can be seen against self (if the cognate Rap is
missing) as Db10 has resistance proteins to neutralize the
other toxins. We believe that other effectors most likely
Fig. 8. Model for action and context of Ssp
and Rap proteins.
A. Wild type S. marcescens Db10 uses its
T6SS to inject multiple different antibacterial
toxins (solid circles), including Ssp2 (green),
into a susceptible target competitor cell,
cumulatively causing a rapid death. Ssp2
attacks the cell wall in the periplasm (peri);
other toxins are likely to attack targets in the
cytoplasm (cyto).
B. Another wild type cell is resistant to T6SS
attack by its neighbour because of the
presence of cognate immunity proteins for all
the toxins (open circles). Rap2a dimers
(purple) form a protective barrier in the
periplasm, rapidly binding and sequestering
Ssp2.
C. When a Drap2a mutant of Db10 is the
target strain, all of the effectors except for
Ssp2 are still neutralized, but Ssp2 secreted
by wild type cells is now able to cause toxicity
in the target.
D. In a putative ancestral cell, T6SS secretion
of Ssp2, but not other toxins later acquired by
horizontal transfer, inhibits a competitor target
cell. In this case, loss of Ssp2 (or resistance
to Ssp2 in the target) would prevent inhibition.
For clarity, Ssp1 and Rap1a are not shown
but would behave similarly to Ssp2 and
Rap2a.
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act on different cellular targets, analogous to the
Pseudomonas-specific, cytoplasmic-acting toxin, Tse2 (Li
et al., 2012). Finally, we speculate that as the Ssp and
Rap proteins are encoded within the T6SS gene cluster,
and related genes are found associated with other T6SSs,
particularly closely related ones, they may represent the
ancestral substrates of the S. marcescens T6SS. Subse-
quently, other toxins could have been horizontally
acquired from diverse sources and adopted by this highly
versatile secretion machine. The exciting task of decipher-
ing how such species- and strain-specific arsenals of
toxins and immunity proteins are co-ordinated by the pro-
ducing cell and how they contribute to the dynamic com-
position of polymicrobial communities in infection and the
environment lies ahead.
Experimental procedures
Bacterial strains, plasmids and culture conditions
All strains and plasmids used in this study are detailed in
Table S1. All mutants constructed in S. marcescens Db10
were in-frame deletion mutants, generated by allelic
exchange as described previously (Murdoch et al., 2011).
Streptomycin-resistant derivatives were generated by phage
fIF3-mediated transduction of the resistance allele from
S. marcescens Db11 (Petty et al., 2006). Plasmids for con-
stitutive expression of proteins in S. marcescens were
derived from pSUPROM, plasmids for arabinose-inducible
protein expression were derived from pBAD18-Kn, and
derivatives of the pET15b-TEV plasmid were generated for
protein overexpression and purification. S. marcescens was
grown at 30°C in LB (10 g l-1 tryptone, 5 g l-1 yeast extract,
10 g l-1 NaCl, with 1.5 g l-1 agar for solid media) or minimal
media (40 mM K2HPO4, 15 mM KH2PO4, 0.1% (NH4)2SO4,
0.4 mM MgSO4, 0.2% glucose) and E. coli was normally
grown at 37°C in LB or M9 minimal media (M9). M9 (Sam-
brook and Russell, 2001) contained 0.5% glycerol (plus
stated concentrations of arabinose and glucose as required).
Growth analyses were performed in 96-well plates in a
BioTek Synergy platereader. When required, media were
supplemented with antibiotics: ampicillin (Ap) 100 mg ml-1,
kanamycin (Kn) 100 mg ml-1, streptomycin (Sm) 100 mg ml-1,
chloramphenicol (Cm) 25 mg ml-1; to maintain repression of
proteins expressed from pBAD18-Kn, 0.5% glucose was
added to the media for cloning and maintenance.
Antibacterial competition/co-culture assays
These were based on the assay described previously
(Murdoch et al., 2011). In brief, the attacker strain and target
strain (both at OD600 0.5) were mixed at an initial ratio of 1:1
attacker : target, co-cultured on solid LB for 7.5 h at 30°C and
then the surviving target cells enumerated by serial dilution
and viable counts on streptomycin-containing media. The
target strain was always the streptomycin-resistant version of
the mutant in question (Table S1). Statistical significance
testing was performed by ANOVA followed by Dunnett’s post
test (GraphPad Prism software).
Bioinformatic identification of homologues of Rap and Ssp
proteins and determination of their genetic contexts utilized
the BLAST servers and sequence databases at the NCBI
(http://www.ncbi.nlm.nih.gov).
Immunodetection of secreted proteins
Anti-Hcp immunoblots were performed as described
(Murdoch et al., 2011). For detection of Ssp1 and Ssp2, cel-
lular and secreted fractions were prepared from 25 ml of
culture grown for 7 h in LB. Secreted proteins were precipi-
tated using 50:50 chloroform : methanol followed by metha-
nol wash and resuspension in 2¥ gel sample buffer (Murdoch
et al., 2011). Cellular samples were prepared by sonicating
harvested cells in 20 mM Tris·HCl pH 7.5, 150 mM NaCl,
1 mM EDTA, 0.5% Triton X-100 and isolating the soluble
fraction by centrifugation. Anti-Ssp1 and anti-Ssp2 rabbit
polyclonal antibodies were raised to the purified proteins
(Eurogentec, Belgium) and used at 1:1000; peroxidase-
conjugated secondary (Thermo Fisher Scientific) was used at
1:10 000. Anti-RNAP b (Neoclone, USA) was used at
1:20 000, with anti-mouse secondary (Roche) at 1:10 000. In
all cases, protein from the same number of cells was loaded
in the secreted versus the cellular samples.
Localization of Rap-HA proteins
Fractionation was performed using a cold osmotic shock
procedure. Following growth of cultures for 5 h in LB, Tris·HCl
pH 7.8 was added to 5 ml of cells to a final concentration of
50 mM and the cells were incubated for 10 min at room
temperature, then recovered by centrifugation and washed
once in LB. Cell pellets were resuspended in 1 ml of 40%
sucrose, 30 mM Tris·HCl pH 7.8, 2 mM EDTA and incubated
for 10 min at 30°C. One hundred microlitres of this fraction
(‘whole cell’) was removed for analysis. Remaining cells were
recovered by centrifugation, resuspended in 900 ml of ice-
cold water and incubated on ice for 10 min, resulting in the
release of the periplasm. After centrifugation, 100 ml of the
supernatant (‘periplasm’ fraction) was retained for analysis.
The pellet, containing the ‘cytoplasm + membranes’ fraction,
was resuspended in 900 ml of 50 mM Tris·HCl pH 7.8 and
100 ml retained for analysis. Equivalent amounts, on a per cell
basis, of each fraction in each strain were assayed. Anti-
RNAP b was used as above, anti-MBP (NEB) was used at
1:10 000 and anti-HA (Roche) was used at 1:6000, all with
anti-mouse secondary as above.
Microscopic analysis of colony and cell morphology
Overnight cultures were normalized to OD600 0.5, diluted 10-2
(culture spots) or to obtain single colonies, 10 ml spotted onto
solid media and grown for 24 or 48 h. Macroscopic morphol-
ogy of culture spots and single colonies were recorded using a
Zeiss MZ16FA Stereo Microscope with a Leica DFC350 FX
camera and Leica AF6000 software. Microscopic analysis of
single cells taken from spots grown on solid media as above
was performed by Differential Interference Contrast (DIC)
microscopy using an Axioskop 2 mot plus (Zeiss) with a SPOT
RT KE camera and SPOT software (Diagnostic Instruments).
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Protein purification and in vitro analysis
A full description of protein purification is provided in the
Supporting information. In brief, proteins were overproduced
in E. coli with a TEV protease-cleavable His6 tag and isolated
by Ni2+ affinity purification. If required, the His6 tag was
cleaved using TEV protease and the protein re-isolated by
reverse Ni2+ chromatography. A final SEC step was then
always performed. For SEC analysis of complex formation,
His6-tagged proteins (10 nmol each) in 50 mM Tris·HCl,
pH 7.5, 250 mM NaCl were separated on a Superdex 75
10/300 GL column, calibrated using molecular weight stand-
ards (GE Healthcare). Quantitative SYPRO Orange staining
was performed as described (Rickman et al., 2004), with
image analysis using ImageJ. Molar ratios were the mean of
at least four quantifications. ITC was performed in 50 mM
Tris·HCl, pH 7.5, 250 mM NaCl at 30°C in a MicroCal iTC200
calorimeter. The sample cell contained 6 mM Rap1a dimer or
Rap2a dimer and the syringe contained 120 mM Ssp1 or
Ssp2. Titrations consisted of 30 ¥ 8 ml injections of Ssp into
Rap (or into buffer alone as control). Data analysis was
performed with the Origin software provided (MicroCal). For
affinity isolation of Ssp1 and Ssp2, 10 mg of His6-tagged Rap
protein was immobilized on magnetic Ni2+ beads (Qiagen),
incubated for 1 h with culture supernatant (after 7 h growth in
LB), beads washed and bound proteins eluted by the addition
of gel sample buffer. Identified proteins were excised from the
Coomassie- (Ssp2) or Silver- (Ssp1) stained gel and identi-
fied by mass spectrometry.
Crystallographic analyses
Well-ordered trigonal and orthorhombic crystals of Rap1b
and Rap2b, respectively, were obtained. The asymmetric unit
for Rap1b consisted of a single subunit, while Rap2b dis-
played two dimers in the asymmetric unit. Diffraction data
were recorded in-house and experimental phases were
derived by single-wavelength anomalous diffraction meas-
urements (Micossi et al., 2002), exploiting the signal from
endogenous S atoms and I- ions that had been added by
soaking. The electron density maps were of high quality, and
the models were completed, then refined to high resolution
using standard methods (Dawson et al., 2008). Full crystal-
lographic details are provided in the Supporting information
and Table 1. Atomic co-ordinates and structure factors have
been deposited in the Protein Data Bank (PDB) with acces-
sion codes 4AX2 (Rap1b) and 4B6I (Rap2b).
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